FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Allgar, VL
   Neal, RD
   Pascoe, SW
AF Allgar, VL
   Neal, RD
   Pascoe, SW
TI Cancer patients consultation patterns in primary care and levels of
   psychological morbidity: Findings from the health survey for England
SO PSYCHO-ONCOLOGY
LA English
DT Article
ID BREAST-CANCER; DEPRESSION; PREVALENCE; MANAGEMENT; DISTRESS
AB Aim. To determine the consultations patterns in general practice, for people with cancer and other chronic illnesses, and to assess the levels of psychological morbidity.
   Methods. The following questions from the 1999 Health Survey for England were analysed: presence of a self-reported long-standing illness and its nature, numbers of contacts with general practitioner (GP) in the previous 2 weeks, contact with a GP in the previous year for anxiety/depression or a mental, nervous or emotional problem, presence of a self-reported long-standing illness of mental illness, anxiety or depression, and GHQ12 scores. For comparison purposes, data from respondents reporting having asthma, arthritis, diabetes, other long-standing illness, and no long-standing illness are presented.
   Results. A third of respondents with cancer had contact with a GP in the last 2 weeks, which was slightly higher than the other illness group, however the pattern of attendances for those respondents who did consult were similar between groups. A quarter of people with cancer had spoken to a GP in the last year about being anxious/depressed, or about a mental, nervous or emotional problem. A third of cancer respondents reported high GHQ12 scores, but self-reported long-standing illness of 'mental illness/anxiety/depression' was low (4%).
   Conclusion. The findings suggest that psychological morbidity may be unrecognised in some cancer patients. There is potential for these symptoms to be identified and treated in primary care, especially given the ongoing nature of the patient-doctor relationship and the easy access primary care affords. Copyright (C) 2003 John Wiley Sons, Ltd.
C1 Univ Leeds, Nuffield Inst Hlth, Ctr Res Primary Care, Leeds LS2 9PL, W Yorkshire, England.
   Meanwood Grp Practice, Leeds, W Yorkshire, England.
RP Allgar, VL (reprint author), Univ Leeds, Nuffield Inst Hlth, Ctr Res Primary Care, 71-75 Clarendon Rd, Leeds LS2 9PL, W Yorkshire, England.
OI Allgar, Victoria/0000-0002-5228-2623
CR *DEP HLTH, 1999, HLTH SURV ENGL
   Department of Health, 2000, NHS CANC PLAN
   Fallowfield L, 2001, BRIT J CANCER, V84, P1011, DOI 10.1054/bjoc.2001.1724
   Goldberg D, 1999, J CLIN PSYCHIAT, V60, P39
   Goldberg D., 1988, USERS GUIDE GEN HLTH
   Gulliford T, 1997, BMJ-BRIT MED J, V314, P174, DOI 10.1136/bmj.314.7075.174
   Hopwood P, 2000, J CLIN ONCOL, V18, P893, DOI 10.1200/JCO.2000.18.4.893
   Macleod U, 2000, BRIT MED J, V320, P1442, DOI 10.1136/bmj.320.7247.1442
   Maguire P, 2000, EUR J CANCER, V36, P556
   MASSIE MJ, 1990, J CLIN PSYCHIAT, V51, P12
   Pascoe S, 2000, AUST NZ J PSYCHIAT, V34, P785, DOI 10.1046/j.1440-1614.2000.00817.x
   Rost K, 1998, GEN HOSP PSYCHIAT, V20, P12, DOI 10.1016/S0163-8343(97)00095-9
   Sellick SM, 1999, PSYCHO-ONCOL, V8, P315, DOI 10.1002/(SICI)1099-1611(199907/08)8:4<315::AID-PON391>3.0.CO;2-G
   Simon GE, 1998, J CLIN PSYCHIAT, V59, P3
   Zabora JR, 1997, J PSYCHOSOC ONCOL, V15, P73, DOI 10.1300/J077v15n02_05
NR 15
TC 9
Z9 9
U1 0
U2 2
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
SN 1057-9249
J9 PSYCHO-ONCOL
JI Psycho-Oncol.
PD OCT-NOV
PY 2003
VL 12
IS 7
BP 736
EP 740
DI 10.1002/pon.692
PG 5
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
   Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA 727PR
UT WOS:000185667800009
PM 14502598
DA 2019-01-08
ER

PT J
AU Lapolla, A
   Dalfra, MG
   Masin, M
   Bruttomesso, D
   Piva, I
   Crepaldi, C
   Tortul, C
   Dalla Barba, B
   Fedele, D
AF Lapolla, A
   Dalfra, MG
   Masin, M
   Bruttomesso, D
   Piva, I
   Crepaldi, C
   Tortul, C
   Dalla Barba, B
   Fedele, D
TI Analysis of outcome of pregnancy in type 1 diabetics treated with
   insulin pump or conventional insulin therapy
SO ACTA DIABETOLOGICA
LA English
DT Article
DE diabetes; pregnancy; insulin therapy; maternal outcome; fetal
   malformations
ID FETAL MALFORMATIONS; METABOLIC-CONTROL; GLYCEMIC CONTROL; WOMEN;
   INFUSION; MELLITUS; INFANTS; GLUCOSE; HEMOGLOBIN-A1C; HYPOGLYCEMIA
AB We evaluated the outcome of pregnancies followed between 1990 and 2000 in 93 women with type I diabetes, treated with conventional intensive insulin therapy (n=68) or continuous subcutaneous insulin infusion (n=25). We evaluated metabolic control (fasting and 1-hour post-prandial plasma glucose and HbA1c levels), spontaneous or induced abortions, time and mode of delivery, maternal outcome (pregnancy-induced hypertension, preeclampsia, placental insufficiency. hydramnios. hypoglycemic coma, ketoacidosis) and fetal outcome (weight, hypoglycemia, hypocalcemia, hyperbilirubinemia, fetal distress, asphyxia, hyaline membrane disease. polycythemia, shoulder dystocia, malformations). Patients treated with insulin pump more frequently had background retinopathy and clinical neuropathy. No significant differences were observed between the two groups in metabolic control and maternal outcome. Glycemic control, nonoptimal in the prepregnancy state, improved significantly during pregnancy, as shown by the progressive reduction in HbA1c levels. As regards fetal outcome, no differences were observed between the two groups in morbidity and especially in malformation rate. Patients with malformed babies did not have optimal metabolic control at conception. Thus, maternal and perinatal outcomes were comparable in patients treated with insulin pump and continuous subcutaneous insulin therapy, and depended on metabolic control. In patients in higher White's class and with more unstable glycemia, we achieved metabolic control and outcomes comparable with those of women of lower White's class and more stable glycemic values using the insulin pump. Our data suggest that insulin pump therapy is useful in problematic, complicated cases of women who want a baby.
C1 Univ Padua, Dept Med & Surg Sci, I-35137 Padua, Italy.
   Univ Padua, Dept Clin & Expt Med, I-35100 Padua, Italy.
   San Bortolo Hosp, Dept Metab Dis, Vicenza, Italy.
   Dept Diabetol ASS2 Isontina, Monfalcone, GO, Italy.
   Univ Padua, Dept Pediat, I-35100 Padua, Italy.
RP Lapolla, A (reprint author), Univ Padua, Dept Med & Surg Sci, Via E Vendramini 7, I-35137 Padua, Italy.
CR Bode BW, 1996, DIABETES CARE, V19, P324, DOI 10.2337/diacare.19.4.324
   CARTA Q, 1986, DIABETES METAB, V12, P121
   Casson IF, 1997, BRIT MED J, V315, P275, DOI 10.1136/bmj.315.7103.275
   COUSTAN DR, 1986, JAMA-J AM MED ASSOC, V255, P631, DOI 10.1001/jama.255.5.631
   Diabet Control Complications Trial Res Grp, 1996, AM J OBSTET GYNECOL, V174, P1343
   FUHRMANN K, 1983, DIABETES CARE, V6, P219, DOI 10.2337/diacare.6.3.219
   Gabbe SG, 2000, AM J OBSTET GYNECOL, V182, P1283, DOI 10.1067/mob.2000.106182
   GOLDMAN JA, 1986, AM J OBSTET GYNECOL, V155, P293, DOI 10.1016/0002-9378(86)90812-4
   HAAKENS K, 1990, J INTERN MED, V228, P457, DOI 10.1111/j.1365-2796.1990.tb00263.x
   HANSON U, 1990, DIABETOLOGIA, V33, P100, DOI 10.1007/BF00401047
   Holing EV, 1998, DIABETES CARE, V21, P889, DOI 10.2337/diacare.21.6.889
   Home P D, 1984, Diabet Med, V1, P41
   HUGGETT ASG, 1957, LANCET, V2, P368
   JAYNES PK, 1985, CLIN BIOCHEM, V18, P32, DOI 10.1016/S0009-9120(85)80020-5
   JORNSAY DL, 1998, DIABETES SPECTRUM, V11, P26
   Kaufman FR, 1999, DIABETES-METAB RES, V15, P338, DOI 10.1002/(SICI)1520-7560(199909/10)15:5<338::AID-DMRR57>3.3.CO;2-P
   KEEN H, 1963, LANCET, V2, P913
   KITZMILLER JL, 1985, OBSTET GYNECOL, V66, P606
   KITZMILLER JL, 1983, MANAGING OB GYN EMER, P44
   KJAER K, 1992, AM J OBSTET GYNECOL, V166, P1412, DOI 10.1016/0002-9378(92)91613-F
   LAURITZEN T, 1983, DIABETOLOGIA, V24, P326
   Lenhard MJ, 2001, ARCH INTERN MED, V161, P2293, DOI 10.1001/archinte.161.19.2293
   LINDENBAUM C, 1993, J REPROD MED, V38, P306
   LUCAS MJ, 1989, AM J OBSTET GYNECOL, V161, P426, DOI 10.1016/0002-9378(89)90536-X
   McElvy S S, 2000, J Matern Fetal Med, V9, P14
   MELANI F, 1970, P NATL ACAD SCI USA, V67, P148, DOI 10.1073/pnas.67.1.148
   MIDTHJELL K, 1994, DIABETES CARE, V17, P1235, DOI 10.2337/diacare.17.10.1235
   MIODOVNIK M, 1988, DIABETES CARE, V11, P713, DOI 10.2337/diacare.11.9.713
   MONTORO MN, 1993, AM J PERINAT, V10, P17, DOI 10.1055/s-2007-994692
   Nordstrom L, 1998, ACTA OBSTET GYN SCAN, V77, P284, DOI 10.1034/j.1600-0412.1998.770305.x
   Platt MJ, 2002, DIABETIC MED, V19, P216, DOI 10.1046/j.1464-5491.2002.00665.x
   Reece EA, 2000, CLIN OBSTET GYNECOL, V43, P32, DOI 10.1097/00003081-200003000-00004
   Simmons D, 2001, DIABETES CARE, V24, P2078, DOI 10.2337/diacare.24.12.2078
   SKYLER JS, 1981, DIABETES CARE, V4, P311, DOI 10.2337/diacare.4.2.311
   Suhonen L, 2000, DIABETOLOGIA, V43, P79, DOI 10.1007/s001250050010
   TAMBORLANE WV, 1979, NEW ENGL J MED, V300, P573, DOI 10.1056/NEJM197903153001101
   Vaarasmaki M, 2002, DIABETIC MED, V19, P589, DOI 10.1046/j.1464-5491.2002.00756.x
   WILLHOITE MB, 1993, DIABETES CARE, V16, P450, DOI 10.2337/diacare.16.2.450
   YLINEN K, 1984, BRIT MED J, V289, P345, DOI 10.1136/bmj.289.6441.345
   YLINEN K, 2002, DIABETES CARE S1, V25, pS82
   YLINEN K, 1998, DIABETES CARE S1, V21, pS56
NR 41
TC 34
Z9 34
U1 0
U2 1
PU SPRINGER-VERLAG ITALIA SRL
PI MILAN
PA VIA DECEMBRIO, 28, MILAN, 20137, ITALY
SN 0940-5429
EI 1432-5233
J9 ACTA DIABETOL
JI Acta Diabetol.
PD SEP
PY 2003
VL 40
IS 3
BP 143
EP 149
DI 10.1007/s00592-003-0103-1
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 737XH
UT WOS:000186257300006
PM 14605971
DA 2019-01-08
ER

PT J
AU Kalro, BN
AF Kalro, BN
TI Impaired fertility caused by endocrine dysfunction in women
SO ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA
LA English
DT Review
ID CONGENITAL ADRENAL-HYPERPLASIA; DEPENDENT DIABETIC WOMEN; RECURRENT
   PREGNANCY LOSS; LONG-TERM TREATMENT; FETAL GROWTH DELAY;
   CUSHINGS-SYNDROME; ANTITHYROID ANTIBODIES; SPONTANEOUS-ABORTION;
   21-HYDROXYLASE DEFICIENCY; PITUITARY-TUMORS
AB The inability to conceive is often a distressing experience for couples. This article addresses the impact of thyroid, adrenal, growth hormone disorders, and diabetes on female reproduction.
C1 Univ Pittsburgh, Sch Med, Magee Womens Hosp, Dept Obstet, Pittsburgh, PA 15213 USA.
   Univ Pittsburgh, Sch Med, Magee Womens Hosp, Dept Gynecol, Pittsburgh, PA 15213 USA.
   Univ Pittsburgh, Sch Med, Magee Womens Hosp, Dept Reprod Sci, Pittsburgh, PA 15213 USA.
RP Kalro, BN (reprint author), Univ Pittsburgh, Sch Med, Magee Womens Hosp, Dept Obstet, 300 Halket St, Pittsburgh, PA 15213 USA.
EM bkalro@mail.magee.edu
CR ABELOVE WA, 1954, J CLIN ENDOCR METAB, V14, P32, DOI 10.1210/jcem-14-1-32
   ABOULKHAIR SA, 1964, CLIN SCI, V27, P195
   AHONEN P, 1987, J CLIN ENDOCR METAB, V64, P494, DOI 10.1210/jcem-64-3-494
   AKANDE EO, 1975, BRIT J OBSTET GYNAEC, V82, P552, DOI 10.1111/j.1471-0528.1975.tb00685.x
   AKANDE EO, 1975, BRIT J OBSTET GYNAEC, V82, P541, DOI 10.1111/j.1471-0528.1975.tb00684.x
   ANDERSON DC, 1974, CLIN ENDOCRINOL, V3, P69, DOI 10.1111/j.1365-2265.1974.tb03298.x
   ANSELL JE, 1991, WERNER INGBARS THYRO, P1022
   Ares S, 1997, J CLIN ENDOCR METAB, V82, P1704, DOI 10.1210/jc.82.6.1704
   ARON DC, 1990, AM J OBSTET GYNECOL, V162, P244, DOI 10.1016/0002-9378(90)90859-6
   ARON DC, 1987, ENDOCRIN METAB CLIN, V16, P705, DOI 10.1016/S0889-8529(18)30470-5
   Atchley DW, 1933, J CLIN INVEST, V12, P297, DOI 10.1172/JCI100504
   BALEN AH, 1990, BRIT J OBSTET GYNAEC, V97, P536, DOI 10.1111/j.1471-0528.1990.tb02526.x
   BETTERLE C, 1993, CLIN ENDOCRINOL, V39, P35, DOI 10.1111/j.1365-2265.1993.tb01748.x
   BEVAN JS, 1987, CLIN ENDOCRINOL, V27, P225, DOI 10.1111/j.1365-2265.1987.tb01148.x
   BIGAZZI M, 1979, J CLIN ENDOCR METAB, V48, P9, DOI 10.1210/jcem-48-1-9
   BLOCH B, 1979, S AFR MED J, V55, P57
   BLUMBERG DL, 1988, NEW ENGL J MED, V319, P951
   BOCCUZZI G, 1975, J CLIN ENDOCR METAB, V40, P892, DOI 10.1210/jcem-40-5-892
   BOHNET HG, 1981, LANCET, V2, P1278
   BRADFORD JMW, 1995, REV PSYCHIAT, V14, P755
   BRAY GA, 1968, J CLIN INVEST, V47, P1640, DOI 10.1172/JCI105855
   Brenner PF, 1996, AM J OBSTET GYNECOL, V175, P766, DOI 10.1016/S0002-9378(96)80082-2
   BRENT F, 1950, AM J SURG, V79, P645, DOI 10.1016/0002-9610(50)90329-1
   BROWN ZA, 1992, DIABETES CARE, V15, P613, DOI 10.2337/diacare.15.5.613
   BUESCHER MA, 1992, OBSTET GYNECOL, V79, P130
   Bussen S, 2000, HUM REPROD, V15, P545, DOI 10.1093/humrep/15.3.545
   CAMARGO CA, 1989, ENDOCRINE DISORDERS, P165
   CARON P, 1995, NEW ENGL J MED, V333, P601, DOI 10.1056/NEJM199508313330918
   Colao A, 1997, J CLIN ENDOCR METAB, V82, P2777, DOI 10.1210/jc.82.9.2777
   COUSINS L, 1983, AM J OBSTET GYNECOL, V145, P411, DOI 10.1016/0002-9378(83)90309-5
   CRANE JP, 1981, FERTIL STERIL, V36, P477
   Daniels GH, 1995, ENDOCR PRACT, V1, P287
   DAVIS LE, 1988, OBSTET GYNECOL, V72, P108
   DAVIS LE, 1989, AM J OBSTET GYNECOL, V160, P63, DOI 10.1016/0002-9378(89)90088-4
   de Menis E, 1999, J CLIN ENDOCR METAB, V84, P1489, DOI 10.1210/jc.84.4.1489
   DELPOZO E, 1979, OBSTET GYNECOL, V53, P282
   Dendrinos S, 2000, GYNECOL ENDOCRINOL, V14, P270, DOI 10.3109/09513590009167693
   DIAMOND MP, 1989, J REPROD FERTIL, V86, P1
   DICKER D, 1988, AM J OBSTET GYNECOL, V158, P1161, DOI 10.1016/0002-9378(88)90245-1
   DISTILLER LA, 1975, DIABETES, V24, P378, DOI 10.2337/diabetes.24.4.378
   DIXIT PK, 1962, ENDOCRINOLOGY, V71, P745, DOI 10.1210/endo-71-5-745
   DJURSING H, 1983, J CLIN ENDOCR METAB, V56, P1016, DOI 10.1210/jcem-56-5-1016
   DRUCKER D, 1984, AM J OBSTET GYNECOL, V149, P229, DOI 10.1016/0002-9378(84)90206-0
   EDEN JA, 1989, AUST NZ J OBSTET GYN, V29, P268, DOI 10.1111/j.1479-828X.1989.tb01738.x
   EDWARDS CRW, 1971, BRIT MED J, V3, P462, DOI 10.1136/bmj.3.5772.462
   ELIAS KA, 1987, ENDOCRINOLOGY, V120, P617, DOI 10.1210/endo-120-2-617
   EZZAT S, 1992, ENDOCRIN METAB CLIN, V21, P753, DOI 10.1016/S0889-8529(18)30212-3
   FEDELE L, 1980, CONTRACEPT FERTIL S, V5, P501
   FELDMAN S, 1992, J CLIN ENDOCR METAB, V74, P635, DOI 10.1210/jc.74.3.635
   FISCH RO, 1974, OBSTET GYNECOL, V43, P861
   FITZGERALD PA, 1982, J CLIN ENDOCR METAB, V54, P413, DOI 10.1210/jcem-54-2-413
   FROHMAN LA, 1991, J CLIN ENDOCR METAB, V72, P1175, DOI 10.1210/jcem-72-6-1175
   FUHRMANN K, 1984, EXP CLIN ENDOCRINOL, V83, P173, DOI 10.1055/s-0029-1210327
   FUHRMANN K, 1983, DIABETES CARE, V6, P219, DOI 10.2337/diacare.6.3.219
   Ghazeeri GS, 2001, CURR OPIN OBSTET GYN, V13, P287, DOI 10.1097/00001703-200106000-00007
   GLASS RH, 1978, FERTIL STERIL, V29, P257
   GLINOER D, 1994, J CLIN ENDOCR METAB, V79, P197, DOI 10.1210/jc.79.1.197
   Glinoer D, 1999, FERTIL STERIL, V72, P373
   GOLDSMITH RE, 1952, J CLIN ENDOCR METAB, V12, P846, DOI 10.1210/jcem-12-7-846
   GOODNER CJ, 1961, J CLIN INVEST, V40, P261, DOI 10.1172/JCI104252
   GORMLEY MJJ, 1982, CLIN ENDOCRINOL, V16, P283, DOI 10.1111/j.1365-2265.1982.tb00718.x
   GREENMAN GW, 1962, NEW ENGL J MED, V267, P426, DOI 10.1056/NEJM196208302670902
   GREER MA, 1987, INTERNAL MED, P1918
   GRIMES EM, 1973, OBSTET GYNECOL, V42, P550, DOI 10.1097/00006250-197310000-00012
   Haddow JE, 1999, NEW ENGL J MED, V341, P549, DOI 10.1056/NEJM199908193410801
   HANSON TH, 1974, JAMA-J AM MED ASSOC, V280, P963
   HARGER JH, 1983, OBSTET GYNECOL, V62, P574
   HELLEDAY J, 1993, J CLIN ENDOCR METAB, V76, P933, DOI 10.1210/jc.76.4.933
   Herman-Bonert V, 1998, J CLIN ENDOCR METAB, V83, P727, DOI 10.1210/jc.83.3.727
   Hierl T, 2000, CLIN ENDOCRINOL, V53, P262, DOI 10.1046/j.1365-2265.2000.01058.x
   HOFFENBERG R, 1987, OXFORD TXB MED, P1030
   Holdaway I M, 1999, Pituitary, V2, P29, DOI 10.1023/A:1009965803750
   HOLMESWALKER DJ, 1995, CLIN ENDOCRINOL, V43, P291
   HONBO KS, 1978, AM J MED, V64, P782, DOI 10.1016/0002-9343(78)90517-X
   HUGHES IA, 1982, HORM RES, V16, P100, DOI 10.1159/000179489
   HURLEY LS, 1976, J NUTR, V106, P1254
   Irvine WJ, 1972, CLINICS ENDOCRINOLOG, V1, P549
   JADRESIC A, 1982, Q J MED, V51, P189
   JENSEN CC, 1954, ACTA ENDOCRINOL-COP, V15, P351, DOI 10.1530/acta.0.0150351
   Joshi J V, 1993, J Postgrad Med, V39, P137
   JOVANOVIC L, 1981, AM J MED, V71, P921, DOI 10.1016/0002-9343(81)90301-6
   JURNEY TH, 1981, CLIN ENDOCRINOL, V14, P539, DOI 10.1111/j.1365-2265.1981.tb02963.x
   Kaider AS, 1999, AM J REPROD IMMUNOL, V42, P335
   KALTER H, 1987, AM J OBSTET GYNECOL, V156, P1243, DOI 10.1016/0002-9378(87)90156-6
   KITZMILLER JL, 1978, AM J OBSTET GYNECOL, V131, P560, DOI 10.1016/0002-9378(78)90120-5
   KJAER K, 1992, J CLIN ENDOCR METAB, V75, P524, DOI 10.1210/jc.75.2.524
   KLEINBERG DL, 1977, NEW ENGL J MED, V296, P589, DOI 10.1056/NEJM197703172961103
   KLINGENSMITH GJ, 1977, J PEDIATR-US, V90, P996, DOI 10.1016/S0022-3476(77)80581-7
   KOERTEN JM, 1986, AM J OBSTET GYNECOL, V154, P626, DOI 10.1016/0002-9378(86)90616-2
   KUHNLE U, 1995, EUR J PEDIATR, V154, P708, DOI 10.1007/BF02276713
   Kutteh WH, 1999, HUM REPROD, V14, P2886, DOI 10.1093/humrep/14.11.2886
   Kutteh WH, 1999, FERTIL STERIL, V71, P843, DOI 10.1016/S0015-0282(99)00091-6
   la Marca A, 1999, HUM REPROD, V14, P298, DOI 10.1093/humrep/14.2.298
   LAMBERTS SWJ, 1982, J CLIN ENDOCR METAB, V54, P286, DOI 10.1210/jcem-54-2-286
   LANDGREN BM, 1990, INT J GYNECOL OBSTET, V32, P95, DOI 10.1016/0020-7292(90)90473-X
   LANDOLT AM, 1989, NEW ENGL J MED, V320, P671
   LEJEUNE B, 1993, BRIT J OBSTET GYNAEC, V100, P669, DOI 10.1111/j.1471-0528.1993.tb14236.x
   Lincoln SR, 1999, J REPROD MED, V44, P455
   LONGCOPE C, 1991, WERNER INGBARS THYRO, P828
   LONGCOPE C, 1991, WERNER INGBARS THYRO, P1052
   LOUVET JP, 1979, LANCET, V1, P1032
   MACGIBBON AL, 1995, AUST NZ J OBSTET GYN, V35, P217, DOI 10.1111/j.1479-828X.1995.tb01878.x
   MAGARO M, 1992, CLIN EXP RHEUMATOL, V10, P67
   MAN EB, 1971, AM J OBSTET GYNECOL, V111, P905, DOI 10.1016/0002-9378(71)90945-8
   MAN EB, 1975, PERINATAL THYROID PH, P117
   Matalon ST, 2001, AM J REPROD IMMUNOL, V45, P72, DOI 10.1111/j.8755-8920.2001.450202.x
   MCEVOY GK, 1987, DRUG INFORMATION 87, P1874
   Melmed Shlomo, 1995, P413
   Meyer-Bahlburg HFL, 1999, J CLIN ENDOCR METAB, V84, P1844, DOI 10.1210/jc.84.6.1844
   MILLS JL, 1979, DIABETES, V28, P292, DOI 10.2337/diabetes.28.4.292
   MILLS JL, 1988, NEW ENGL J MED, V318, P671, DOI 10.1056/NEJM198803173181104
   MIMOUNI F, 1987, OBSTET GYNECOL, V70, P85
   MIODOVNIK M, 1984, AM J OBSTET GYNECOL, V150, P372, DOI 10.1016/S0002-9378(84)80141-6
   MIODOVNIK M, 1985, AM J OBSTET GYNECOL, V153, P439, DOI 10.1016/0002-9378(85)90083-3
   MOLEY KH, 1991, J REPROD FERTIL, V93, P325
   MOLEY KH, 1994, HUM REPROD, V9, P113, DOI 10.1093/oxfordjournals.humrep.a138298
   MOLITCH ME, 1992, ENDOCRIN METAB CLIN, V21, P597, DOI 10.1016/S0889-8529(18)30204-4
   MONTINI M, 1990, J ENDOCRINOL INVEST, V13, P193, DOI 10.1007/BF03349537
   MONTORO M, 1981, ANN INTERN MED, V94, P31, DOI 10.7326/0003-4819-94-1-31
   Mozas J, 1999, INT J GYNECOL OBSTET, V65, P71, DOI 10.1016/S0020-7292(98)00221-5
   MULAIKAL RM, 1987, NEW ENGL J MED, V316, P178, DOI 10.1056/NEJM198701223160402
   NADER S, 1999, MATERNAL FETAL MED, P1015
   NAGAMANI M, 1980, OBSTET GYNECOL, V56, P258
   NASSER M, 2002, MAYO CLIN P, V77, P297
   OHARE JA, 1987, AM J MED, V83, P1080, DOI 10.1016/0002-9343(87)90945-4
   PARRA A, 1966, AM J MED, V40, P961, DOI 10.1016/0002-9343(66)90208-7
   PEDERSEN JF, 1981, BRIT MED J, V283, P269, DOI 10.1136/bmj.283.6286.269
   PLOCKINGER U, 1990, J CLIN ENDOCR METAB, V71, P1658
   PLOTZ CM, 1952, AM J MED, V13, P597, DOI 10.1016/0002-9343(52)90027-2
   PONTIKIDES N, 1990, J ENDOCRINOL INVE S2, V13, P164
   PRATT D, 1993, AM J OBSTET GYNECOL, V168, P837, DOI 10.1016/S0002-9378(12)90830-3
   PRATT DE, 1993, FERTIL STERIL, V60, P1001
   REIS RA, 1958, AM J OBSTET GYNECOL, V76, P1148, DOI 10.1016/0002-9378(58)90194-7
   RODRIGUEZ S, 1981, J ENDOCRINOL INVEST, V4, P37, DOI 10.1007/BF03349411
   ROSENFIELD RL, 1980, OBSTET GYNECOL, V56, P208
   RZEPKA I, 1977, GINEKOL POL, V46, P157
   SAKAKURA M, 1975, J CLIN ENDOCR METAB, V40, P774, DOI 10.1210/jcem-40-5-774
   SEMPLE CG, 1985, BRIT J OBSTET GYNAEC, V92, P295
   SHUM L, 1991, DIABETOLOGIA, V34, P289, DOI 10.1007/BF00404998
   SONINO N, 1987, NEW ENGL J MED, V317, P812
   SOUTH SA, 1993, J CLIN ENDOCR METAB, V76, P1048, DOI 10.1210/jc.76.4.1048
   SOUTHREN AL, 1974, J CLIN ENDOCR METAB, V38, P207, DOI 10.1210/jcem-38-2-207
   STAGNAROGREEN A, 1990, JAMA-J AM MED ASSOC, V264, P1422, DOI 10.1001/jama.264.11.1422
   Stewart-Akers AM, 1998, AM J REPROD IMMUNOL, V39, P1
   STRATFORD GA, 2000, HUM FERTIL, V3, P203
   STRICKLAND DM, 1990, AM J OBSTET GYNECOL, V163, P262, DOI 10.1016/S0002-9378(11)90744-3
   TACHMAN ML, 1984, ENDOCR REV, V5, P456, DOI 10.1210/edrv-5-3-456
   TAFT P, 1970, AUSTRALAS ANN MED, V19, P295
   Takeuchi K, 1999, OBSTET GYNECOL, V93, P848, DOI 10.1016/S0029-7844(98)00461-X
   THO PT, 1979, FERTIL STERIL, V32, P389
   THOMAS R, 1987, OBSTET GYNECOL, V70, P789
   Tolino A, 1991, Acta Eur Fertil, V22, P275
   TOYOSHIMA K, 1991, INT J FERTIL, V36, P89
   TUIMALA R, 1985, ANN CHIR GYNAECOL FE, V74, P61
   WHITE P, 1932, DIABETES CHILDHOOD A, P110
   WILANSKY DL, 1989, AM J OBSTET GYNECOL, V160, P673, DOI 10.1016/S0002-9378(89)80056-0
   WINIKOFF D, 1975, BRIT J OBSTET GYNAEC, V82, P760, DOI 10.1111/j.1471-0528.1975.tb00719.x
   Winters SJ, 1997, ENDOCRINOLOGIST, V7, P167, DOI 10.1097/00019616-199707030-00006
   YAMADA T, 1976, J CLIN ENDOCR METAB, V42, P87
   YAP AS, 1990, AM J OBSTET GYNECOL, V163, P477, DOI 10.1016/0002-9378(90)91178-F
   YESHAYA A, 1995, INT J FERTIL MENOP S, V40, P269
   ZAKARIJA M, 1983, J CLIN ENDOCR METAB, V57, P1036, DOI 10.1210/jcem-57-5-1036
   ZELISSEN PMJ, 1995, J AUTOIMMUN, V8, P121, DOI 10.1006/jaut.1995.0009
   ZUSMAN I, 1987, TERATOLOGY, V35, P77, DOI 10.1002/tera.1420350111
NR 164
TC 12
Z9 13
U1 1
U2 2
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0889-8529
EI 1558-4410
J9 ENDOCRIN METAB CLIN
JI Endocrinol. Metabol. Clin. North Amer.
PD SEP
PY 2003
VL 32
IS 3
BP 573
EP +
DI 10.1016/S0889-8529(03)00041-0
PG 21
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 727DL
UT WOS:000185641300003
PM 14575026
DA 2019-01-08
ER

PT J
AU Goldacre, MJ
   Duncan, ME
   Cook-Mozaffari, P
   Griffith, M
AF Goldacre, MJ
   Duncan, ME
   Cook-Mozaffari, P
   Griffith, M
TI Trends in mortality rates comparing underlying-cause and multiple-cause
   coding in an English population 1979-1998
SO JOURNAL OF PUBLIC HEALTH MEDICINE
LA English
DT Article
DE death certificates; multiple-cause coding; mortality
ID DISEASE
AB Until recently, national coding and analysis of routine mortality statistics in most countries included only underlying cause of death. There were changes in the rules for selection and coding of underlying cause in England in 1984 and 1993. We report on trends in mortality rates in an English region from 1979 to 1998, comparing multiple-cause and underlying-cause coded rates, for individual diseases that were affected by coding changes. Among many others, these include pneumonia, venous thromboembolism, heart failure, respiratory distress syndrome, tuberculosis, diabetes, dementia, alcohol and drug abuse, epilepsy, multiple sclerosis, stroke, asthma, peptic ulcer, appendicitis, and cancers of the breast, colon and prostate. Comparisons over time of mortality rates based on underlying cause alone will be misleading when the time-period crosses years in which rules changed for selecting underlying cause.
C1 Univ Oxford, Dept Publ Hlth, Inst Hlth Sci, Unit Hlth Care Epidemiol, Oxford OX3 7LF, England.
RP Goldacre, MJ (reprint author), Univ Oxford, Dept Publ Hlth, Inst Hlth Sci, Unit Hlth Care Epidemiol, Oxford OX3 7LF, England.
EM michael.goldacre@dphpc.ox.ac.uk
RI Duncan, Marie/A-4081-2012
CR GOLDACRE MJ, 1993, J EPIDEMIOL COMMUN H, V47, P491, DOI 10.1136/jech.47.6.491
   GURALNICK L, 1966, J CHRON DIS, V19, P979, DOI 10.1016/0021-9681(66)90031-2
   HARVEY I, 1991, LANCET, V338, P1407, DOI 10.1016/0140-6736(91)92291-9
   HEASMAN M, 1966, STUDIES MED POPULATI, V20
   *OFF NAT STAT, 1996, MORT STAT CAUS 1993, pR25
   *OFF POP CENS SURV, 1985, SER OFF POP CENS SUR, pR5
   Rooney C, 1996, Popul Trends, P29
   World Health Organisation, 1977, MAN INT STAT CLASS D, V1, P699
NR 8
TC 50
Z9 52
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0957-4832
J9 J PUBLIC HEALTH MED
JI J. Public Health Med.
PD SEP
PY 2003
VL 25
IS 3
BP 249
EP 253
DI 10.1093/pubmed/fdg058
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 723JX
UT WOS:000185430200013
PM 14575203
OA Bronze
DA 2019-01-08
ER

PT J
AU Eaton, SEM
   Harris, ND
   Ibrahim, S
   Patel, KA
   Selmi, F
   Radatz, M
   Ward, JD
   Tesfaye, S
AF Eaton, SEM
   Harris, ND
   Ibrahim, S
   Patel, KA
   Selmi, F
   Radatz, M
   Ward, JD
   Tesfaye, S
TI Increased sural nerve epineurial blood flow in human subjects with
   painful diabetic neuropathy
SO DIABETOLOGIA
LA English
DT Article
DE diabetes mellitus; diabetic neuropathy; painful; pain; hypoxia;
   epineurium; fluorescein angiography; spectrophotometry
ID CAPILLARY ABNORMALITIES; POLYNEUROPATHY; PATHOGENESIS; SEVERITY;
   PATTERNS; DAMAGE
AB Aims/hypothesis. The pathogenesis of painful diabetic neuropathy remains unknown. As a consequence we still do not have any effective, rational treatments and a greater understanding of the mechanisms is urgently required. Previous studies have shown no consistent morphological differences in the nerves of patients with and without painful neuropathy. The aim of this study was to compare epineurial haemodynamics in patients with chronic painful and painless neuropathy.
   Methods. The techniques of microlightguide spectrophotometry and fluorescein angiography were used to measure epineurial intravascular oxygen saturation and blood flow respectively. Eleven patients with painful and eight with painless neuropathy were studied, with the groups matched carefully in terms of severity of neuropathy and diabetes control.
   Results. Intravascular oxygen saturation was higher in the painful neuropathy group compared to those without pain (median 73.8% vs 67.7%, respectively; p=0.021). Fluorescein rise time was also faster in those with painful symptoms (median 18.3 s vs 53.6 s; p=0.046) indicating higher epineurial blood flow in these subjects.
   Conclusion/interpretation. These results indicate that there are distinct differences in haemodynamics within the epineurium of the sural nerve in subjects with painful and painless neuropathy. Haemodynamic factors could therefore have an important role in the pathogenesis of neuropathic pain and might offer further insight into potential treatments for this distressing condition.
C1 Royal Hallamshire Hosp, Diabet Res Unit, Sheffield S10 2JF, S Yorkshire, England.
   Royal Hallamshire Hosp, Dept Phys Med, Sheffield S10 2JF, S Yorkshire, England.
   Royal Hallamshire Hosp, Dept Surg & Anaesthet Sci, Sheffield S10 2JF, S Yorkshire, England.
   Royal Hallamshire Hosp, Dept Neurosurg, Sheffield S10 2JF, S Yorkshire, England.
RP Tesfaye, S (reprint author), Royal Hallamshire Hosp, Diabet Res Unit, Glossop Rd, Sheffield S10 2JF, S Yorkshire, England.
OI Tesfaye, Solomon/0000-0003-1190-1472
CR ARCHER AG, 1984, DIABETOLOGIA, V27, P563, DOI 10.1007/BF00276968
   ASBURY AK, 1984, NEUROLOGY, V34, P1587, DOI 10.1212/WNL.34.12.1587
   BRITLAND ST, 1990, DIABETES, V39, P909, DOI 10.2337/diabetes.39.8.909
   BRITLAND ST, 1990, DIABETES, V39, P898, DOI 10.2337/diabetes.39.8.898
   BROWN MJ, 1976, ARCH NEUROL-CHICAGO, V33, P164, DOI 10.1001/archneur.1976.00500030020004
   Cameron NE, 2001, DIABETOLOGIA, V44, P1973, DOI 10.1007/s001250100001
   DYCK PJ, 1988, MUSCLE NERVE, V11, P21, DOI 10.1002/mus.880110106
   Eaton S, 1999, DIABETES REV, V7, P312
   FRANK KH, 1989, PHYS MED BIOL, V34, P1883, DOI 10.1088/0031-9155/34/12/011
   Ibrahim S, 1999, PHYSIOL MEAS, V20, P65, DOI 10.1088/0967-3334/20/1/005
   Ibrahim S, 1999, DIABETOLOGIA, V42, P737, DOI 10.1007/s001250051222
   LLEWELYN JG, 1991, BRAIN, V114, P867, DOI 10.1093/brain/114.2.867
   LOW PA, 1987, MUSCLE NERVE, V10, P121, DOI 10.1002/mus.880100204
   MALIK RA, 1989, DIABETOLOGIA, V32, P92, DOI 10.1007/BF00505180
   MALIK RA, 1993, DIABETOLOGIA, V36, P454, DOI 10.1007/BF00402283
   Malik RA, 1997, DIABETES, V46, pS50, DOI 10.2337/diab.46.2.S50
   NEWRICK PG, 1986, BRIT MED J, V293, P1053, DOI 10.1136/bmj.293.6554.1053
   OBRIEN IAD, 1986, BRIT HEART J, V55, P348
   PERBECK L, 1985, CLIN PHYSIOL, V5, P281
   Tesfaye S, 1996, LANCET, V348, P1698, DOI 10.1016/S0140-6736(96)02467-1
   Tesfaye S, 1996, DIABETOLOGIA, V39, P329
   TESFAYE S, 1997, DIABETIC NEUROPATHY, P159
   TSIGOS C, 1993, DIABETES CARE, V16, P722, DOI 10.2337/diacare.16.5.722
   WATKINS PJ, 1984, BRIT MED J, V288, P168, DOI 10.1136/bmj.288.6412.168
   WATKINS PJ, 1983, DIABETOLOGIA, V25, P73
   Woolf CJ, 1999, LANCET, V353, P1959, DOI 10.1016/S0140-6736(99)01307-0
   YOUNG RJ, 1986, DIABETES, V35, P192, DOI 10.2337/diabetes.35.2.192
   YOUNG RJ, 1997, TXB DIABETES
NR 28
TC 42
Z9 42
U1 0
U2 1
PU SPRINGER-VERLAG
PI NEW YORK
PA 175 FIFTH AVE, NEW YORK, NY 10010 USA
SN 0012-186X
J9 DIABETOLOGIA
JI Diabetologia
PD JUL
PY 2003
VL 46
IS 7
BP 934
EP 939
DI 10.1007/s00125-003-1127-3
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 709VB
UT WOS:000184644300008
PM 12819899
OA Bronze
DA 2019-01-08
ER

PT J
AU Sussman, N
AF Sussman, N
TI The implications of weight changes with antipsychotic treatment
SO JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
LA English
DT Article; Proceedings Paper
CT International Meeting on Improvement Without Impairment in Psychotic and
   Mood Disorders
CY JUN 20-21, 2001
CL MONTREUX, SWITZERLAND
ID DEPENDENT DIABETES-MELLITUS; CORONARY HEART-DISEASE; LIPID
   ABNORMALITIES; BIPOLAR DISORDER; GLYCEMIC CONTROL; OBESE PATIENTS;
   BODY-WEIGHT; GAIN; SCHIZOPHRENIA; LEPTIN
AB Patients receiving treatment with atypical antipsychotics commonly experience weight gain, which can cause considerable distress and can have deleterious effects on cardiovascular health. Because of the associated weight gain and potential direct effects on glucose metabolism, atypical antipsychotics have also been linked to the development of type II diabetes mellitus. Data on long-term treatment with these agents show that clozapine and olanzapine, followed by risperidone, were associated with the greatest degree of weight gain. A large body of data suggests that during long-term treatment, patients receiving the atypical antipsychotic quetiapine experience minimal weight gain. Data also suggest that quetiapine treatment does not increase the risk of developing type II diabetes. The use of atypical antipsychotics is increasing, as these agents are being prescribed for schizophrenia in lieu of conventional antipsychotics. Furthermore, these drugs have efficacy for treating other conditions such as bipolar disorder. Physicians prescribing atypical antipsychotics must be aware of the risk of weight gain and its associated comorbidities.
C1 NYU, Sch Med, Dept Psychiat, New York, NY 10016 USA.
RP Sussman, N (reprint author), NYU, Sch Med, Dept Psychiat, 550 1St Ave, New York, NY 10016 USA.
CR Allison DB, 1999, AM J PSYCHIAT, V156, P1686
   Baile CA, 2000, ANNU REV NUTR, V20, P105, DOI 10.1146/annurev.nutr.20.1.105
   Bickerdike MJ, 1999, DIABETES OBES METAB, V1, P207, DOI 10.1046/j.1463-1326.1999.00037.x
   Brecher M, 2000, INT J PSYCHIAT CLIN, V4, P287, DOI 10.1080/13651500050517849
   Breum L, 1995, METABOLISM, V44, P1570, DOI 10.1016/0026-0495(95)90077-2
   Bustillo JR, 1996, AM J PSYCHIAT, V153, P817
   Bymaster FP, 1996, NEUROPSYCHOPHARMACOL, V14, P87, DOI 10.1016/0893-133X(94)00129-N
   Carnahan RM, 2001, PHARMACOTHERAPY, V21, P717, DOI 10.1592/phco.21.7.717.34575
   Casey DE, 2001, INT CLIN PSYCHOPHARM, V16, pS15, DOI 10.1097/00004850-200101001-00004
   Cassidy F, 1999, AM J PSYCHIAT, V156, P1417
   CHAN JM, 1994, DIABETES CARE, V17, P961, DOI 10.2337/diacare.17.9.961
   COLDITZ GA, 1995, ANN INTERN MED, V122, P481, DOI 10.7326/0003-4819-122-7-199504010-00001
   Conley RR, 2000, J CLIN PSYCHIAT, V61, P20
   Daubresse JC, 1996, OBES RES, V4, P391, DOI 10.1002/j.1550-8528.1996.tb00247.x
   Dixon L, 2000, SCHIZOPHRENIA BULL, V26, P903, DOI 10.1093/oxfordjournals.schbul.a033504
   Fakhoury WKH, 2001, INT CLIN PSYCHOPHARM, V16, P153, DOI 10.1097/00004850-200105000-00004
   Fontaine KR, 2001, PSYCHIAT RES, V101, P277, DOI 10.1016/S0165-1781(01)00234-7
   Ford ES, 1997, AM J EPIDEMIOL, V146, P214
   Green AI, 2000, GEN HOSP PSYCHIAT, V22, P224, DOI 10.1016/S0163-8343(00)00081-5
   Guille C, 2000, J CLIN PSYCHIAT, V61, P638, DOI 10.4088/JCP.v61n0907
   Hajduch E, 1999, J BIOL CHEM, V274, P13563, DOI 10.1074/jbc.274.19.13563
   HARRIS MI, 1995, NIH PUBLICATION, P1
   Henderson DC, 2000, AM J PSYCHIAT, V157, P975, DOI 10.1176/appi.ajp.157.6.975
   Henderson DC, 2002, CNS DRUGS, V16, P77, DOI 10.2165/00023210-200216020-00001
   Houseknecht KL, 1998, J ANIM SCI, V76, P1405
   HUTTUNEN M, 1995, J CLIN PSYCHOPHARM, V15, pS4, DOI 10.1097/00004714-199502001-00002
   Jeanrenaud B, 2001, ANNU REV MED, V52, P339, DOI 10.1146/annurev.med.52.1.339
   Kasper S, 2000, Expert Opin Pharmacother, V1, P783, DOI 10.1517/14656566.1.4.783
   KENNY SJ, 1995, NIH PUBLICATION, P47
   Kinon BJ, 2001, J CLIN PSYCHIAT, V62, P92, DOI 10.4088/JCP.v62n0204
   Kinon BJ, 1998, J CLIN PSYCHIAT, V59, P18
   Kraus T, 1999, AM J PSYCHIAT, V156, P312
   Kurzthaler I, 2001, J CLIN PSYCHIAT, V62, P32
   Maheux P, 1997, INT J OBESITY, V21, P97, DOI 10.1038/sj.ijo.0800372
   Martin BC, 2001, SCHIZOPHR RES, V47, P281, DOI 10.1016/S0920-9964(00)00108-0
   McIntyre RS, 2001, CAN J PSYCHIAT, V46, P273, DOI 10.1177/070674370104600308
   Melkersson KI, 2000, J CLIN PSYCHIAT, V61, P742, DOI 10.4088/JCP.v61n1006
   Melkersson KI, 1999, J CLIN PSYCHIAT, V60, P783, DOI 10.4088/JCP.v60n1112
   Nemeroff CB, 2000, J CLIN PSYCHIAT, V61, P19
   Newcomer JW, 2002, ARCH GEN PSYCHIAT, V59, P337, DOI 10.1001/archpsyc.59.4.337
   *NHLBI OB ED IN EX, 1998, NIH PUBL
   Nonogaki K, 1998, NAT MED, V4, P1152, DOI 10.1038/2647
   *PFIZ INC, 2001, GEOD PRESCR INF
   *PFIZ INC, 2000, BRIEF DOC ZELDOX CAP
   Reinstein MJ, 1999, CLIN DRUG INVEST, V18, P99, DOI 10.2165/00044011-199918020-00002
   RICHARD FJ, 1999, BIOL REPROD, V60, P10
   Rosengren A, 1999, EUR HEART J, V20, P269, DOI 10.1053/euhj.1998.1235
   Sernyak MJ, 2002, AM J PSYCHIAT, V159, P561, DOI 10.1176/appi.ajp.159.4.561
   Sowell MO, 2002, J CLIN ENDOCR METAB, V87, P2918, DOI 10.1210/jc.87.6.2918
   Sussman N, 2001, J CLIN PSYCHIAT, V62, P5
   UMBRICHT DSG, 1994, J CLIN PSYCHIAT, V55, P157
   Weigle DS, 1997, ANN ENDOCRINOL-PARIS, V58, P132
   WILLETT WC, 1995, JAMA-J AM MED ASSOC, V273, P461, DOI 10.1001/jama.273.6.461
   ZOLER ML, 1999, CLIN PSYCHIAT NEWS, V27, P20
NR 54
TC 54
Z9 57
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0271-0749
J9 J CLIN PSYCHOPHARM
JI J. Clin. Psychopharmacol.
PD JUN
PY 2003
VL 23
IS 3
SU 1
BP S21
EP S26
DI 10.1097/00004714-200306001-00005
PG 6
WC Pharmacology & Pharmacy; Psychiatry
SC Pharmacology & Pharmacy; Psychiatry
GA 699AH
UT WOS:000184033400005
PM 12832946
DA 2019-01-08
ER

PT J
AU Garcia-Patterson, A
   Martin, E
   Ubeda, J
   Maria, MA
   Adelantado, JM
   Ginovart, G
   de Leiva, A
   Corcoy, R
AF Garcia-Patterson, A
   Martin, E
   Ubeda, J
   Maria, MA
   Adelantado, JM
   Ginovart, G
   de Leiva, A
   Corcoy, R
TI Nurse-based management in patients with gestational diabetes
SO DIABETES CARE
LA English
DT Article
ID INTERNATIONAL WORKSHOP-CONFERENCE; PRIMARY-CARE; PRACTITIONERS;
   MELLITUS; RECOMMENDATIONS
AB Objective-To compare the rate of insulin treatment and perinatal outcome in women with gestational diabetes mellitus (GDM) under endocrinologist-based versus diabetes nurse-based metabolic management.
   Research Design and Methods-in a retrospective analysis, maternal characteristics, rate of insulin treatment, and perinatal outcome of patients with GDM delivering between 1 January 1995 and 30 June 1997 (n=244) receiving endocrinologist-based care were compared with those delivering between 1 July 1997 and 31 December 1999 (n=283) who received diabetes nurse-based care. The diabetes nurse's role was similar to that of an advanced practice nurse in the U.S. There were no changes in the metabolic goals and instruments or in obstetric and neonatal management. Quantitative data were compared with the Mann-Whitney U test and categorical data, with Fisher's exact test.
   Results-Maternal characteristics (age, BMI, family history of diabetes, prior glucose intolerance, gestational age, and blood glucose at diagnosis of GDM) did not differ between groups treated during the two periods. Rates of insulin treatment and perinatal Outcome (hypertension, preterm delivery, cesarean section, low Apgar score, macrosomia, small- and large-for-gestational-age newborns, obstetric trauma, major malformations, hypoglycermia, hypocalcemia, polycythemia, jaundice, respiratory distress, and mortality) were also similar in both groups.
   Conclusions-Comparison of periods of endocrinologist-based and diabetes nurse-based metabolic management of women with GDM showed no differences in the rate of insulin treatment and perinatal outcome. This supports a more active role of nurses in the management of women with GDM.
C1 Autonomous Univ Barcelona, Dept Endocrinol, Hosp Santa Creu & San Pau, Barcelona, Spain.
   Autonomous Univ Barcelona, Dept Obstet, Hosp Santa Creu & San Pau, Barcelona, Spain.
   Autonomous Univ Barcelona, Dept Pediat, Hosp Santa Creu & San Pau, Barcelona, Spain.
RP Corcoy, R (reprint author), Hosp Santa Creu & Sant Pau, Endocrinol & Nutr Dept, Avgda St Antoni Ma Claret 167, Barcelona 08025, Spain.
CR *AM DIAB ASS, 2002, DIABETES CARE S1, V25, pS94
   [Anonymous], 1990, AM J OBSTET GYNECOL, V163, P1689
   BANKS P, 1993, CLIN ED SERIES
   Barnes L P, 1994, MCN Am J Matern Child Nurs, V19, P175
   BURNIP R, 1976, AM J DIS CHILD, V130, P51, DOI 10.1001/archpedi.1976.02120020053008
   CARR S, 1989, OBSTET GYNECOL, V73, P727
   Corcoy R, 1988, AV DIABETOL, V1, P90
   Garcia-Patterson A, 1998, AM J OBSTET GYNECOL, V179, P481, DOI 10.1016/S0002-9378(98)70383-7
   Horrocks S, 2002, BRIT MED J, V324, P819, DOI 10.1136/bmj.324.7341.819
   KASSIRER JP, 1994, NEW ENGL J MED, V330, P204, DOI 10.1056/NEJM199401203300310
   Keohane N S, 1991, J Obstet Gynecol Neonatal Nurs, V20, P189, DOI 10.1111/j.1552-6909.1991.tb02530.x
   LANGER O, 1994, AM J OBSTET GYNECOL, V170, P1036, DOI 10.1016/S0002-9378(94)70097-4
   Meltzer S, 1998, CAN MED ASSOC J, V159, pS1
   MERAUD B, 1985, SOINS GYNECOL OBSTET, V54, P33
   METZGER BE, 1991, DIABETES, V40, P197, DOI 10.2337/diab.40.2.S197
   Metzger BE, 1998, DIABETES CARE, V21, pB161
   Mundinger MO, 2000, JAMA-J AM MED ASSOC, V283, P59, DOI 10.1001/jama.283.1.59
   Nagusky D, 1991, Nurse Pract Forum, V2, P196
   RENDERS CM, 2002, COCHRANE DATABASE SY, V1, DOI UNSP CD001481
   Robinson S, 1999, LANCET, V354, P1319, DOI 10.1016/S0140-6736(99)00342-6
   Simmons D, 2001, PRAC DIABETES INT, V18, P119
   SMITS MW, 1995, DIABETES EDUCATOR, V21, P129, DOI 10.1177/014572179502100209
   Vrijhoef HJM, 2001, J ADV NURS, V36, P546, DOI 10.1046/j.1365-2648.2001.02007.x
   WEINER CP, 1987, AM J OBSTET GYNECOL, V156, P1085, DOI 10.1016/0002-9378(87)90115-3
NR 24
TC 11
Z9 11
U1 1
U2 5
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
J9 DIABETES CARE
JI Diabetes Care
PD APR
PY 2003
VL 26
IS 4
BP 998
EP 1001
DI 10.2337/diacare.26.4.998
PG 4
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 724UP
UT WOS:000185505300005
PM 12663563
OA Bronze
DA 2019-01-08
ER

PT J
AU Melchionda, N
   Marchesini, G
   Apolone, G
   Cuzzolaro, M
   Mannucci, E
   Grossi, E
AF Melchionda, N
   Marchesini, G
   Apolone, G
   Cuzzolaro, M
   Mannucci, E
   Grossi, E
CA QUOVADIS Study Grp
TI The QUOVADIS Study: Features of obese Italian patients seeking treatment
   at specialist centers
SO DIABETES NUTRITION & METABOLISM
LA English
DT Article
DE obesity; anthropometry; quality of life; behavior; therapy
ID QUALITY-OF-LIFE; BODY-FAT DISTRIBUTION; PERSONS SEEKING; CHRONIC
   ILLNESS; HEALTH SURVEY; SUBJECTS SOS; WEIGHT-LOSS; MASS INDEX;
   QUESTIONNAIRE; OVERWEIGHT
AB Obesity is a major risk factor for several chronic diseases, but the burden associated with it also extends to psychosocial areas and to perceived health status. In 1999 an observational study on health-related quality of life in obesity was planned. The study was entirely web-based. Case Report Forms and the individual items of 7 self-administered questionnaires were directly implemented on a general database via an extranet system from 25 Italian centers. By December 2001, after enrolment had stopped, the database included anthropometric, socioeconomic and clinical data of 1944 patients (78% females). Weight-cycling was reported in over 80% of cases, overeating in 60-65%, structured physical activity in only 13-15%. Several chronic illnesses were associated. Whereas the prevalence of diabetes and hypertension was related to the degree of obesity, hyperlipidemia and coronary heart disease did not increase further with increasing obesity. A disturbed psychological mood was twice more common in females. Concern for present health was the main reason for seeking treatment in both genders; concern for body appearance was more common in females. Male subjects were more frequently assigned to dietary counseling and physical exercise, whereas in fen ales psychotherapy was more frequently considered. Various forms of behavioral approach were planned in approximately 50% of patients. Finally, very few patients were initially considered for pharmacological intervention or bariatric surgery. The study provides a comprehensive picture of Italian patients seeking treatment for obesity. Data on perceived health status, psychological well being, body image awareness, eating behavior disorders and psychopathological distress will provide clues to a comprehensive assessment of obesity, the effects of treatments and reasons for failure. (C) 2003, Editrice Kurtis.
C1 Univ Bologna, I-40126 Bologna, Italy.
   Mario Negri Inst Pharmacol Res, I-20157 Milan, Italy.
   Univ Roma La Sapienza, Rome, Italy.
   Univ Florence, Florence, Italy.
   Bracco Imaging SPA, Milan, Italy.
RP Marchesini, G (reprint author), Univ Bologna, Serv Malattie Mebab, Azienda Osped S Orsola Malpighi, Via Massarenti 9, I-40138 Bologna, Italy.
EM marchreg@med.unibo.it
RI Apolone, Giovanni/R-9799-2016
OI Apolone, Giovanni/0000-0001-5179-104X; Molinari,
   Enrico/0000-0001-8132-694X; VITACOLONNA, Ester/0000-0003-1756-661X;
   Compare, Angelo/0000-0002-3336-7920; Marchesini,
   Giulio/0000-0003-2407-9860
CR American Psychiatric Association, 2000, DIAGN STAT MAN MENT
   Apolone G, 1998, J CLIN EPIDEMIOL, V51, P1025, DOI 10.1016/S0895-4356(98)00094-8
   Apolone G, 2001, PHARMACOECONOMICS, V19, P187, DOI 10.2165/00019053-200119020-00005
   Astrup A, 2001, Public Health Nutr, V4, P499
   BERENSON GS, 2001, PREV CARDIOL, V4, P116
   Brownell K. D., 1995, EATING DISORDERS OBE
   Collazo-Clavell ML, 1999, MAYO CLIN PROC, V74, P1255, DOI 10.4065/74.12.1255
   DEROGATIS LR, 1976, BRIT J PSYCHIAT, V128, P280, DOI 10.1192/bjp.128.3.280
   DiPietro L, 1995, Exerc Sport Sci Rev, V23, P275
   DIPIETRO L, 1992, INT J OBESITY, V16, P745
   Doll HA, 2000, OBES RES, V8, P160, DOI 10.1038/oby.2000.17
   Dupuy HJ., 1984, ASSESSMENT QUALITY L, P170
   Finkelstein MM, 2000, J FAM PRACTICE, V49, P734
   Fontaine KR, 1996, J FAM PRACTICE, V43, P265
   Fontaine KR, 2000, INT J EAT DISORDER, V27, P101, DOI 10.1002/(SICI)1098-108X(200001)27:1<101::AID-EAT12>3.3.CO;2-4
   Fontaine KR, 1997, J NERV MENT DIS, V185, P120, DOI 10.1097/00005053-199702000-00011
   Fontaine KR, 1999, QUAL LIFE RES, V8, P275, DOI 10.1023/A:1008835602894
   GORMALLY J, 1982, ADDICT BEHAV, V7, P47, DOI 10.1016/0306-4603(82)90024-7
   Han TS, 1998, AM J PUBLIC HEALTH, V88, P1814, DOI 10.2105/AJPH.88.12.1814
   James PT, 2001, OBES RES, V9, p228S, DOI 10.1038/oby.2001.123
   KARLSSON J, 1995, J CLIN EPIDEMIOL, V48, P817, DOI 10.1016/0895-4356(94)00196-W
   Katz DA, 2000, J GEN INTERN MED, V15, P789, DOI 10.1046/j.1525-1497.2000.90906.x
   KLESGES RC, 1990, MED SCI SPORT EXER, V22, P690, DOI 10.1249/00005768-199010000-00022
   Kopelman P, 1999, J ROY COLL PHYS LOND, V33, P31
   Lean MEJ, 1998, EXP CLIN ENDOCR DIAB, V106, P22, DOI 10.1055/s-0029-1212032
   Mannucci E, 1999, ADDICT BEHAV, V24, P345, DOI 10.1016/S0306-4603(98)00055-0
   Marchesini G, 2000, DIABETES NUTR METAB, V13, P156
   Oster G, 1999, AM J PUBLIC HEALTH, V89, P1536, DOI 10.2105/AJPH.89.10.1536
   Prochaska JO, 1997, AM J HEALTH PROMOT, V12, P38, DOI 10.4278/0890-1171-12.1.38
   PROCHASKA JO, 1994, HEALTH PSYCHOL, V13, P47, DOI 10.1037/0278-6133.13.1.47
   RAND CSW, 1990, SOUTHERN MED J, V83, P1390, DOI 10.1097/00007611-199012000-00006
   Ray GT, 2000, MED CARE RES REV, V57, P92, DOI 10.1177/107755870005700106
   Rosmond R, 2000, BEHAV MED, V26, P90, DOI 10.1080/08964280009595757
   SOBAL J, 1991, CLIN SOCIOL REV, V9, P125
   SORENSEN TIA, 1982, HUM BIOL, V54, P765
   STUNKARD AJ, 1986, AM J PSYCHIAT, V143, P417
   STUNKARD AJ, 1985, J PSYCHOSOM RES, V29, P71, DOI 10.1016/0022-3999(85)90010-8
   STUNKARD AJ, 1992, AM J CLIN NUTR, V55, P524
   SULLIVAN M, 1993, INT J OBESITY, V17, P503
   Thompson D, 1999, ARCH INTERN MED, V159, P2177, DOI 10.1001/archinte.159.18.2177
   WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002
   Whitelaw DC, 2001, INT J OBESITY, V25, P1042, DOI 10.1038/sj.ijo.0801596
   Williams M, 1999, ENVIRON HIST, V4, P103, DOI 10.2307/3985331
   WILSON GT, 1994, ADV BEHAV RES THER, V16, P31, DOI 10.1016/0146-6402(94)90002-7
   WOOLEY SC, 1994, BMJ-BRIT MED J, V309, P655
NR 45
TC 28
Z9 28
U1 0
U2 3
PU EDITRICE KURTIS S R L
PI MILAN
PA VIA LUIGI ZOJA 30, 20153 MILAN, ITALY
SN 0394-3402
J9 DIABETES NUTR METAB
JI Diabetes Nutr. Metab.
PD APR
PY 2003
VL 16
IS 2
BP 115
EP 124
PG 10
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA 689KW
UT WOS:000183492700006
PM 12846451
DA 2019-01-08
ER

PT J
AU van der Ven, NCW
   Weinger, K
   Yi, J
   Pouwer, F
   Ader, H
   van der Ploeg, HM
   Snoek, FJ
AF van der Ven, NCW
   Weinger, K
   Yi, J
   Pouwer, F
   Ader, H
   van der Ploeg, HM
   Snoek, FJ
TI The confidence in diabetes self-care scale - Psychometric properties of
   a new measure of diabetes-specific self-efficacy in Dutch and US
   patients with type 1 diabetes
SO DIABETES CARE
LA English
DT Article
ID ADOLESCENTS; ADHERENCE; MELLITUS; BEHAVIORS; ADULTS; QUESTIONNAIRE;
   DEPRESSION; VARIABLES; DISTRESS; VALIDITY
AB Objective-To examine psychometric properties of the Confidence in Diabetes Self-Care (CIDS) scale, a newly developed instrument assessing diabetes-specific self-efficacy in Dutch and U.S. patients with type 1 diabetes.
   Research Design and Methods-Reliability and validity of the CIDS scale were evaluated in Dutch (n=151) and U.S. (n=190) outpatients with type 1 diabetes. In addition to the CIDS scale, assessment included HbA(1c) emotional distress, fear of hypoglycemia self-esteem, anxiety, depression, and self-care behavior. The Dutch sample completed additional measures on perceived burden and importance of self-care. Test-retest reliability was established in a second Dutch sample (n=62).
   Results-internal consistency (Cronbach's alpha=0.86 for Dutch patients and 0.90 U.S. patients) and test-retest reliability (Spearman's r=0.85, P<0.0001) of the CIDS scale were high. Exploratory factor analysis showed one strong general factor. Spearman's correlations between the CIDS scale and other measures were moderate and in the expected directions, and high HbA(1c) levels were associated with low CIDS scores in the U.S. sample only. Low CIDS scores were positively associated with self-care but not with glycemic control in the original samples. CIDS scores in the U.S. and Dutch samples did not show any statistically significant differences. U.S. men had higher CIDS scores than U.S. women.
   Conclusions-The CIDS scale is a reliable and valid measure of diabetes-specific self-efficacy for use in patients with type 1 diabetes. High psychometric similarity allows for cross-cultural comparisons.
C1 Vrije Univ Amsterdam, Med Ctr, Dept Psychol Med, NL-1081 BT Amsterdam, Netherlands.
   Vrije Univ Amsterdam, Res Inst Endocrinol Reprod & Metab, Med Ctr, Amsterdam, Netherlands.
   Joslin Diabet Ctr, Behav & Mental Hlth Res Sect, Boston, MA 02215 USA.
   Harvard Univ, Sch Med, Boston, MA USA.
   Vrije Univ Amsterdam, Inst Res Extramural Med, Med Ctr, Amsterdam, Netherlands.
RP van der Ven, NCW (reprint author), Vrije Univ Amsterdam, Med Ctr, Dept Psychol Med, Van Boechorststr 7, NL-1081 BT Amsterdam, Netherlands.
EM ncw.van_der_ven.psychol@med.vu.nl
FU NIDDK NIH HHS [DK-42315, R01 DK042315]
CR Aalto AM, 1997, PATIENT EDUC COUNS, V30, P215, DOI 10.1016/S0738-3991(96)00963-9
   Aalto AM, 1997, INT J BEHAV MED, V4, P191, DOI 10.1207/s15327558ijbm0403_1
   Anderson RM, 2000, DIABETES CARE, V23, P739, DOI 10.2337/diacare.23.6.739
   BANDURA A, 1977, PSYCHOL REV, V84, P191, DOI 10.1037/0033-295X.84.2.191
   Bandura A, 1988, COGNITIVE PERSPECTIV, P37, DOI DOI 10.1007/978-94-009-2792-6
   Bandura A., 1997, SELF EFFICACY EXERCI
   Blascovich J., 1993, MEASURES PERSONALITY, P115
   CONNELL CM, 1994, HEALTH PSYCHOL, V13, P263, DOI 10.1037//0278-6133.13.3.263
   DEROGATIS LR, 1983, SCL90R ADM SCORING P, V2
   Fournier M, 2002, PERS INDIV DIFFER, V33, P1163, DOI 10.1016/S0191-8869(02)00006-5
   GLASGOW RE, 1989, HEALTH PSYCHOL, V8, P285, DOI 10.1037/0278-6133.8.3.285
   GRECO P, 1990, DIABETES S1, V40, pA657
   Grey M, 1998, DIABETES CARE, V21, P902, DOI 10.2337/diacare.21.6.902
   Griva K, 2000, PSYCHOL HEALTH, V15, P733, DOI 10.1080/08870440008405578
   GROSSMAN HY, 1987, DIABETES CARE, V10, P324, DOI 10.2337/diacare.10.3.324
   Hurley A C, 1992, Diabetes Educ, V18, P146, DOI 10.1177/014572179201800208
   HURLEY AC, 1989, DIABETES HLTH BELIEF
   *INT RES CTR HLTH, 1991, SCOR MOS 36 IT SHORT
   IRVINE A, 2004, HDB PSYCHOL DIABETES, P133
   KAVANAGH DJ, 1993, J BEHAV MED, V16, P509, DOI 10.1007/BF00844820
   LITTLEFIELD CH, 1992, DIABETES CARE, V15, P90, DOI 10.2337/diacare.15.1.90
   LUTEIJN F, 1975, MANUAL DUTCH PERSONA
   Maddux J. E., 1995, SELF EFFICACY ADAPTA, P37, DOI DOI 10.1007/978-1-4419-6868-5_2
   MAIBACH E, 1995, HEALTH EDUC RES, V10, P37, DOI 10.1093/her/10.1.37
   MCCAUL KD, 1987, MED CARE, V25, P868, DOI 10.1097/00005650-198709000-00005
   Mollem ED, 1996, PATIENT EDUC COUNS, V29, P277, DOI 10.1016/S0738-3991(96)00926-3
   Ott J, 2000, CHILD HEALTH CARE, V29, P47, DOI 10.1207/S15326888CHC2901_4
   PADGETT DK, 1991, PATIENT EDUC COUNS, V18, P139, DOI 10.1016/0738-3991(91)90006-Q
   POLONSKY WH, 1995, DIABETES CARE, V18, P754, DOI 10.2337/diacare.18.6.754
   Pouwer F, 1999, DIABETES CARE, V22, P2004, DOI 10.2337/diacare.22.12.2004
   Rosenberg M., 1979, CONCEIVING SELF
   Rubin R. R., 1993, DIABETES ED, V19, P210, DOI [DOI 10.1177/014572179301900308, 10.1177/014572179301900308]
   Ruggiero L, 1997, DIABETES CARE, V20, P568, DOI 10.2337/diacare.20.4.568
   Schlundt DG, 1999, BEHAV MODIF, V23, P79, DOI 10.1177/0145445599231004
   Senecal C, 2000, HEALTH PSYCHOL, V19, P452, DOI 10.1037//0278-6133.19.5.452
   SNAITH RP, 1994, HOSPITAL ANXIETY DEP
   Snoek F, 1996, GEDRAG GEZONDHEID, V24, P287
   Snoek FJ, 2001, PATIENT EDUC COUNS, V45, P143, DOI 10.1016/S0738-3991(01)00113-6
   Snoek FJ, 2000, DIABETES CARE, V23, P1305, DOI 10.2337/diacare.23.9.1305
   Spinhoven P, 1997, PSYCHOL MED, V27, P363, DOI 10.1017/S0033291796004382
   *SPSS, 2000, SPSS BAS 9 0 WIND US
   Talbot F, 1997, J BEHAV MED, V20, P291, DOI 10.1023/A:1025508928696
   van der Bijl J, 1999, J ADV NURS, V30, P352, DOI 10.1046/j.1365-2648.1999.01077.x
   Weinger K, 2000, DIABETES, V49, pA318
NR 44
TC 90
Z9 91
U1 1
U2 16
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
EI 1935-5548
J9 DIABETES CARE
JI Diabetes Care
PD MAR
PY 2003
VL 26
IS 3
BP 713
EP 718
DI 10.2337/diacare.26.3.713
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 724UM
UT WOS:000185505100027
PM 12610027
OA Bronze, Green Accepted
DA 2019-01-08
ER

PT J
AU Antai-Otong, D
AF Antai-Otong, D
TI Anxiety disorders: treatment considerations
SO NURSING CLINICS OF NORTH AMERICA
LA English
DT Article
ID POSTTRAUMATIC-STRESS-DISORDER; NATIONAL-COMORBIDITY-SURVEY; DISEASE;
   CYTOKINES; BURDEN
AB Anxiety disorders are among the most widespread, recurring or chronic, and treatable mental health disorders, with a lifetime prevalence of 25% [1]. These disorders are the primary reason that people seek medical and psychiatric treatment and are often a precursor to or comorbid with mood disorders [2]. Anxiety disorders cause a considerable burden of distress and disability similar to other medical conditions, such as diabetes [3,4]. Anxiety disorders have a predictable debilitating course of anxiety and reduced productivity and interference with functioning. These disorders rarely occur as a single disorder.
C1 VA N Texas Hlth Care Syst, Employee Support Program, Mental Hlth Outpatient Clin, Dallas, TX 75216 USA.
RP Antai-Otong, D (reprint author), VA N Texas Hlth Care Syst, Employee Support Program, Mental Hlth Outpatient Clin, 4500 S Lancaster Rd, Dallas, TX 75216 USA.
EM Deborah.antai-otong@med.va.gov
CR American Psychiatric Association, 2000, DIAGN STAT MAN MENT
   Andrews G, 1998, BRIT J PSYCHIAT, V173, P123, DOI 10.1192/bjp.173.2.123
   Antai-Otong D, 2000, Issues Ment Health Nurs, V21, P71, DOI 10.1080/016128400248275
   BECK A. T., 1985, ANXIETY DISORDER PHO
   Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397
   Greenberg PE, 1999, J CLIN PSYCHIAT, V60, P427, DOI 10.4088/JCP.v60n0702
   Grossman R, 2002, PSYCHIAT CLIN N AM, V25, P317, DOI 10.1016/S0193-953X(01)00011-9
   Hettema JM, 2001, AM J PSYCHIAT, V158, P1568, DOI 10.1176/appi.ajp.158.10.1568
   JUDD LL, 1998, ACTA PSYCHIAT SCAN S, V393, P6
   Kendler KS, 2001, ARCH GEN PSYCHIAT, V58, P1005, DOI 10.1001/archpsyc.58.11.1005
   KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012
   KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8
   McClane SJ, 1999, JPEN-PARENTER ENTER, V23, pS20, DOI 10.1177/014860719902300506
   Noyes Jr R, 1998, ANXIETY DISORDERS
   Schweizer E, 1997, J CLIN PSYCHIAT, V58, P27
   Uhlenhuth E H, 1999, Depress Anxiety, V9, P107, DOI 10.1002/(SICI)1520-6394(1999)9:3<107::AID-DA2>3.0.CO;2-T
   Yehuda R, 2002, PSYCHIAT CLIN N AM, V25, P341, DOI 10.1016/S0193-953X(02)00002-3
   Yudkin JS, 2000, ATHEROSCLEROSIS, V148, P209, DOI 10.1016/S0021-9150(99)00463-3
NR 18
TC 0
Z9 1
U1 0
U2 2
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399 USA
SN 0029-6465
J9 NURS CLIN N AM
JI Nurs. Clin. North Am.
PD MAR
PY 2003
VL 38
IS 1
BP 35
EP +
DI 10.1016/S0029-6465(02)00059-2
PG 11
WC Nursing
SC Nursing
GA 656RX
UT WOS:000181623200005
PM 12712667
DA 2019-01-08
ER

PT J
AU Taylor, MD
   Frier, BM
   Gold, AE
   Deary, IJ
AF Taylor, MD
   Frier, BM
   Gold, AE
   Deary, IJ
TI Psychosocial factors and diabetes-related outcomes following diagnosis
   of Type 1 diabetes in adults: The Edinburgh Prospective Diabetes Study
SO DIABETIC MEDICINE
LA English
DT Article
DE Type 1 diabetes; glycaemic control; quality of life; coping; adults
ID QUALITY-OF-LIFE; YOUNG-ADULTS; GLYCEMIC CONTROL; PSYCHIATRIC-ILLNESS;
   SELF-REGULATION; MELLITUS; ADJUSTMENT; EDUCATION; ADOLESCENTS;
   PERSONALITY
AB Aims To examine prospectively the relationships between psychosocial variables and diabetes-related outcomes in adults with newly diagnosed Type 1 diabetes.
   Methods A total of 84 adults (48 male) with a median (range) age of 30.8 (17-51) years with newly diagnosed Type 1 diabetes were recruited for the study. Shortly after initial diagnosis each participant's personality, cognitive ability, and recent psychiatric distress were assessed. At 4 months (n = 69) and at 12 months (n = 66) after diagnosis diabetes-related outcomes were measured, including each respondent's knowledge of diabetes, satisfaction with diabetes treatment and diabetes-related quality of life. Glycated haemoglobin (HbA(1c) ) was recorded at each clinic attendance.
   Results Social class (Spearman's correlation r = -0.30 and -0.28, respectively, P < 0.05) and scores on the National Adult Reading Test (r = 0.38 and 0.36, respectively, P < 0.01) were consistently associated with knowledge of diabetes at 4 months and at 12 months after diagnosis. Hierarchical regression revealed that alcohol consumption recorded at diagnosis and knowledge of diabetes at 4 months were independent predictors of glycaemic control at 12 months (adjusted r (2) = 0.16). Total scores on the Diabetes Treatment Satisfaction Questionnaire (DTSQ) at 12 months were significantly predicted by age at diagnosis (adjusted r (2) = 0.08). High neuroticism at diagnosis was consistently associated with poorer self-reported diabetes quality of life at 4 months and at 12 months after diagnosis (r s between -0.30 and -0.39, P < 0.05).
   Conclusions Long-standing psychosocial factors have a significant influence on self-reported outcomes during the 12 months following diagnosis of Type 1 diabetes but may not be reliable predictors of glycaemic control. Further follow-up is necessary to determine the longer-term predictors of objective (e.g. glycaemic control) and subjective (e.g. quality of life) indicators of coping in people with diabetes.
C1 Univ Edinburgh, Sch Philosophy Psychol & Language Sci, Dept Psychol, Edinburgh EH8 9JZ, Midlothian, Scotland.
   Royal Infirm, Dept Diabet, Edinburgh EH3 9YW, Midlothian, Scotland.
RP Deary, IJ (reprint author), Univ Edinburgh, Sch Philosophy Psychol & Language Sci, Dept Psychol, 7 George Sq, Edinburgh EH8 9JZ, Midlothian, Scotland.
EM Ian.Deary@ed.ac.uk
RI Deary, Ian/C-6297-2009
OI Deary, Ian/0000-0002-1733-263X
CR Ackerman P. L., 2000, J GERONTOL B-PSYCHOL, V55, P69, DOI DOI 10.1093/GERONB/55.2.P69
   Ackerman PL, 1999, PSYCHOL AGING, V14, P314, DOI 10.1037//0882-7974.14.2.314
   BRADLEY C, 1978, STRESS
   Bradley C., 1994, HDB PSYCHOL DIABETES
   Bryden KS, 2001, DIABETES CARE, V24, P1536, DOI 10.2337/diacare.24.9.1536
   CLEMENT S, 1995, DIABETES CARE, V18, P1204, DOI 10.2337/diacare.18.8.1204
   Cohen ST, 1997, PSYCHOSOMATICS, V38, P98, DOI 10.1016/S0033-3182(97)71477-4
   COSTA PT, 1987, J PERS, V55, P299, DOI 10.1111/j.1467-6494.1987.tb00438.x
   CRAWFORD JR, 1989, PERS INDIV DIFFER, V10, P585, DOI 10.1016/0191-8869(89)90043-3
   DCCT Res Grp, 1988, DIABETES CARE, V11, P725
   Deary IJ, 1997, BRIT J HEALTH PSYCH, V2, P35, DOI 10.1111/j.2044-8287.1997.tb00522.x
   Diabet Control Complications Trial Res Grp, 1996, DIABETES CARE, V19, P195
   Eysenck HJ ES., 1975, MANUAL EYSENCK PERSO
   FONAGY P, 1987, ARCH DIS CHILD, V62, P1009, DOI 10.1136/adc.62.10.1009
   Glasgow RE, 1999, DIABETES CARE, V22, P832, DOI 10.2337/diacare.22.5.832
   Glasgow RE, 1997, DIABETES CARE, V20, P562, DOI 10.2337/diacare.20.4.562
   GLASGOW RE, 1994, HDB PSYCHOL DIABETES
   GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644
   Goldthorpe J.H., 1987, SOCIAL MOBILITY CLAS
   GORDON D, 1993, DIABETIC MED, V10, P530, DOI 10.1111/j.1464-5491.1993.tb00115.x
   GRAJWER LA, 1977, J PEDIATR, V9, P42
   GREY M, 1995, DIABETES CARE, V18, P1330, DOI 10.2337/diacare.18.10.1330
   Hampson SE, 2000, BRIT J HEALTH PSYCH, V5, P27, DOI 10.1348/135910700168748
   HANSON CL, 1987, DIABETES CARE, V10, P752, DOI 10.2337/diacare.10.6.752
   HEPBURN DA, 1994, DIABETIC MED, V11, P578, DOI 10.1111/j.1464-5491.1994.tb02039.x
   HORN JL, 1966, J EDUC PSYCHOL, V57, P253, DOI 10.1037/h0023816
   *INT RES CTR HLTH, 1991, SCOR MOS 36 IT SHORT
   Jacobson AM, 1997, QUAL LIFE RES, V6, P11
   JACOBSON AM, 1994, DIABETES CARE, V17, P267, DOI 10.2337/diacare.17.4.267
   Jacobson AM, 1996, NEW ENGL J MED, V334, P1249, DOI 10.1056/NEJM199605093341907
   Jacobson AM, 1997, DIABETIC MED, V14, P73, DOI 10.1002/(SICI)1096-9136(199701)14:1<73::AID-DIA294>3.0.CO;2-Q
   KOVACS M, 1986, DIABETES CARE, V9, P472, DOI 10.2337/diacare.9.5.472
   KOVACS M, 1985, J PEDIATR-US, V106, P827, DOI 10.1016/S0022-3476(85)80368-1
   LANE JD, 1988, DIABETES CARE, V11, P778
   LLOYD CE, 1992, DIABETIC MED, V9, P661, DOI 10.1111/j.1464-5491.1992.tb01863.x
   LLOYD CE, 1991, DIABETES CARE, V15, P278
   LUSTMAN PJ, 1986, J NERV MENT DIS, V174, P736, DOI 10.1097/00005053-198612000-00005
   Lustman PJ, 2000, DIABETES CARE, V23, P934, DOI 10.2337/diacare.23.7.934
   MADSBAD S, 1978, DIABETES, V27, P262, DOI 10.2337/diab.27.1.S262
   NELSON HE, 1992, NATL ADULT READING T
   Petterson T, 1998, DIABETES CARE, V21, P930, DOI 10.2337/diacare.21.6.930
   Robinson DL, 1997, MED PRIN PRACT, V6, P186
   RUBIN RR, 1991, DIABETES CARE, V14, P335, DOI 10.2337/diacare.14.4.335
   SHAMOON H, 1993, NEW ENGL J MED, V329, P977
   Skinner TC, 2002, HEALTH PSYCHOL, V21, P61, DOI 10.1037//0278-6133.21.1.61
   TEBBI CK, 1990, DIABETES CARE, V13, P98, DOI 10.2337/diacare.13.2.98
   Watkins KW, 2000, DIABETES CARE, V23, P1511, DOI 10.2337/diacare.23.10.1511
   WATSON D, 1989, PSYCHOL REV, V96, P234, DOI 10.1037//0033-295X.96.2.234
NR 48
TC 39
Z9 41
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0742-3071
EI 1464-5491
J9 DIABETIC MED
JI Diabetic Med.
PD FEB
PY 2003
VL 20
IS 2
BP 135
EP 146
DI 10.1046/j.1464-5491.2003.00887.x
PG 12
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 645GP
UT WOS:000180968100008
PM 12581265
DA 2019-01-08
ER

PT J
AU Egede, LE
   Bonadonna, RJ
AF Egede, LE
   Bonadonna, RJ
TI Diabetes self-management in African Americans: An exploration of the
   role of fatalism
SO DIABETES EDUCATOR
LA English
DT Article
ID FOCUS GROUPS; PSYCHOLOGICAL DISTRESS; HEALTH BELIEFS; BLACK-WOMEN;
   LOCUS; CANCER; EDUCATION; RESOURCES; SYMPTOMS; CULTURE
AB PURPOSE This study was conducted to explore the concept of fatalism in relation to diabetes self-management behavior in African Americans with type 2 diabetes.
   METHODS Participants (n=39) were recruited from a clinic sample of African Americans with type 2 diabetes. Seven focus groups were conducted; the sessions were recorded, transcribed, and analyzed to identify themes related to fatalism and diabetes self-management. The ISAS paradigm (individual, symbols, audience, situation), a social psychology theory, provided the theoretical framework for the study.
   RESULTS Four dimensions of fatalism were identified: the meaning of diabetes, the illness experience, the individual's coping response, and the individual's religious and spiritual beliefs. For the participants in this study, fatalism seemed to characterize the nature of the interaction between the individual with diabetes and others, the meanings they attached to such interactions, and the decision to adopt an effective or ineffective diabetes self-management behavior.
   CONCLUSIONS Fatalism was associated with diabetes self-management in African Americans with diabetes and was multidimensional in this population; the construct appeared to differ conceptually from the perspective of current measures.
C1 Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA.
   Med Univ S Carolina, Coll Nursing, Charleston, SC 29425 USA.
RP Egede, LE (reprint author), Diabet Educator, 367 W Chicago Ave, Chicago, IL 60610 USA.
FU AHRQ HHS [1K08HS11418]
CR Anderson RM, 1996, DIABETES EDUCATOR, V22, P28, DOI 10.1177/014572179602200104
   ANDERSON RM, 1994, DIABETES EDUCATOR, V20, P399, DOI 10.1177/014572179402000506
   ANDERSON RM, 1991, DIABETES CARE, V14, P605, DOI 10.2337/diacare.14.7.605
   BASCH CE, 1987, HEALTH EDUC QUART, V14, P411, DOI 10.1177/109019818701400404
   BOONE C, 1990, PSYCHOL REP, V66, P1107, DOI 10.2466/PR0.66.3.1107-1111
   CALDER BJ, 1977, J MARKETING RES, V14, P353, DOI 10.2307/3150774
   Chavez LR, 1997, AM J PREV MED, V13, P418
   CLEMENT S, 1995, DIABETES CARE, V18, P1204, DOI 10.2337/diacare.18.8.1204
   Conrad ME, 1996, ANN INTERN MED, V125, P941, DOI 10.7326/0003-4819-125-11-199612010-00026
   DAVISON C, 1992, SOC SCI MED, V34, P675, DOI 10.1016/0277-9536(92)90195-V
   Edelstein J, 1987, Diabetes Educ, V13, P51, DOI 10.1177/014572178701300111
   Egede LE, 2002, DIABETES EDUCATOR, V28, P258, DOI 10.1177/014572170202800211
   HARRIS MI, 1993, DIABETES CARE, V16, P1116, DOI 10.2337/diacare.16.8.1116
   HUSSEY LC, 1989, NURS CLIN N AM, V24, P605
   Joiner TE, 2001, BEHAV RES THER, V39, P887, DOI 10.1016/S0005-7967(00)00062-0
   KITZINGER J, 1995, BRIT MED J, V311, P299, DOI 10.1136/bmj.311.7000.299
   KNODEL J, 1993, SUCCESSFUL FOCUS GRO
   Krueger R. A., 2000, FOCUS GROUPS PRACTIC
   Maillet NA, 1996, DIABETES EDUCATOR, V22, P39, DOI 10.1177/014572179602200106
   Mayo RM, 2001, J WOMEN AGING, V13, P57, DOI 10.1300/J074v13n01_05
   *MERR WEBST INC, 1998, MERR WEBST COLL DICT
   Miles M., 1994, QUALITATIVE DATA ANA
   Morgan D. L., 1997, FOCUS GROUPS QUALITA
   Morgan DL, 1993, SUCCESSFUL FOCUS GRO
   NEFF JA, 1993, J COMMUNITY PSYCHOL, V21, P3, DOI 10.1002/1520-6629(199301)21:1<3::AID-JCOP2290210102>3.0.CO;2-9
   Neighbors Harold W., 1996, Ethnicity and Disease, V6, P167
   Norris SL, 2001, DIABETES CARE, V24, P561, DOI 10.2337/diacare.24.3.561
   Patton M., 1990, QUALITATIVE EVALUATI
   PEYROT M, 1994, DIABETES CARE, V17, P994, DOI 10.2337/diacare.17.9.994
   Phillips J M, 1999, Oncol Nurs Forum, V26, P561
   Powe B D, 1995, Oncol Nurs Forum, V22, P1355
   Powe B D, 1999, Oncol Nurs Forum, V26, P583
   POWE BD, 1995, J RELIG HEALTH, V34, P119, DOI 10.1007/BF02248767
   Powe BD, 1996, NURS OUTLOOK, V44, P18, DOI 10.1016/S0029-6554(96)80020-0
   POWE BD, 1995, CANCER NURS, V18, P385
   *RCMAR MEAS COR, 2001, P MEAS ISS HLTH DISP
   Roberts RE, 2000, PSYCHIATRY, V63, P239, DOI 10.1080/00332747.2000.11024917
   ROSS CE, 1983, AM J COMMUN PSYCHOL, V11, P383, DOI 10.1007/BF00894055
   ROTTER JB, 1966, PSYCHOL MONOGR, V80, P1, DOI 10.1037/h0092976
   SADOWSKI CJ, 1982, J PSYCHOL, V112, P227, DOI 10.1080/00223980.1982.9915378
   Schoenberg NE, 1998, DIABETES EDUCATOR, V24, P319, DOI 10.1177/014572179802400306
   SCHWAB T, 1994, DIABETES EDUCATOR, V20, P221, DOI 10.1177/014572179402000308
   Sofaer S, 1999, HEALTH SERV RES, V34, P1101
   Talbot F, 1996, J CLIN PSYCHOL, V52, P559, DOI 10.1002/(SICI)1097-4679(199609)52:5<559::AID-JCLP11>3.0.CO;2-D
   Tillotson LM, 1996, DIABETES EDUCATOR, V22, P133, DOI 10.1177/014572179602200206
   *US DEP HHS, 2002, NAT I DIAB DIG KIDN
   Vernon G. M., 1981, SOCIAL PSYCHOL SHARE
   Vetter N J, 1991, Health Visit, V64, P191
   WALLSTON BS, 1976, J CONSULT CLIN PSYCH, V44, P580, DOI 10.1037//0022-006X.44.4.580
   WHEATON B, 1980, J HEALTH SOC BEHAV, V21, P100, DOI 10.2307/2136730
   WHEATON B, 1983, J HEALTH SOC BEHAV, V24, P208, DOI 10.2307/2136572
NR 51
TC 65
Z9 65
U1 1
U2 3
PU AMER ASSOC DIABETES EDUCATORS
PI CHICAGO
PA STE 1240, 444 NORTH MICHIGAN AVE, CHICAGO, IL 60611-3901 USA
SN 0145-7217
J9 DIABETES EDUCATOR
JI Diabetes Educ.
PD JAN-FEB
PY 2003
VL 29
IS 1
BP 105
EP 115
DI 10.1177/014572170302900115
PG 11
WC Endocrinology & Metabolism; Public, Environmental & Occupational Health
SC Endocrinology & Metabolism; Public, Environmental & Occupational Health
GA 643UZ
UT WOS:000180880400009
PM 12632689
DA 2019-01-08
ER

PT J
AU Quattrini, C
   Tesfaye, S
AF Quattrini, C
   Tesfaye, S
TI Understanding the impact of painful diabetic neuropathy
SO DIABETES-METABOLISM RESEARCH AND REVIEWS
LA English
DT Article
DE diabetes; diabetic neuropathy; peripheral neuropathy; painful diabetic
   neuropathy; quality of life
ID IMPAIRED GLUCOSE-TOLERANCE; QUALITY-OF-LIFE; PERIPHERAL NEUROPATHY;
   GLYCEMIC CONTROL; SENSORY NEUROPATHY; NATURAL-HISTORY; PREVALENCE;
   POPULATION; MELLITUS; SYMPTOMS
AB Painful neuropathy is a common and often distressing complication of diabetes, It has considerable impact on the social and psychological well-being of affected individuals. There are two distinct forms of painful neuropathy: an acute and self-limiting form that resolves within a year or a chronic form that can go on for years. There are now a number of drugs available for the treatment of neuropathic pain. However, some may fail to respond to these drugs or may have unacceptable adverse side effects. When this is the case, the patient's quality of life can be severely affected.
   Health care professionals need to assess the full impact of painful neuropathy. In this article we review a number of instruments that are used to assess the severity of painful neuropathy and its impact on the quality of life. Copyright (C), 2003 John Wiley Sons, Ltd.
C1 Royal Hallamshire Hosp, Diabet Res Unit, Sheffield S10 2JF, S Yorkshire, England.
RP Tesfaye, S (reprint author), Royal Hallamshire Hosp, Diabet Res Unit, Glossop Rd, Sheffield S10 2JF, S Yorkshire, England.
OI Tesfaye, Solomon/0000-0003-1190-1472
CR Amos AF, 1997, DIABETIC MED, V14, pS7, DOI 10.1002/(SICI)1096-9136(199712)14:5+<S7::AID-DIA522>3.3.CO;2-I
   ARCHER AG, 1983, J NEUROL NEUROSUR PS, V46, P491, DOI 10.1136/jnnp.46.6.491
   ASBURY AK, 1970, BRAIN, V93, P555, DOI 10.1093/brain/93.3.555
   Benbow SJ, 1998, QJM-MON J ASSOC PHYS, V91, P733, DOI 10.1093/qjmed/91.11.733
   BENBOW SJ, 1994, DIABETIC MED, V11, P17, DOI 10.1111/j.1464-5491.1994.tb00223.x
   Bennett M, 2001, PAIN, V92, P147, DOI 10.1016/S0304-3959(00)00482-6
   BOULTON AJM, 1983, POSTGRAD MED J, V59, P556, DOI 10.1136/pgmj.59.695.556
   Bradley C, 1999, QUAL LIFE RES, V8, P79, DOI 10.1023/A:1026485130100
   Caravati C, 1933, VA MED MON, V59, P745
   Carrington AL, 1996, DIABETES RES CLIN PR, V32, P19, DOI 10.1016/0168-8227(96)01198-9
   CASEY EB, 1972, BMJ-BRIT MED J, V1, P656, DOI 10.1136/bmj.1.5801.656
   CHAN A W, 1990, Pain Clinic, V3, P147
   CHIMENES H, 1978, LANCET, V1, P883
   Cleeland C. S., 1994, Annals Academy of Medicine Singapore, V23, P129
   CLEELAND CS, 1990, ADV PAIN RES THER, V16, P47
   Clouet F, 2001, DIABETES METAB, V27, P711
   Currie CJ, 1997, DIABETIC MED, V14, P686, DOI 10.1002/(SICI)1096-9136(199708)14:8<686::AID-DIA434>3.0.CO;2-D
   DUNITZ M, 2000, CHRONIC PAIN, P7
   DYCK PJ, 1993, NEUROLOGY, V43, P817, DOI 10.1212/WNL.43.4.817
   DYCK PJ, 1999, DIABETIC NEUROPATHY, P262
   ELLENBERG M, 1974, DIABETES, V23, P418, DOI 10.2337/diab.23.5.418
   Ellenberg M, 1978, Diabetes Care, V1, P10, DOI 10.2337/diacare.1.1.10
   FORREST RD, 1986, DIABETIC MED, V3, P338, DOI 10.1111/j.1464-5491.1986.tb00776.x
   Galer BS, 1997, NEUROLOGY, V48, P332, DOI 10.1212/WNL.48.2.332
   GUY RJC, 1985, DIABETOLOGIA, V28, P131
   HARRIS MI, 1987, DIABETES, V36, P523, DOI 10.2337/diabetes.36.4.523
   HAYES FJ, 1994, IRISH MED J, V87, P150
   KIHARA M, 1994, AM J PHYSIOL, V266, pE980
   Levitt NS, 1996, DIABETES CARE, V19, P751, DOI 10.2337/diacare.19.7.751
   LLEWELYN JG, 1986, ACTA NEUROPATHOL, V72, P157, DOI 10.1007/BF00685978
   MASSON EA, 1989, PAIN, V38, P25, DOI 10.1016/0304-3959(89)90068-7
   MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5
   Meyer-Rosberg K, 2001, EUR J PAIN, V5, P391, DOI 10.1053/eujp.2001.0260
   NAGHMI R, 1990, HORM METAB RES, V22, P38, DOI 10.1055/s-2007-1004844
   Novella SP, 2001, MUSCLE NERVE, V24, P1229, DOI 10.1002/mus.1137
   PARRY GJ, 1989, NEUROLOGY, V39, P1488, DOI 10.1212/WNL.39.11.1488
   Rijken PM, 1998, DISABIL REHABIL, V20, P330, DOI 10.3109/09638289809166090
   ROBINSON N, 1990, DIABETIC MED, V7, P16, DOI 10.1111/j.1464-5491.1990.tb01300.x
   Russell JW, 2001, MUSCLE NERVE, V24, P1109, DOI 10.1002/mus.1122
   SCOTT J, 1976, PAIN, V2, P175, DOI 10.1016/0304-3959(76)90113-5
   SIMMONS D, 1991, Q J MED, V81, P1021, DOI 10.1093/qjmed/81.3.1021
   Singleton JR, 2001, DIABETES CARE, V24, P1448, DOI 10.2337/diacare.24.8.1448
   Singleton JR, 2001, MUSCLE NERVE, V24, P1225, DOI 10.1002/mus.1136
   Snoek FJ, 2000, DIABETES CARE, V23, P1305, DOI 10.2337/diacare.23.9.1305
   TENVALL GR, 2000, DIABETES COMPLICATIO, V14, P235
   Tesfaye S, 1996, LANCET, V348, P1698, DOI 10.1016/S0140-6736(96)02467-1
   Tesfaye S, 1996, DIABETOLOGIA, V39, P1377, DOI 10.1007/s001250050586
   Tesfaye S, 1996, DIABETOLOGIA, V39, P329
   TESFAYE S, 1992, DIABETOLOGIA, V35, P155, DOI 10.1007/BF00402548
   TESFAYE S, 1996, DIABETIC NEUROPATHY, pCH9
   THOMAS P K, 1973, Journal of the Royal College of Physicians of London, V7, P154
   Vileikyte L, 1998, DIABETES, V47, pA44
   Vileikyte L, 1999, DIABETES REV, V7, P387
   Vinik AI, 2000, DIABETOLOGIA, V43, P957, DOI 10.1007/s001250051477
   WARD JD, 1983, J ROY SOC MED, V76, P1011, DOI 10.1177/014107688307601206
   WATKINS PJ, 1984, BRIT MED J, V288, P168, DOI 10.1136/bmj.288.6412.168
   WATKINS PJ, 1997, TXB DIABETES, V2, P1
   White Christine A, 2002, BMC Nephrol, V3, P3, DOI 10.1186/1471-2369-3-3
   Wu SY, 1998, DIABETES CARE, V21, P725, DOI 10.2337/diacare.21.5.725
   YOUNG MJ, 1993, DIABETOLOGIA, V36, P150, DOI 10.1007/BF00400697
   Ziegler D, 1992, J Diabetes Complications, V6, P49, DOI 10.1016/1056-8727(92)90049-Q
   ZIEGLER D, 1995, DIABETOLOGIA, V38, P1425, DOI 10.1007/BF00400603
   ZORRILLA E, 1967, ANN INTERN MED, V67, P968, DOI 10.7326/0003-4819-67-5-968
   ZRUSTOVA M, 1979, ACTA DIABETOL LAT, V16, P55, DOI 10.1007/BF02590763
NR 64
TC 74
Z9 76
U1 1
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1520-7560
J9 DIABETES-METAB RES
JI Diabetes-Metab. Res. Rev.
PD JAN-FEB
PY 2003
VL 19
SU 1
BP S2
EP S8
DI 10.1002/dmrr.360
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 651TA
UT WOS:000181337100002
PM 12577252
DA 2019-01-08
ER

PT J
AU Watkins, PJ
   Buxton-Thomas, MS
   Howard, ER
AF Watkins, PJ
   Buxton-Thomas, MS
   Howard, ER
TI Long-term outcome after gastrectomy for intractable diabetic
   gastroparesis
SO DIABETIC MEDICINE
LA English
DT Article
DE diabetic autonomic neuropathy; gastroparesis; gastrectomy
ID AUTONOMIC NEUROPATHY; GASTRIC ATONY; MELLITUS; JEJUNOSTOMY; MANAGEMENT
AB Aims To examine the long-term outlook for patients with intractable vomiting from diabetic gastroparesis who underwent major gastric surgery.
   Methods Of 18 patients with problems from vomiting referred to the King's Diabetes Centre during the years 1994-2000, seven were considered to suffer irreversible symptoms not alleviated by protracted periods of medical treatment. They were all Type 1 Caucasian diabetic women, mean age 32 years (range 28-37 years) with multiple symptoms of severe autonomic neuropathy. They underwent major gastric surgery comprising 70% gastric resection including pylorus and antrum, with a 60-cm Roux-en-Y loop of jejunum to prevent reflux gastritis.
   Results The vomiting was relieved in six of the seven patients almost immediately after surgery and during review up to more than 6 years post-operatively. There have been no serious relapses, resulting in considerable improvement in quality of life. Unfortunately, three of the patients developed renal failure, two of them needing renal support treatments 2 and 3 years after successful gastrectomy. One patient died suddenly 5 months after successful surgery and one 3 months after starting dialysis.
   Conclusions Major gastric surgery can, after careful patient selection, effectively relieve distressing vomiting from severe gastroparesis and give a greatly improved quality of life to a small group of seriously disadvantaged patients where risk of subsequent renal failure is high and where life expectancy is poor.
C1 Kings Coll Hosp London, Kings Diabet Ctr, London SE5 9RS, England.
   Kings Coll Hosp London, Dept Nucl Med, London SE5 9RS, England.
   Kings Coll Hosp London, Dept Surg, London SE5 9RS, England.
RP Watkins, PJ (reprint author), Kings Coll Hosp London, Kings Diabet Ctr, Denmark Hill, London SE5 9RS, England.
EM peter.watkins1@virgin.net
CR Bell DSH, 1999, DIABETES CARE, V22, P1000, DOI 10.2337/diacare.22.6.1000
   Devendra D, 2000, DIABETES CARE, V23, P426, DOI 10.2337/diacare.23.3.426
   DOWLING CJ, 1985, BRIT MED J, V310, P308
   Ejskjaer NT, 1999, DIABETIC MED, V16, P488, DOI 10.1046/j.1464-5491.1999.00086.x
   Ejskjaer NT, 1998, DIABETIC MED, V15, P723, DOI 10.1002/(SICI)1096-9136(199809)15:9<723::AID-DIA674>3.0.CO;2-7
   GUY RJC, 1984, J NEUROL NEUROSUR PS, V47, P686, DOI 10.1136/jnnp.47.7.686
   Horowitz M, 1996, DIABETIC MED, V13, pS16
   JACOBER SJ, 1986, DIABETES CARE, V9, P217, DOI 10.2337/diacare.9.2.217
   KARLSTROM L, 1989, AM J SURG, V157, P44, DOI 10.1016/0002-9610(89)90418-2
   Kong MF, 1999, CLIN GERIATR MED, V15, P321
   Kong MFSC, 1996, DIABETIC MED, V13, P112, DOI 10.1002/(SICI)1096-9136(199602)13:2<112::AID-DIA37>3.3.CO;2-8
   LIPP RW, 1993, EUR J NUCL MED, V20, P260
   Morris AD, 1997, LANCET, V350, P1505, DOI 10.1016/S0140-6736(97)06234-X
   PFEIFER M, 1999, DIABETIC NEUROPATHY, P174
   REARDON TM, 1989, J CLIN GASTROENTEROL, V11, P204, DOI 10.1097/00004836-198904000-00018
   ROON AJ, 1972, CALIF MED, V116, P58
   SAID G, 1983, BRAIN, V106, P791, DOI 10.1093/brain/106.4.791
   SAMPSON MJ, 1990, Q J MED, V75, P635
   Stacher G, 2001, DIABETOLOGIA, V44, P1080, DOI 10.1007/s001250100619
   Winkler AS, 2000, DIABETIC MED, V17, P457, DOI 10.1046/j.1464-5491.2000.00298.x
   WINKLER AS, 1999, DIABETIC MED, V16, P1
   WOOTEN RL, 1961, JAMA-J AM MED ASSOC, V176, P1082, DOI 10.1001/jama.1961.03040260016004
   ZANONE MM, 1993, DIABETOLOGIA, V36, P564, DOI 10.1007/BF02743275
NR 23
TC 40
Z9 41
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0742-3071
J9 DIABETIC MED
JI Diabetic Med.
PD JAN
PY 2003
VL 20
IS 1
BP 58
EP 63
DI 10.1046/j.1464-5491.2003.00872.x
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 632XT
UT WOS:000180250700009
PM 12519321
DA 2019-01-08
ER

PT J
AU Welch, G
   Weinger, K
   Anderson, B
   Polonsky, WH
AF Welch, G
   Weinger, K
   Anderson, B
   Polonsky, WH
TI Responsiveness of the problem areas in diabetes (PAID) questionnaire
SO DIABETIC MEDICINE
LA English
DT Article
DE diabetes mellitus; emotional distress; PAID; validity; responsiveness
ID GLYCEMIC CONTROL; INTENSIVE TREATMENT; SCALE; INTERVENTION; VALIDATION;
   EDUCATION; DISTRESS; CARE
AB Aim Responsiveness (sensitivity to change over time) is a key psychometric quality for an outcome measure. We examined the responsiveness of the Problem Areas In Diabetes (PAID) questionnaire, a measure of diabetes-specific emotional distress.
   Methods PAID data were obtained from seven diabetes intervention studies following a literature search that included both published papers and conference abstracts. To estimate responsiveness we used two indices: (i) a statistical test (the dependent t -test), and (ii) a commonly used effect size index (Cohen's d).
   Results Mean patient PAID scores improved from baseline to follow-up for all seven studies. Specifically, t -statistics ranged from t = 8.5 (P < 0.001) to t = 2.1 (P < 0.06). Effect size results ranged from 0.32 (i.e. small) for a disease management intervention to 0.65 (i.e. moderate) for an intensive medical/educational intervention.
   Conclusions Despite the pilot nature of the studies, the pattern of findings provided strong support for the responsiveness of the PAID. Information on responsiveness helps clinical researchers select measures, accurately estimate sample size to ensure adequate statistical power, and prioritize outcomes to be assessed.
C1 Joslin Diabet Ctr, Behav & Mental Hlth Res Div, Boston, MA 02115 USA.
   Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA.
RP Welch, G (reprint author), Joslin Diabet Ctr, Behav & Mental Hlth Res Div, Boston, MA 02115 USA.
CR Bott U, 1998, DIABETES CARE, V21, P757, DOI 10.2337/diacare.21.5.757
   Clark CM, 2001, DIABETES CARE, V24, P1079, DOI 10.2337/diacare.24.6.1079
   COHEN J, 1985, STAT POWER ANAL BEHA
   DCCT Res Grp, 1988, DIABETES CARE, V11, P725
   DELEON OA, 1995, INT J PSYCHIAT MED, V25, P81, DOI 10.2190/95FU-2TVW-UA8C-LPN8
   GLASGOW RE, 1997, DIABETES SPECTRUM, V10, P12
   ISHII H, 1999, DIABETES, V48, P1397
   IZQUIERDO R, 2000, DIABETES, V49, P1441
   JACKSON RA, 1999, DIABETES, V48, P1866
   KAZIS LE, 1989, MED CARE S, V27, P178
   MELKUS GD, 1999, DIABETES, V48, P158
   Mollema ED, 2001, J PSYCHOSOM RES, V51, P665, DOI 10.1016/S0022-3999(01)00229-X
   Nichols GA, 2000, DIABETES CARE, V23, P273, DOI 10.2337/diacare.23.3.273
   POLONSKY WH, 1995, DIABETES CARE, V18, P754, DOI 10.2337/diacare.18.6.754
   POLONSKY WH, 2000, DIABETES BURNOUT
   RUBIN RR, 2000, J CLIN PSYCHOL, V57, P457
   Snoek FJ, 2001, PATIENT EDUC COUNS, V45, P143, DOI 10.1016/S0738-3991(01)00113-6
   Snoek FJ, 2000, DIABETES CARE, V23, P1305, DOI 10.2337/diacare.23.9.1305
   SPILKER B, 1996, QUALITY PHARMACOECON
   TODD C, 1994, HDB PSYCHOL DIABETES
   Trief PM, 2001, DIABETES CARE, V24, P1384, DOI 10.2337/diacare.24.8.1384
   TURRENTINE LA, 2001, DIABETES, V50
   Weinger K, 2001, PATIENT EDUC COUNS, V42, P123, DOI 10.1016/S0738-3991(00)00098-7
   Welch GW, 1997, DIABETES CARE, V20, P760, DOI 10.2337/diacare.20.5.760
   WELCH GW, 1995, DIABETES, V44, pA958
NR 25
TC 129
Z9 133
U1 2
U2 11
PU BLACKWELL PUBLISHING LTD
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND
SN 0742-3071
J9 DIABETIC MED
JI Diabetic Med.
PD JAN
PY 2003
VL 20
IS 1
BP 69
EP 72
DI 10.1046/j.1464-5491.2003.00832.x
PG 4
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 632XT
UT WOS:000180250700011
PM 12519323
DA 2019-01-08
ER

PT J
AU Roose, SP
AF Roose, SP
TI Depression: Links with ischemic heart disease and erectile dysfunction
SO JOURNAL OF CLINICAL PSYCHIATRY
LA English
DT Article
ID NOCTURNAL PENILE TUMESCENCE; CORONARY-ARTERY DISEASE;
   MYOCARDIAL-INFARCTION; RISK-FACTORS; SYMPTOMS; MEN; PROGNOSIS; MORTALITY
AB This article examines the relationships among depression, ischemic heart disease, and erectile dysfunction. Depression is an independent risk factor for the development of ischemic heart disease, and depression in the post-myocardial infarction patient is associated with increased morbidity and mortality. Ischemic heart disease and erectile dysfunction are also frequently comorbid and share many common risk factors including age, hypertension, diabetes, dyslipidemia, obesity, sedentary lifestyle, and smoking. Depression and erectile dysfunction often occur together; however, the causal relation may be difficult to determine because erectile dysfunction may be a symptom of depression, social distress accompanying erectile dysfunction may precipitate depressive symptoms, or both conditions may result from a common factor such as vascular disease.
C1 Columbia Univ Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA.
RP Roose, SP (reprint author), New York State Psychiat Inst & Hosp, 1051 Riverside Dr, New York, NY 10032 USA.
EM spr2@columbia.edu
CR Araujo AB, 1998, PSYCHOSOM MED, V60, P458, DOI 10.1097/00006842-199807000-00011
   Arborelius L, 1999, J ENDOCRINOL, V160, P1, DOI 10.1677/joe.0.1600001
   Ariyo AA, 2000, CIRCULATION, V102, P1773
   AROMAA A, 1994, ACTA PSYCHIAT SCAND, V89, P77, DOI 10.1111/j.1600-0447.1994.tb05807.x
   Burchardt M, 2000, J UROLOGY, V164, P1188, DOI 10.1016/S0022-5347(05)67138-8
   Carney RM, 2002, J PSYCHOSOM RES, V53, P897, DOI 10.1016/S0022-3999(02)00311-2
   Carney RM, 2001, CIRCULATION, V104, P2024, DOI 10.1161/hc4201.097834
   Chung WS, 1999, EUR UROL, V36, P68, DOI 10.1159/000019929
   Connerney I, 2001, LANCET, V358, P1766, DOI 10.1016/S0140-6736(01)06803-9
   Derby CA, 2000, UROLOGY, V56, P302, DOI 10.1016/S0090-4295(00)00614-2
   DEROGATIS LR, 1981, AM J PSYCHIAT, V138, P757
   FELDMAN HA, 1994, J UROLOGY, V151, P54, DOI 10.1016/S0022-5347(17)34871-1
   Ford DE, 1998, ARCH INTERN MED, V158, P1422, DOI 10.1001/archinte.158.13.1422
   FRASURESMITH N, 1993, JAMA-J AM MED ASSOC, V270, P1819, DOI 10.1001/jama.270.15.1819
   FRASURESMITH N, 1995, CIRCULATION, V91, P999, DOI 10.1161/01.CIR.91.4.999
   Greenstein A, 1997, INT J IMPOT RES, V9, P123, DOI 10.1038/sj.ijir.3900282
   KEMPER JW, 1957, ANN INTERN MED, V46, P831, DOI 10.7326/0003-4819-46-5-831
   Krishnan KRR, 1997, AM J PSYCHIAT, V154, P497
   LaghrissiThode F, 1997, BIOL PSYCHIAT, V42, P290, DOI 10.1016/S0006-3223(96)00345-9
   Lesperance F, 2000, ARCH INTERN MED, V160, P1354, DOI 10.1001/archinte.160.9.1354
   Manica A L, 1999, Arq Bras Cardiol, V73, P237, DOI 10.1590/S0066-782X1999000800012
   McVary KT, 2001, J UROLOGY, V166, P1624, DOI 10.1016/S0022-5347(05)65641-8
   Musselman DL, 1998, ARCH GEN PSYCHIAT, V55, P580, DOI 10.1001/archpsyc.55.7.580
   O'Kane PD, 2001, INT J CLIN PRACT, V55, P219
   ROOSE SP, 1991, J CLIN PSYCHIAT, V52, P34
   Seidman S N, 2000, Curr Psychiatry Rep, V2, P201, DOI 10.1007/s11920-996-0008-0
   Seidman SN, 2001, AM J PSYCHIAT, V158, P1623, DOI 10.1176/appi.ajp.158.10.1623
   Shabsigh R, 1998, UROLOGY, V52, P848, DOI 10.1016/S0090-4295(98)00292-1
   STEIGER A, 1993, ACTA PSYCHIAT SCAND, V87, P358, DOI 10.1111/j.1600-0447.1993.tb03387.x
   Sullivan ME, 2001, BJU INT, V87, P838, DOI 10.1046/j.1464-410x.2001.02211.x
   THASE ME, 1988, BIOL PSYCHIAT, V24, P33, DOI 10.1016/0006-3223(88)90119-9
   WEI M, 1994, AM J EPIDEMIOL, V140, P930, DOI 10.1093/oxfordjournals.aje.a117181
NR 32
TC 25
Z9 25
U1 0
U2 2
PU PHYSICIANS POSTGRADUATE PRESS
PI MEMPHIS
PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA
SN 0160-6689
EI 1555-2101
J9 J CLIN PSYCHIAT
JI J. Clin. Psychiatry
PY 2003
VL 64
SU 10
BP 26
EP 30
PG 5
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 724LL
UT WOS:000185489000005
PM 12971813
DA 2019-01-08
ER

PT J
AU Kelly, PA
   Samandouras, G
   Grossman, AB
   Afshar, F
   Besser, GM
   Jenkins, PJ
AF Kelly, PA
   Samandouras, G
   Grossman, AB
   Afshar, F
   Besser, GM
   Jenkins, PJ
TI Neurosurgical treatment of Nelson's syndrome
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID CUSHINGS-DISEASE; PITUITARY IRRADIATION; ADRENALECTOMY; RADIOTHERAPY;
   EXPERIENCE; MANAGEMENT; SURGERY
AB Total bilateral adrenalectomy remains the definitive procedure for cure in Cushing's disease. It is complicated by the development of Nelson's syndrome, the treatment of which remains troublesome. We report the long-term follow-up, median 17 yr (range, 8-22 yr), of 13 patients (3 males and 10 females) treated with pituitary surgery for Nelson's syndrome at a median age of 35 yr (range, 21-67 yr). The presence of a pituitary mass lesion necessitated neurosurgery in all. Pre-operatively, the median plasma ACTH level was 664 pmol/liter (range, 92-3665 pmol/liter); this fell to 29 pmol/liter (range, <2 to 1124 pmol/liter) postoperatively (P < 0.0005). Cutaneous hyperpigmentation was reduced in all and resolved in 11 patients. The pituitary tumor bulk was clearly reduced in 12 patients. There was no perioperative mortality. No patient developed a visual field defect attributable to surgery. New anterior pituitary hormone deficiency occurred in seven patients, and permanent diabetes insipidus occurred in five patients. At latest follow-up, the median plasma ACTH is 73 pmol/liter (range, <2 to 7759 pmol/liter); six patients have levels of less than 44 pmol/liter and also have a resolution of their pigmentation and no evidence of a recurrence of a pituitary mass lesion. We conclude that pituitary surgery is an efficacious treatment for mass lesions associated with Nelson's syndrome, has long-term benefit with minimal side effects, and must be considered in the management of this distressing complication.
C1 St Bartholomews & Royal London Hosp, Dept Endocrinol, London EC1A 7BE, England.
   St Bartholomews & Royal London Hosp, Dept Neurosurg, London EC1A 7BE, England.
RP Jenkins, PJ (reprint author), St Bartholomews Hosp, Dept Endocrinol, London EC1A 7BE, England.
EM p.j.jenkins@qmul.ac.uk
OI Kelly, Philip/0000-0003-4338-6225
CR ATKINSON AB, 1991, CLIN ENDOCRINOL, V34, P507, DOI 10.1111/j.1365-2265.1991.tb00332.x
   BARNETT AH, 1983, CLIN ENDOCRINOL OXF, V39, P91
   BENNETT AH, 1973, J UROLOGY, V109, P321, DOI 10.1016/S0022-5347(17)60417-8
   BURKE CW, 1990, CLIN ENDOCRINOL, V33, P525, DOI 10.1111/j.1365-2265.1990.tb03890.x
   DORNHORST A, 1983, J CLIN ENDOCR METAB, V56, P985, DOI 10.1210/jcem-56-5-985
   FUKUSHIMA T, 1985, NEUROSURG REV, V8, P185, DOI 10.1007/BF01815443
   GANZ JC, 1993, STEREOT FUNCT NEUROS, V61, P30
   GILKES JJH, 1977, BRIT MED J, V1, P996, DOI 10.1136/bmj.1.6067.996
   GLENN F, 1972, ANN SURG, V175, P948, DOI 10.1097/00000658-197206010-00015
   GUTHRIE FW, 1981, SURG NEUROL, V16, P316, DOI 10.1016/0090-3019(81)90262-7
   HOPWOOD NJ, 1977, AM J DIS CHILD, V131, P1353, DOI 10.1001/archpedi.1977.02120250035005
   HOWLETT TA, 1989, CLIN ENDOCRINOL, V31, P309, DOI 10.1111/j.1365-2265.1989.tb01255.x
   JENKINS PJ, 1995, J CLIN ENDOCR METAB, V80, P165, DOI 10.1210/jc.80.1.165
   KELLY WF, 1983, Q J MED, V206, P224
   Kemink SAG, 2001, CLIN ENDOCRINOL, V54, P45, DOI 10.1046/j.1365-2265.2001.01187.x
   LAMBERTS SWJ, 1980, J CLIN ENDOCR METAB, V51, P307, DOI 10.1210/jcem-51-2-307
   LUDECKE DK, 1982, ACTA NEUROCHIR, V65, P3, DOI 10.1007/BF01405437
   MANOLAS KJ, 1984, WORLD J SURG, V8, P374, DOI 10.1007/BF01655082
   MCCANCE DR, 1993, CLIN ENDOCRINOL, V39, P315, DOI 10.1111/j.1365-2265.1993.tb02371.x
   MELBY JC, 1988, ANN INTERN MED, V109, P445, DOI 10.7326/0003-4819-109-6-445
   MercadoAsis LB, 1997, J CLIN ENDOCR METAB, V82, P514, DOI 10.1210/jc.82.2.514
   MONTGOMERY DAD, 1978, BRIT J SURG, V65, P221, DOI 10.1002/bjs.1800650402
   MOORE TJ, 1976, ANN INTERN MED, V85, P731, DOI 10.7326/0003-4819-85-6-731
   NELSON DH, 1966, J CLIN ENDOCR METAB, V26, P722, DOI 10.1210/jcem-26-7-722
   NELSON DH, 1960, ANN INTERN MED, V52, P560, DOI 10.7326/0003-4819-52-3-560
   NELSON DH, 1958, NEW ENGL J MED, V259, P161, DOI 10.1056/NEJM195807242590403
   Newell-Price J, 2002, J CLIN ENDOCR METAB, V87, P1640, DOI 10.1210/jc.87.4.1640
   ORTH DN, 1971, NEW ENGL J MED, V285, P243, DOI 10.1056/NEJM197107292850501
   Pereira MAA, 1998, CLIN ENDOCRINOL, V49, P533, DOI 10.1046/j.1365-2265.1998.00578.x
   Plowman PN, 1999, CLIN ENDOCRINOL, V51, P265
   PRINZ RA, 1979, ARCH SURG-CHICAGO, V114, P481
   REES LH, 1971, ENDOCRINOLOGY, V89, P254, DOI 10.1210/endo-89-1-254
   SCOTT HW, 1977, ANN SURG, V185, P524, DOI 10.1097/00000658-197705000-00004
   SCOTT RS, 1978, CLIN ENDOCRINOL, V9, P571, DOI 10.1111/j.1365-2265.1978.tb01516.x
   SPRAGUE RG, 1953, JAMA-J AM MED ASSOC, V151, P629
   TRAINER PJ, 1993, CLIN ENDOCRINOL, V38, P73, DOI 10.1111/j.1365-2265.1993.tb00975.x
   WELBOURN RB, 1971, BRIT J SURG, V58, P1, DOI 10.1002/bjs.1800580102
   WISLAWSKI J, 1985, J NEUROSURG, V62, P68, DOI 10.3171/jns.1985.62.1.0068
   Wolffenbuttel BHR, 1998, CLIN NEUROL NEUROSUR, V100, P60, DOI 10.1016/S0303-8467(97)00124-8
NR 39
TC 37
Z9 37
U1 0
U2 0
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0021-972X
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD DEC
PY 2002
VL 87
IS 12
BP 5465
EP 5469
DI 10.1210/jc.2002-020299
PG 5
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 628DC
UT WOS:000179976300019
PM 12466338
OA Bronze
DA 2019-01-08
ER

PT J
AU Fisher, L
   Chesla, CA
   Skaff, MM
   Mullan, JT
   Kanter, RA
AF Fisher, L
   Chesla, CA
   Skaff, MM
   Mullan, JT
   Kanter, RA
TI Depression and anxiety among partners of European-American and Latino
   patients with type 2 diabetes
SO DIABETES CARE
LA English
DT Article
ID GENDER-DIFFERENCES; EXPRESSED EMOTION; GLYCEMIC CONTROL; SOCIAL SUPPORT;
   SYMPTOMS; SPOUSES; DISTRESS; FAMILY; HEALTH; PERSPECTIVE
AB OBJECTIVE- To assess the levels of and the independent contributors to depressive affect and anxiety among partners of patients with type 2 diabetes.
   RESEARCH DESIGN AND METHODS- The partners of 75 Latino and 113 European-American patients with type 2 diabetes were Assessed for level of depressive affect and anxiety and for three groups of potential stressors: demographics (age, gender, and education), patient disease status (time since diagnosis, HbA(1c)-comorbidities, And BMI), and family stress (disease impact, spouse conflict, and family closeness). Dependent variables were partner depressive affect (Center for Epidemiological Studies-Depression scale) and anxiety (Symptom Checklist [SCL-90] anxiety). Predictors of partner depressive affect and anxiety and partner-patient con-cordance rates were computed.
   RESULTS- Levels of depressive affect and anxiety and rates of likely depression (21.4%) were as high for partners as they were for patients. No differences were found on depressive affect or anxiety by ethnicity, but female partner's scored higher than male partners on both measures. Partner-patient concordance rates were low. The family level variables accounted for the most variance in both depressive affect and anxiety, with demographics and disease status variables contributing modest or nonsignificant independent variance.
   CONCLUSIONS- Partners of patients with type 2 diabetes experience levels of psychological distress as. high or even higher than patients, especially if the partner is female. Low levels of concordance suggest that partners can be distressed even if patients are not. Many life stresses contribute to psychological distress among. partners, not just disease-related indicators. The findings suggest the utility of evaluating both partners and patients using a life-centered rather than a disease-focused perspective.
C1 Univ Calif San Francisco, Dept Family & Community Med, San Francisco, CA 94143 USA.
   No Calif Kaiser Permanente, San Francisco, CA USA.
RP Fisher, L (reprint author), Univ Calif San Francisco, Dept Family & Community Med, Box 0900, San Francisco, CA 94143 USA.
EM fisher@itsa.ucsf.edu
FU NIDDK NIH HHS [DK-49816, DK-53203]
CR Almeida DM, 1998, J PERS SOC PSYCHOL, V75, P670, DOI 10.1037/0022-3514.75.3.670
   BEACH SRH, 1994, BEHAV THER, V25, P345, DOI 10.1016/S0005-7894(05)80152-2
   Benazon NR, 2000, J ABNORM PSYCHOL, V109, P550, DOI 10.1037//0021-843X.109.3.550
   BLOOD GW, 1994, J COMMUN DISORD, V27, P19, DOI 10.1016/0021-9924(94)90008-6
   Bookwala J, 1996, PSYCHOL AGING, V11, P582, DOI 10.1037//0882-7974.11.4.582
   Brummett BH, 1998, PSYCHOSOM MED, V60, P707, DOI 10.1097/00006842-199811000-00008
   CAMWATH TC, 1987, BRIT MED J, V294, P409
   Ciechanowski PS, 2000, ARCH INTERN MED, V160, P3278, DOI 10.1001/archinte.160.21.3278
   COYNE JC, 1991, J PERS SOC PSYCHOL, V61, P404, DOI 10.1037/0022-3514.61.3.404
   COYNE JC, 1987, J CONSULT CLIN PSYCH, V55, P347, DOI 10.1037//0022-006X.55.3.347
   COYNE JC, 1994, PSYCHOL BULL, V116, P29, DOI 10.1037/0033-2909.116.1.29
   DCCT Res Grp, 1988, DIABETES CARE, V11, P725
   De Groot M, 2001, DIABETES CARE, V24, P407, DOI 10.2337/diacare.24.2.407
   DEGROOT M, 1994, PSYCHOSOM MED, V56, pA176
   DEROGATIS L R, 1973, Psychopharmacology Bulletin, V9, P13
   DUFORT GG, 1994, PSYCHOL MED, V24, P431, DOI 10.1017/S0033291700027409
   FISHER L, 1993, FAM PROCESS, V32, P69, DOI 10.1111/j.1545-5300.1993.00069.x
   Fisher L, 2001, DIABETES CARE, V24, P1751, DOI 10.2337/diacare.24.10.1751
   Fisher L, 2000, J FAM PRACTICE, V49, P561
   Fisher L, 1998, DIABETES EDUCATOR, V24, P599, DOI 10.1177/014572179802400504
   Fisher L, 2000, DIABETES CARE, V23, P267, DOI 10.2337/diacare.23.3.267
   Gilligan C, 1982, DIFFERENT VOICE PSYC
   HOOLEY JM, 1986, BRIT J PSYCHIAT, V148, P642, DOI 10.1192/bjp.148.6.642
   HOOLEY JM, 1985, CLIN PSYCHOL REV, V5, P119, DOI 10.1016/0272-7358(85)90018-2
   Kiecolt-Glaser JK, 2001, PSYCHOL BULL, V127, P472, DOI 10.1037//0033-2909.127.4.472
   LEWIS FM, 1989, SOC SCI MED, V29, P1261, DOI 10.1016/0277-9536(89)90066-X
   LUSTMAN PJ, 1988, DIABETES CARE, V11, P605, DOI 10.2337/diacare.11.8.605
   Lustman PJ, 2000, DIABETES CARE, V23, P934, DOI 10.2337/diacare.23.7.934
   MARIN G, 1991, RES HISPANIC POPULAT, V23
   MCLEOD JD, 1993, J AFFECT DISORDERS, V27, P43, DOI 10.1016/0165-0327(93)90096-3
   Northouse LL, 2000, SOC SCI MED, V50, P271, DOI 10.1016/S0277-9536(99)00281-6
   Pearlin LI, 1981, J HEALTH SOC BEHAV, V22, P333
   Piccinelli M, 2000, BRIT J PSYCHIAT, V177, P486, DOI 10.1192/bjp.177.6.486
   Pieper B A, 1990, Diabetes Educ, V16, P108, DOI 10.1177/014572179001600206
   Pruchno R. A., 1990, J GERONTOL, V45, P192
   RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306
   Revenson T A, 1991, Arthritis Care Res, V4, P63, DOI 10.1002/art.1790040203
   RIDEOUT EM, 1990, INT J PSYCHIAT MED, V20, P37, DOI 10.2190/YBXJ-WPDJ-QB0Y-183G
   SCHWARTZ L, 1991, PAIN, V44, P61, DOI 10.1016/0304-3959(91)90148-Q
   TAMBS K, 1991, J AFFECT DISORDERS, V21, P117, DOI 10.1016/0165-0327(91)90058-Z
   Tower RB, 1996, PSYCHOL AGING, V11, P683, DOI 10.1037/0882-7974.11.4.683
   Tschann JM, 1999, J MARRIAGE FAM, V61, P269, DOI 10.2307/353747
   VanderDoes FEE, 1996, DIABETES CARE, V19, P204, DOI 10.2337/diacare.19.3.204
NR 43
TC 36
Z9 36
U1 0
U2 2
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
EI 1935-5548
J9 DIABETES CARE
JI Diabetes Care
PD SEP
PY 2002
VL 25
IS 9
BP 1564
EP 1570
DI 10.2337/diacare.25.9.1564
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 724UE
UT WOS:000185504400012
PM 12196428
OA Bronze
DA 2019-01-08
ER

PT J
AU Takii, M
   Uchigata, Y
   Nozaki, T
   Nishikata, H
   Kawai, K
   Komaki, G
   Iwamoto, Y
   Kubok, C
AF Takii, M
   Uchigata, Y
   Nozaki, T
   Nishikata, H
   Kawai, K
   Komaki, G
   Iwamoto, Y
   Kubok, C
TI Classification of type 1 diabetic females with bulimia nervosa into
   subgroups 4D according to purging behavior
SO DIABETES CARE
LA English
DT Article
ID EATING DISORDERS; INSULIN OMISSION; YOUNG-WOMEN; MELLITUS; IDDM;
   DEPRESSION; INVENTORY; SCALE
AB OBJECTIVE- To classify type 1 diabetic females with bulimia nervosa (BN) by type of inappropriate compensatory behavior in order to prevent weight gain (ICB) and to investigate the group differences.
   RESEACH DESIGN AND METHODS- Type I diabetic females with BN, diagnosed by structured diagnostic interview based on DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, 4th ed.) criteria, were classified by type of ICB as follows: 1) only severe insulin omission as an ICB (BN-I) (n = 22), 2) both severe insulin omission and self-induced vomiting = and/or laxative abuse (BN-IP) (n = 22), or 3) no insulin omission but another ICB (BN-NI) (n = 11). The clinical characteristics of these three groups and a binge-eating disorder (BED) group (n = 24) were compared.
   RESULTS- The BN-IP and BN-I groups had the highest HbA(1c) levels. The BN-IP group had the highest rates of diabetic neuropathy, retinopathy, and nephropathy. The BN-NI group had the second highest rates of neuropathy and retinopathy. The BN-IP group had the highest frequencies of diabetes- and ketoacidosis-related hospital admissions, and the BN-I group had the second highest frequencies. The BN-NI group showed the highest scores on psychological tests related to depression, anxiety, eating disorder psychopathology, and perfectionism. The had a BN-NI group had the highest rate of history of visits to a psychiatrist, and the BN-IP group the second highest history.
   CONCLUSIONS- Type I diabetic females with BN seem not to be homogenous and can be classified into three distinctive subgroups by type of ICB. Individuals with BN-IP had the most severe problems with both medical and psychological/behavioral aspects. Individuals with BN-NI manifested the highest psychological distress. The BN-I group had comparatively mild distress despite having the poorest metabolic control. Each BN group manifested more severe pathology than the BED group.
C1 Kyushu Univ, Grad Sch Med Sci, Dept Psychosomat Med, Hiyashi Ku, Fukuoka 8128582, Japan.
   Tokyo Womens Med Univ, Sch Med, Ctr Diabet, Tokyo, Japan.
   Natl Ctr Neurol & Psychiat, NIMH, Div Psychosomat Med, Chiba, Japan.
RP Takii, M (reprint author), Kyushu Univ, Grad Sch Med Sci, Dept Psychosomat Med, Hiyashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.
CR American Psychiatric Association, 1994, DIAGN STAT MAN MENT
   FAIRBURN CG, 1991, BRIT MED J, V303, P17, DOI 10.1136/bmj.303.6793.17
   First M. B., 1996, USERS GUIDE STRUCTUR
   FROST RO, 1990, COGNITIVE THER RES, V14, P449, DOI 10.1007/BF01172967
   GARNER DM, 1983, INT J EAT DISORDER, V2, P15, DOI 10.1002/1098-108X(198321)2:2<15::AID-EAT2260020203>3.0.CO;2-6
   HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56
   LAGRECA AM, 1987, DIABETES CARE, V10, P659
   MARCUS MD, 1990, NEUROPSYCHOLOGICAL B, P102
   POLONSKY WH, 1994, DIABETES CARE, V17, P1178, DOI 10.2337/diacare.17.10.1178
   RODIN GM, 1992, DIABETES CARE, V15, P1402, DOI 10.2337/diacare.15.10.1402
   RODIN GM, 1986, INT J PSYCHIAT MED, V16, P49, DOI 10.2190/HULH-CTPR-4V17-383C
   RUBIN RR, 1992, DIABETES CARE, V15, P1640, DOI 10.2337/diacare.15.11.1640
   Rydall AC, 1997, NEW ENGL J MED, V336, P1849, DOI 10.1056/NEJM199706263362601
   SPIELBERGER CD, 1983, MANUAL STATETRAIT AN
   Takii M, 1999, J PSYCHOSOM RES, V47, P221, DOI 10.1016/S0022-3999(99)00031-8
   ZUNG WWK, 1972, J CLIN PSYCHOL, V28, P539, DOI 10.1002/1097-4679(197210)28:4<539::AID-JCLP2270280427>3.0.CO;2-S
NR 16
TC 15
Z9 17
U1 0
U2 0
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
J9 DIABETES CARE
JI Diabetes Care
PD SEP
PY 2002
VL 25
IS 9
BP 1571
EP 1575
DI 10.2337/diacare.25.9.1571
PG 5
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 724UE
UT WOS:000185504400013
PM 12196429
OA Bronze
DA 2019-01-08
ER

PT J
AU Trief, PM
   Wade, MJ
   Britton, KD
   Weinstock, RS
AF Trief, PM
   Wade, MJ
   Britton, KD
   Weinstock, RS
TI A prospective analysis of marital relationship factors and quality of
   life in diabetes
SO DIABETES CARE
LA English
DT Article
ID HEALTH SURVEY SF-36; GLYCEMIC CONTROL; PSYCHOSOCIAL FACTORS; CHRONIC
   ILLNESS; SOCIAL SUPPORT; MELLITUS; FAMILY; ADJUSTMENT; INTERVENTION;
   FRAMEWORK
AB OBJECTIVE - To prospectively assess the relation between marital relationship domains (i.e., intimacy and adjustment) and health-related quality of life (HRQoL) and glycemic control of individuals with diabetes.
   RESEARCH DESIGN AND METHODS - A previous cross-sectional study assessed the relationship between marital quality and adaptation to diabetes for 78 insulin-treated adults. Each participant completed two marital quality measures (Spanier Dyadic Adjustment Scale and Personal Assessment of Intimacy in Relationships Scale) at time 1 (T1). A total of 61 subjects were contacted two years later (time 2 [T2]) and re-administered four HRQoL measures (Diabetes Quality of Life Scale, Medical Outcomes Study Health Survey-SF36, Problem Areas in Diabetes Scale, and Positive and Negative Affect Schedule). Glycemic control was assessed by HbA(1c). Demographic data (age, sex, type and duration of diabetes, years married, other medical problems, family history, and years of education) were gathered from charts and questionnaires. Linear regression analyses were used to assess the ability of the two marital measures at T1 to predict HRQoL at T2, controlling for confounding HRQoL and baseline subject variables.
   RESULTS - Both of the marital quality measures at T1 were prospective predictors of aspects of HRQoL at T2. Less diabetes-related distress at T2 was predicted by better marital adjustment at T1. Greater satisfaction with aspects of the diabetes care regimen at T2 was predicted by better marital adjustment and greater perceived marital intimacy at T1. Neither marital measure predicted general HRQoL or glycemic control.
   CONCLUSIONS - For insulin-treated adults with diabetes, quality of marriage prospectively predicts diabetes-related quality of life. This study highlights the sensitivity of diabetes-specific measures. Future work should explore the value of interventions that target the spouse and/or couple.
C1 SUNY Upstate Med Univ, Dept Psychiat, Syracuse, NY 13210 USA.
   Vet Adm Med Ctr, Syracuse, NY 13210 USA.
RP Trief, PM (reprint author), SUNY Upstate Med Univ, Dept Psychiat, 750 E Adams St, Syracuse, NY 13210 USA.
OI Trief, Paula/0000-0002-2827-5722
CR Anderson RM, 1997, DIABETES CARE, V20, P299, DOI 10.2337/diacare.20.3.299
   Bowling A, 1997, MEASURING HLTH REV Q
   CARDENAS L, 1987, AM J MED SCI, V293, P28, DOI 10.1097/00000441-198701000-00007
   Coyne JC, 1994, J FAMILY PSYCHOL, V8, P43, DOI DOI 10.1037/0893-3200.8.1.43
   *DCCT RES GROUP, 1988, DIABETES CARE, V11, P727
   Fisher L, 1998, DIABETES EDUCATOR, V24, P599, DOI 10.1177/014572179802400504
   GARAYSEVILA ME, 1995, J DIABETES COMPLICAT, V9, P81, DOI 10.1016/1056-8727(94)00021-F
   GILDEN JL, 1989, J AM GERIATR SOC, V37, P1023, DOI 10.1111/j.1532-5415.1989.tb06915.x
   HANNUM J W, 1991, Journal of Psychosocial Oncology, V9, P1, DOI 10.1300/J077v09n02_01
   JACOBSON AM, 1994, DIABETES CARE, V17, P267, DOI 10.2337/diacare.17.4.267
   KLAUSNER EJ, 1995, INT J MENT HEALTH, V24, P64
   LLOYD CE, 1992, DIABETES CARE, V15, P166, DOI 10.2337/diacare.15.2.166
   LOCKE HJ, 1959, J MARRIAGE FAMILY LI, V21, P251
   Lustman PJ, 2000, DIABETES CARE, V23, P934, DOI 10.2337/diacare.23.7.934
   MCHORNEY CA, 1994, MED CARE, V32, P40, DOI 10.1097/00005650-199401000-00004
   Meadows K, 1996, QUAL LIFE RES, V5, P242, DOI 10.1007/BF00434746
   Nouwen A, 1997, HEALTH PSYCHOL, V16, P263
   PEYROT M, 1985, PSYCHOSOM MED, V47, P542, DOI 10.1097/00006842-198511000-00004
   POLONSKY WH, 1995, DIABETES CARE, V18, P754, DOI 10.2337/diacare.18.6.754
   Polonsky WH, 2000, DIABETES SPECTRUM, V13, P36
   PRIMOMO J, 1990, RES NURS HEALTH, V13, P153, DOI 10.1002/nur.4770130304
   Quittner AL, 1998, HEALTH PSYCHOL, V17, P112, DOI 10.1037/0278-6133.17.2.112
   RUBIN RR, 1992, DIABETES CARE, V15, P1640, DOI 10.2337/diacare.15.11.1640
   SCHAEFER MT, 1981, J MARITAL FAM THER, V7, P47, DOI 10.1111/j.1752-0606.1981.tb01351.x
   SCHWARTZ LS, 1991, GEN HOSP PSYCHIAT, V13, P19, DOI 10.1016/0163-8343(91)90005-H
   SPANIER GB, 1976, J MARRIAGE FAM, V38, P15, DOI 10.2307/350547
   Staquet MJ, 1998, QUALITY LIFE ASSESSM
   TESTA M, 1998, DIABETES CARE S3, V21, P44
   THARP RG, 1966, J CONSULT PSYCHOL, V30, P426, DOI 10.1037/h0023835
   Trief PM, 1998, DIABETES CARE, V21, P241, DOI 10.2337/diacare.21.2.241
   TRIEF PM, 2001, DIABETES CARE, V23, P1384
   WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002
   WARE JE, 1994, SF 36 PHYSLICAL MENT
   WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063
   WEINGER K, 1998, ANN BEHAV MED, V20, pS118
   Welch GW, 1997, DIABETES CARE, V20, P760, DOI 10.2337/diacare.20.5.760
   WING RR, 1991, J CONSULT CLIN PSYCH, V59, P156, DOI 10.1037/0022-006X.59.1.156
NR 37
TC 73
Z9 77
U1 0
U2 8
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
J9 DIABETES CARE
JI Diabetes Care
PD JUL
PY 2002
VL 25
IS 7
BP 1154
EP 1158
DI 10.2337/diacare.25.7.1154
PG 5
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 724UA
UT WOS:000185504000008
PM 12087013
OA Bronze
DA 2019-01-08
ER

PT J
AU Vaarasmaki, M
   Gissler, M
   Ritvanen, A
   Hartikainen, AL
AF Vaarasmaki, M
   Gissler, M
   Ritvanen, A
   Hartikainen, AL
TI Congenital anomalies and first life year surveillance in Type 1 diabetic
   births
SO DIABETIC MEDICINE
LA English
DT Article
DE congenital anomaly; diabetic pregnancy; infant mortality; perinatal
   mortality
ID PREGNANCY; POPULATION; WOMEN; MALFORMATIONS; MORTALITY; OUTCOMES;
   NEWBORN; COHORT; INFANT; TRIAL
AB Aims To evaluate the rate of congenital anomalies (CA) and the reasons for mortality from 22 weeks of gestation until 1 year of age in births by Type I diabetic mothers.
   Methods Population-based cohort study using combined data from four national health registers in Finland during 1991-1995, including 954 singleton pregnancies complicated by Type 1 diabetes.
   Results Sixty births (629/10 000) involved registered major CA, of which 68% (n = 41) were isolated and 22% (n = 13) multiple anomalies, and in six cases, a syndrome was diagnosed (10%). After the exclusion of syndromes, the total number of anomalies was 73. Of the malformed infants, 63% were boys. The total rate of deaths among births until 1 year of age was higher in diabetic than in non-diabetic mothers (19.9/1000 vs. 8.1/1000): especially the rates of stillborns (odds ratio 2.4; 95% confidence interval 1.2-4.7) and post-neonatal deaths (3.8; 1.6-9.2) were higher. Of perinatal mortality (PNM) from the 22nd gestational week to the age of 7 days (13.6/1000), 23% were due to CA, 23% to prematurity, and the rest were intrauterine, mostly unexplained, deaths. Respiratory distress syndrome was the main cause of death among infants.
   Conclusions The rate of CAs in Type 1 diabetic pregnancies is still high, but their proportion as a cause of PNM has decreased. Though PNM rate was low, post-neonatal mortality was significantly increased, reflecting the shift of deaths from the perinatal period to a later age.
C1 Univ Oulu, Dept Obstet & Gynaecol, Oulu, Finland.
   STAKES, Helsinki, Finland.
RP Vaarasmaki, M (reprint author), Univ Hosp Oulu, Dept Obstet & Gynaecol, PL 24, OYS 90029, Finland.
CR ANTTILA M, 1993, ACTA U OUL D, V273
   Casson IF, 1997, BRIT MED J, V315, P275, DOI 10.1136/bmj.315.7103.275
   CNATTINGIUS S, 1994, DIABETIC MED, V11, P696, DOI 10.1111/j.1464-5491.1994.tb00335.x
   DAMM P, 1989, AM J OBSTET GYNECOL, V161, P1163, DOI 10.1016/0002-9378(89)90656-X
   Gissler M, 1999, ACTA PAEDIATR, V88, P310, DOI 10.1080/08035259950170088
   GISSLER M, 1995, SCAND J SOC MED, V23, P75, DOI 10.1177/140349489502300113
   Gissler M, 1997, EUR J EPIDEMIOL, V13, P169, DOI 10.1023/A:1007379029182
   HANSON U, 1986, DIABETES RES CLIN EX, V3, P71
   Hawthorne G, 1997, BRIT MED J, V315, P279, DOI 10.1136/bmj.315.7103.279
   Machado AF, 2001, DIABETES, V50, P1193, DOI 10.2337/diabetes.50.5.1193
   REECE EA, 1994, SEMIN PERINATOL, V18, P459
   RITVANEN A, 1996, EPAMUODOSTUMAREKISTE, P1
   RITVANEN A, 1998, MED GENETICS
   SAARIKEMPPAINEN A, 1994, J PERINAT MED, V22, P279, DOI 10.1515/jpme.1994.22.4.279
   SAARIKEMPPAINEN A, 1990, LANCET, V336, P387, DOI 10.1016/0140-6736(90)91941-3
   Schwartz R, 2000, SEMIN PERINATOL, V24, P120, DOI 10.1053/sp.2000.6363
   Suhonen L, 2000, DIABETOLOGIA, V43, P79, DOI 10.1007/s001250050010
   Vaarasmaki MS, 2000, EARLY HUM DEV, V59, P61, DOI 10.1016/S0378-3782(00)00087-6
   vonKries R, 1997, EUR J PEDIATR, V156, P963, DOI 10.1007/s004310050752
NR 19
TC 19
Z9 19
U1 0
U2 3
PU BLACKWELL PUBLISHING LTD
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND
SN 0742-3071
J9 DIABETIC MED
JI Diabetic Med.
PD JUL
PY 2002
VL 19
IS 7
BP 589
EP 593
DI 10.1046/j.1464-5491.2002.00756.x
PG 5
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 568BL
UT WOS:000176522500010
PM 12099963
DA 2019-01-08
ER

PT J
AU Hultman, CM
   Sparen, P
   Cnattingius, S
AF Hultman, CM
   Sparen, P
   Cnattingius, S
TI Perinatal risk factors for infantile autism
SO EPIDEMIOLOGY
LA English
DT Article
DE infantile autism; perinatal; risk factors; maternal; intrauterine growth
ID INTRAUTERINE-GROWTH; MATERNAL SMOKING; POPULATION; PREGNANCY;
   SCHIZOPHRENIA; DISORDER; DELIVERY; COMPLICATIONS; EPIDEMIOLOGY;
   CHILDHOOD
AB Background. Etiologic hypotheses in infantile autism suggest a strong genetic component, as well as possible environmental risks linked to early fetal development. We evaluated the association of maternal, pregnancy, delivery, and infant characteristics and risk of infantile autism.
   Methods. We conducted a case-control study nested within a population-based cohort (all Swedish children born in 1974-1993). We used prospectively recorded data from the Swedish Birth Register, which were individually linked to the Swedish Inpatient Register. Cases were 408 children (321 boys and 87 girls) discharged with a main diagnosis ion infantile autism from any hospital in Sweden before 10 years of age in the period 1987-1994, plus 2,040 matched controls. Conditional logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs).
   Results. The risk of autism was associated with daily smoking in early pregnancy (OR = 1.4; CI = 1.1-1.8), maternal birth outside Europe and North America (OR - 3.0; CI = 1.7-5.2), cesarean delivery (OR = 1.6; CI = 1.1-2.3), being small for gestational age (SGA; OR = 2.1; CI = 1.1-3.0), a 5-minute Apgar score below 7 (OR = 3.2, CI = 1.2-8.2), and congenital malformations (OR = 1.8, CI = 1.1-3.1). No association was found between autism and head circumference, maternal diabetes, being a twin, or season of birth.
   Conclusions. Our findings suggest that intrauterine and neonatal factors related to deviant intrauterine growth or fetal distress are important in the pathogenesis of autism.
C1 Karolinska Inst, Dept Med Epidemiol, S-17177 Stockholm, Sweden.
   Univ Uppsala, Dept Neurosci, S-75105 Uppsala, Sweden.
   Univ Coll S Stockholm, Stockholm Ctr Hlth Soc Transit, Huddinge, Sweden.
RP Hultman, CM (reprint author), Karolinska Inst, Dept Med Epidemiol, S-17177 Stockholm, Sweden.
CR BAILEY A, 1995, PSYCHOL MED, V25, P63, DOI 10.1017/S0033291700028099
   Bolton PF, 1997, J AM ACAD CHILD PSY, V36, P272, DOI 10.1097/00004583-199702000-00018
   BRESLOW NE, 1980, IARC SCI PUB, V32
   BROOKE OG, 1989, BRIT MED J, V298, P795, DOI 10.1136/bmj.298.6676.795
   Bryson SE, 1998, MENT RETARD DEV D R, V4, P97, DOI 10.1002/(SICI)1098-2779(1998)4:2<97::AID-MRDD6>3.3.CO;2-J
   Burd L, 1999, J PERINAT MED, V27, P441, DOI 10.1515/JPM.1999.059
   CEFALO RC, 1978, J REPROD MED, V21, P300
   CNATTINGIUS S, 1992, J EPIDEMIOL COMMUN H, V46, P218, DOI 10.1136/jech.46.3.218
   CNATTINGIUS S, 1990, SCAND J SOC MED, V18, P143, DOI 10.1177/140349489001800209
   Cryan E, 1996, J AUTISM DEV DISORD, V26, P453, DOI 10.1007/BF02172829
   Dalen P., 1975, SEASON BIRTH STUDY S
   David AS, 1997, PSYCHOL MED, V27, P1311, DOI 10.1017/S0033291797005680
   ERICSON A, 1984, ACTA PAEDIATR SCAND, V73, P69, DOI 10.1111/j.1651-2227.1984.tb09900.x
   FERGUSSON DM, 1993, PEDIATRICS, V92, P815
   Fergusson DM, 1998, ARCH GEN PSYCHIAT, V55, P721, DOI 10.1001/archpsyc.55.8.721
   Fombonne E, 1999, PSYCHOL MED, V29, P769, DOI 10.1017/S0033291799008508
   Gillberg C, 1999, DEV PSYCHOPATHOL, V11, P567, DOI 10.1017/S0954579499002217
   Gillberg C, 1999, ACTA PSYCHIAT SCAND, V99, P399, DOI 10.1111/j.1600-0447.1999.tb00984.x
   Gillberg IC, 1996, J INTELL DISABIL RES, V40, P24, DOI 10.1111/j.1365-2788.1996.tb00599.x
   Hultman CM, 1999, BRIT MED J, V318, P421, DOI 10.1136/bmj.318.7181.421
   Jedrychowski W, 1998, J EXPO ANAL ENV EPID, V8, P347
   Jones PB, 1998, AM J PSYCHIAT, V155, P355, DOI 10.1176/ajp.155.3.355
   Juul-Dam N, 2001, PEDIATRICS, V107, part. no., DOI 10.1542/peds.107.4.e63
   Kiely J L, 1991, Paediatr Perinat Epidemiol, V5, P243, DOI 10.1111/j.1365-3016.1991.tb00707.x
   KYLLERMAN M, 1982, ACTA PAEDIATR SCAND, V71, P551, DOI 10.1111/j.1651-2227.1982.tb09473.x
   Lindmark G, 1991, Acta Obstet Gynecol Scand, V70, P105, DOI 10.3109/00016349109006190
   LOBASCHER ME, 1970, BRIT J PSYCHIAT, V117, P525, DOI 10.1192/bjp.117.540.525
   London E, 2000, ENVIRON HEALTH PERSP, V108, P401, DOI 10.1289/ehp.00108s3401
   Marsal K, 1996, ACTA PAEDIATR, V85, P843, DOI 10.1111/j.1651-2227.1996.tb14164.x
   Matsuishi T, 1999, J AUTISM DEV DISORD, V29, P161, DOI 10.1023/A:1023048812202
   MILLBERGER S, 1996, AM J PSYCHIAT, V153, P1138
   NELSON KB, 1991, PEDIATRICS, V87, P761
   PALO P, 1993, AM J PERINAT, V10, P88, DOI 10.1055/s-2007-994712
   Rodier PM, 1996, J COMP NEUROL, V370, P247, DOI 10.1002/(SICI)1096-9861(19960624)370:2<247::AID-CNE8>3.0.CO;2-2
   SMALLEY SL, 1988, ARCH GEN PSYCHIAT, V45, P953
   STROMLAND K, 1994, DEV MED CHILD NEUROL, V36, P351
   THORNGRENJERNEC.K, 2001, AM COLL OBSTET GYNEC, V98, P65
   TSAI LY, 1987, NEUROBIOLOGICAL ISSU, P180
   WARREN RP, 1986, J AUTISM DEV DISORD, V16, P189, DOI 10.1007/BF01531729
   Wyszynski DF, 1997, CLEFT PALATE-CRAN J, V34, P206, DOI 10.1597/1545-1569(1997)034<0206:MCSAOC>2.3.CO;2
NR 40
TC 320
Z9 329
U1 2
U2 41
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1044-3983
J9 EPIDEMIOLOGY
JI Epidemiology
PD JUL
PY 2002
VL 13
IS 4
BP 417
EP 423
DI 10.1097/01.EDE.0000016968.14007.E6
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 565PL
UT WOS:000176378600009
PM 12094096
DA 2019-01-08
ER

PT J
AU Feinstein, KW
   Grunden, N
   Harrison, EI
AF Feinstein, KW
   Grunden, N
   Harrison, EI
TI A region addresses patient safety
SO AMERICAN JOURNAL OF INFECTION CONTROL
LA English
DT Article
AB The Pittsburgh Regional Healthcare Initiative (PRHI) is a coalition of 35 hospitals, 4 major insurers, more than 30 major and small-business health care purchasers, dozens of corporate and civic leaders, organized labor, and partnerships with state and federal government all working together to deliver perfect patient care throughout Southwestern Pennsylvania. PRHI believes that in pursuing perfection, many of the challenges facing today's health care delivery system (eg, waste and error in the delivery of care, rising costs, frustration and shortage among clinicians and workers, financial distress, overcapacity, and lack of access to care) will be addressed. PRHI has identified patient safety (nosocomial infections and medication errors) and 5 clinical areas (obstetrics, orthopedic surgery, cardiac surgery, depression, and diabetes) as ideal starting points. In each of these areas of work, PRHI partners have assembled multifacility/multidisciplinary groups charged with defining perfection, establishing region-wide reporting systems, and devising and implementing recommended improvement strategies and interventions. Many design and conceptual elements of the PRHI strategy are adapted from the Toyota Production System and its Pittsburgh derivative, the Alcoa Business System. PRHI is in the proof-of-concept phase of development.
C1 Jewish Healthcare Fdn, Pittsburgh Reg Healthcare Initiat, Pittsburgh, PA 15222 USA.
RP Harrison, EI (reprint author), Jewish Healthcare Fdn, Pittsburgh Reg Healthcare Initiat, Ctr City Tower,650 Smithfield St,Suite 2330, Pittsburgh, PA 15222 USA.
CR Institute of Medicine, 1999, ERR HUM
NR 1
TC 7
Z9 7
U1 0
U2 2
PU MOSBY, INC
PI ST LOUIS
PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA
SN 0196-6553
J9 AM J INFECT CONTROL
JI Am. J. Infect. Control
PD JUN
PY 2002
VL 30
IS 4
BP 248
EP 251
AR UNSP 17/49/122645
DI 10.1067/mic.2002.122645
PG 4
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA 559VB
UT WOS:000176045100009
PM 12032502
DA 2019-01-08
ER

PT J
AU Turan, B
   Osar, Z
   Turan, JM
   Damci, T
   Ilkova, H
AF Turan, B
   Osar, Z
   Turan, JM
   Damci, T
   Ilkova, H
TI The role of coping with disease in adherence to treatment regimen and
   disease control in type 1 and insulin treated type 2 diabetes mellitus
SO DIABETES & METABOLISM
LA English
DT Article
DE coping; diabetes mellitus; self-care; microangiopathic complications;
   glycemic control
ID BREAST-CANCER; STRESS; STRATEGIES; DISTRESS
AB Background: Coping is defined as the behavioral and cognitive efforts used in an attempt to deal with stressful events. The objective of this study was to explore the relationship between coping with diabetes and the following outcome variables in type I and insulin treated type 2 diabetes mellitus: glycemic control, microangiopathic complications, adherence to self monitoring of blood glucose, adherence to insulin injections, and adherence to diet.
   Methods: Subjects were 196 insulin treated adult diabetes patients visiting an outpatient clinic at a government university hospital in Istanbul, Turkey. Coping with disease was measured with the Turkish version of the Diabetes Coping Measure and adherence to treatment regimen was measured with a questionnaire adapted from the subscales of the Summary of Diabetes Self-Care Activities Questionnaire. Data on patients' HbA(1c) levels and severity of microangiopathic complications were obtained from their medical records.
   Results: Partial correlations controlling for background variables suggested that coping was a good predictor of outcome for both type I and insulin treated type 2 diabetes mellitus. These associations were more pronounced for type I patients when compared to type 2 patients. Regressing the outcome variables on the two second-order coping factors (obtained by a factor analysis) also supported the hypothesis that coping is an important construct in explaining the outcome variables. Finally, the effect of coping on HbA(1c) was only partially mediated by adherence.
   Conclusion: Coping with diabetes-related issues is an important factor in both types of diabetes, with type 1 patients showing slightly stronger associations. Therefore, training and education programs for diabetic adults might benefit from including a component that is aimed at improving coping with issues specific to diabetes.
C1 Univ Istanbul, Cerrahpasa Med Fac, Dept Internal Med, Div Metab Endocrinol & Diabet, Istanbul, Turkey.
   Univ Istanbul, Inst Child Hlth, Dept Family Hlth, Istanbul, Turkey.
RP Turan, B (reprint author), Stanford Univ, Dept Psychol, Bldg 420,Jordan Hall,450 Serra Mall, Stanford, CA 94305 USA.
OI Turan, Bulent/0000-0003-2008-227X
CR ARMITAGE P, 1987, STAT METHODS MED RES
   BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037//0022-3514.51.6.1173
   BILLINGS AG, 1984, J PERS SOC PSYCHOL, V46, P877, DOI 10.1037/0022-3514.46.4.877
   CARVER CS, 1993, J PERS SOC PSYCHOL, V65, P375, DOI 10.1037/0022-3514.65.2.375
   DAVIS MD, 1997, INT TXB DIABETES MEL, V2, P1413
   DELAMATER AM, 1987, J DEV BEHAV PEDIATR, V8, P136
   FEIFEL H, 1987, PSYCHOSOM MED, V49, P616, DOI 10.1097/00006842-198711000-00007
   FEIFEL H, 1987, J PSYCHOSOM RES, V31, P91, DOI 10.1016/0022-3999(87)90103-6
   FELTON BJ, 1984, J CONSULT CLIN PSYCH, V52, P343, DOI 10.1037/0022-006X.52.3.343
   Glasgow RE, 1999, DIABETES CARE, V22, P832, DOI 10.2337/diacare.22.5.832
   GOETSCH VL, 1994, BEHAV RES THER, V32, P503, DOI 10.1016/0005-7967(94)90137-6
   HANSON CL, 1989, J CONSULT CLIN PSYCH, V57, P644, DOI 10.1037//0022-006X.57.5.644
   Holmbeck GN, 1997, J CONSULT CLIN PSYCH, V65, P599, DOI 10.1037/0022-006X.65.4.599
   JOHNSON SB, 1992, DIABETES CARE, V15, P1658, DOI 10.2337/diacare.15.11.1658
   Lazarus R. S, 1984, STRESS APPRAISAL COP
   Miller SM, 1989, STRESS PERSONAL CONT, P107
   Peyrot M, 1999, J HEALTH SOC BEHAV, V40, P141, DOI 10.2307/2676370
   Schwartz CE, 1998, BEHAV MED, V24, P41, DOI 10.1080/08964289809596380
   SHAMOON H, 1993, NEW ENGL J MED, V329, P977
   Smari J, 1997, PERS INDIV DIFFER, V22, P151, DOI 10.1016/S0191-8869(96)00199-7
   STANTON AL, 1993, HEALTH PSYCHOL, V12, P16, DOI 10.1037//0278-6133.12.1.16
   STONE AA, 1992, HOSTILITY, COPING & HEALTH, P203, DOI 10.1037/10105-014
   TOOBERT DJ, 1989, HDB PSYCHOL DIABETES, P351
   Turner RC, 1998, LANCET, V352, P837
   Welch G., 1994, HDB PSYCHOL DIABETES, P223
   Welch G, 1994, HDB PSYCHOL DIABETES, P400
   Welch GW, 1997, DIABETES CARE, V20, P760, DOI 10.2337/diacare.20.5.760
   *WHO, 1985, WHO TECH REP SER, V727
NR 28
TC 23
Z9 23
U1 2
U2 15
PU MASSON EDITEUR
PI PARIS 06
PA 120 BLVD SAINT-GERMAIN, 75280 PARIS 06, FRANCE
SN 1262-3636
J9 DIABETES METAB
JI Diabetes Metab.
PD JUN
PY 2002
VL 28
IS 3
BP 186
EP 193
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 576CJ
UT WOS:000176985000003
PM 12149598
DA 2019-01-08
ER

PT J
AU DeVries, JH
   Eskes, SA
   Snoek, FJ
   Pouwer, F
   van Ballegooie, E
   Spijker, AJ
   Kostense, PJ
   Seubert, M
   Heine, RJ
AF DeVries, JH
   Eskes, SA
   Snoek, FJ
   Pouwer, F
   van Ballegooie, E
   Spijker, AJ
   Kostense, PJ
   Seubert, M
   Heine, RJ
TI Continuous intraperitioneal insulin infusion in patients with 'brittle'
   diabetes: favourable effects on glycaemic control and hospital stay
SO DIABETIC MEDICINE
LA English
DT Article
DE continuous intraperitoneal insulin infusion; insulin infusion systems;
   quality of life
ID LONG-TERM SAFETY; IMPLANTABLE PUMPS; CLINICAL-TRIAL; DELIVERY;
   COMPLICATIONS; MELLITUS; VALIDITY; DISTRESS; EFFICACY; SYSTEMS
AB Aims To evaluate the effects of continuous intraperitoneal insulin infusion (CIPII) using implantable pumps on glycaemic control and duration of hospital stay in poorly controlled 'brittle' Dutch diabetes patients, and to assess their current quality of life.
   Methods Thirty-three patients were included. Glycaemic control was retrospectively assessed with HbA(1c) levels acquired before implantation, I year later and at long-term follow up of 58 months. Duration of hospital stay the year before and the year following first implantation was extracted from hospital records. Determinants of long-term glycaemic response were sought. Self-report questionnaires were administered at 58 months follow-up only, to assess current psychopathology and quality of life.
   Results Mean HbA(1c) decreased from -10.0 +/- 2.3% to 9.0 +/- 1.8% (P = 0.039) 1 year after implantation and stabilized at 9.0 +/- 1.6% (P = 0.023) during long-term follow-up. Median number of hospital days in the 20 patients suffering from hospital admission before implantation decreased from 45 the year before implantation to 13 the year after (P = 0.005). Patients with a higher baseline HbA(1c) showed a larger long-term response (P < 0.001). Relatively low levels for quality of life were found, as well as a higher than expected number of patients with psychiatric symptoms.
   Conclusions CIPII proved effective in complex patients with a history of poor control and hospital admission. Despite a substantial long-term improvement in glycaemic control and diminished hospital stay, normal levels of glycaemic control and quality of life were not attained.
C1 Vrije Univ Amsterdam Med Ctr, Dept Endocrinol, NL-1007 MB Amsterdam, Netherlands.
   Vrije Univ Amsterdam Med Ctr, Res Inst Endocrinol Reprod & Metab, NL-1007 MB Amsterdam, Netherlands.
   Vrije Univ Amsterdam Med Ctr, Dept Psychol Med, NL-1007 MB Amsterdam, Netherlands.
   Isala Hosp, Zwolle, Netherlands.
   Laurentius Hosp, Roermond, Netherlands.
   Vrije Univ Amsterdam Med Ctr, Dept Clin Epidemiol, NL-1007 MB Amsterdam, Netherlands.
RP DeVries, JH (reprint author), Vrije Univ Amsterdam Med Ctr, Dept Endocrinol, 1 OBU 42,POB 7057, NL-1007 MB Amsterdam, Netherlands.
EM hans.devries@vumc.nl
CR Arrindell W, 1981, NEDERLANDS TIJDSCHRI, V36, P77
   BROUSSOLLE C, 1994, LANCET, V343, P514, DOI 10.1016/S0140-6736(94)91462-1
   DCCT Res Grp, 1988, DIABETES CARE, V11, P725
   Derogatis L. R., 1977, SCL 90 ADM SCORING P
   Diabet Control Complications Trial Res Grp, 1996, DIABETES CARE, V19, P195
   GARDNER SB, 1989, STAT CONFIDENCE
   GILL GV, 1991, BRIT MED J, V303, P285, DOI 10.1136/bmj.303.6797.285
   HAARDT MJ, 1994, DIABETES CARE, V17, P847, DOI 10.2337/diacare.17.8.847
   HEPP KD, 1988, LANCET, V2, P866
   Irsigler K, 1990, DIABETES NUTR METAB, V3, P191
   JACOBSON AM, 1990, DIABETES CARE, V13, P375, DOI 10.2337/diacare.13.4.375
   Jacobson AM, 1997, QUAL LIFE RES, V6, P11
   JEANDIDIER N, 1992, TRANSPLANT P, V24, P948
   LLOYD CE, 1992, DIABETES CARE, V15, P166, DOI 10.2337/diacare.15.2.166
   MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006
   *MED OUTC TRUST, 1994, SCOR SF 36 HLTH SURV
   OLSEN CL, 1993, INT J ARTIF ORGANS, V16, P847
   Pinget M, 1998, HORM METAB RES, V30, P475, DOI 10.1055/s-2007-978916
   PITT HA, 1992, ANN SURG, V216, P483, DOI 10.1097/00000658-199210000-00011
   POLONSKY WH, 1995, DIABETES CARE, V18, P754, DOI 10.2337/diacare.18.6.754
   Pouwer F, 1999, DIABETES CARE, V22, P2004, DOI 10.2337/diacare.22.12.2004
   RENARD E, 1995, DIABETES CARE, V18, P300, DOI 10.2337/diacare.18.3.300
   Renard E, 1999, DIABETES CARE, V22, P1371, DOI 10.2337/diacare.22.8.1371
   Rubin RR, 1998, DIABETES SPECTRUM, V11, P81
   Rydall AC, 1997, NEW ENGL J MED, V336, P1849, DOI 10.1056/NEJM199706263362601
   Saudek CD, 1996, JAMA-J AM MED ASSOC, V276, P1322, DOI 10.1001/jama.276.16.1322
   SAUDEK CD, 1989, NEW ENGL J MED, V321, P574, DOI 10.1056/NEJM198908313210904
   SELAM JL, 1992, DIABETES CARE, V15, P877, DOI 10.2337/diacare.15.7.877
   SELAM JL, 1992, DIABETES CARE, V15, P53, DOI 10.2337/diacare.15.1.53
   SHAMOON H, 1993, NEW ENGL J MED, V329, P977
   Snoek FJ, 2000, DIABETES CARE, V23, P1305, DOI 10.2337/diacare.23.9.1305
   *SPSS, 2000, SPSS BASE 9 0 APPL G
NR 32
TC 22
Z9 22
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0742-3071
EI 1464-5491
J9 DIABETIC MED
JI Diabetic Med.
PD JUN
PY 2002
VL 19
IS 6
BP 496
EP 501
DI 10.1046/j.1464-5491.2002.00727.x
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 559LQ
UT WOS:000176028000010
PM 12060062
OA Green Published
DA 2019-01-08
ER

PT J
AU Mestman, JH
AF Mestman, JH
TI Historical notes on diabetes and pregnancy
SO ENDOCRINOLOGIST
LA English
DT Review
ID RESPIRATORY-DISTRESS SYNDROME; METABOLIC CONTROL; AMNIOTIC-FLUID;
   BLOOD-GLUCOSE; MOTHERS; MANAGEMENT; MELLITUS; INSULIN; RISK;
   MALFORMATION
AB During the past two decades, as the culmination of many years of basic and clinical research in different fields of maternal-fetal-neonatal medicine, there has been a dramatic improvement in perinatal mortality and morbidity in diabetes pregnancy. Today, the chances for most women with diabetes mellitus to have a successful pregnancy are almost as good as those of a woman without diabetes mellitus, providing the health care professional and the patient adhere to the guidelines and recommendations accepted by most workers in this area. In this brief historical review, several stages in the diagnosis and management of diabetes and pregnancy are discussed, based on hallmark articles from the medical literature. After a review of the years before the discovery of insulin, the author describes each decade from 1922 until the end of 1970, [Fig. 1), in which, in his opinion, the most remarkable gains in the care of pregnant women with diabetes and neonatal health had occurred. During the past twenty years, numerous reports in the literature have reaffirmed the success of strict metabolic control, before and during pregnancy, and the proper use and interpretation of fetal well-being tests in the improvement of fetal outcome. The mechanisms of the cause of congenital malformations, the multiple factors affecting fetal growth and development, and its potential long-term effects on the offspring of diabetic mothers are the focus at the present time of intensive investigation.
C1 Univ So Calif, Keck Sch Med, Ctr Diabet & Metab Dis, Los Angeles, CA USA.
RP Mestman, JH (reprint author), 1355 San Pablo St,Suite 121, Los Angeles, CA 90033 USA.
CR Allen E, 1939, AM J OBSTET GYNECOL, V38, P982, DOI 10.1016/S0002-9378(39)90641-1
   BARNES PH, 1961, CAN MED ASSOC J, V85, P681
   BENNEWITZ HG, 1828, EDINBURGH MED SURG J, V30, P217
   BHAGWANANI SG, 1972, LANCET, V1, P159
   BLOT, 1883, COMPTES RENDUS SOC B, V5, P193
   BROCARD, 1898, THESIS PARIS
   BROWN JB, 1963, J OBSTET GYN BR COMM, V70, P219
   CAMPBELL S, 1968, Journal of Obstetrics and Gynaecology of the British Commonwealth, V75, P568
   CARRINGTON ER, 1957, OBSTET GYNECOL, V9, P664, DOI 10.1097/00006250-195706000-00008
   CARRINGTON ER, 1958, JAMA-J AM MED ASSOC, V166, P245, DOI 10.1001/jama.1958.02990030043009
   CARRINGTON ER, 1963, AM J OBSTET GYNECOL, V85, P669, DOI 10.1016/0002-9378(63)90314-4
   CLEMENTS JA, 1972, NEW ENGL J MED, V286, P1077, DOI 10.1056/NEJM197205182862004
   Coetzee EJ, 1985, DIABETES RES CLIN PR, V1, P281
   COLLIER E, 1991, DIABETES, V40, P197, DOI 10.2337/diabetes.40.2.197
   CONN JW, 1961, AM J MED, V31, P839, DOI 10.1016/0002-9343(61)90023-7
   COUSTAN DR, 1980, AM J MED, V68, P845, DOI 10.1016/0002-9343(80)90204-1
   COUSTAN DR, 1984, AM J OBSTET GYNECOL, V150, P836, DOI 10.1016/0002-9378(84)90459-9
   DISTLER W, 1978, AM J OBSTET GYNECOL, V130, P424, DOI 10.1016/0002-9378(78)90284-3
   DUBREUIL G, 1920, ANDREODIAS COMPT REN, V133, P1490
   Duncan JM, 1882, T OBSTET SOC LONDON, V24, P256
   ESSEX NL, 1973, BMJ-BRIT MED J, V4, P89, DOI 10.1136/bmj.4.5884.89
   FRAINKEL N, 1980, DIABETES CARE, V3, P399
   FREINKEL N, 1980, DIABETES, V29, P1023, DOI 10.2337/diabetes.29.12.1023
   FUHRMANN K, 1984, EXP CLIN ENDOCRINOL, V83, P173, DOI 10.1055/s-0029-1210327
   GABBE SG, 1977, AM J OBSTET GYNECOL, V129, P723, DOI 10.1016/0002-9378(77)90388-X
   GABBE SG, 1977, AM J OBSTET GYNECOL, V127, P465, DOI 10.1016/0002-9378(77)90436-7
   GILLMER MDG, 1975, BRIT MED J, V3, P399, DOI 10.1136/bmj.3.5980.399
   GILLMER MDG, 1975, CARBOHYD METABOL, P168
   GLUCK L, 1971, AM J OBSTET GYNECOL, V109, P440, DOI 10.1016/0002-9378(71)90342-5
   Graham G, 1924, Proc R Soc Med, V17, P102
   GREENE JW, 1963, AM J OBSTET GYNECOL, V85, P1
   GREENE MF, 1989, TERATOLOGY, V39, P225, DOI 10.1002/tera.1420390303
   HAGBARD L, 1960, DIABETES, V9, P296, DOI 10.2337/diab.9.4.296
   HARLEY JMG, 1965, BMJ-BRIT MED J, V1, P14, DOI 10.1136/bmj.1.5426.14
   HERZSTEIN J, 1946, AM J OBSTET GYNECOL, V51, P420, DOI 10.1016/S0002-9378(16)40022-0
   HOET JJ, 1979, CIBA F S, V63, P283
   HOET JP, 1954, DIABETES, V3, P1
   HUNTINGFORD P J, 1969, Journal of Obstetrics and Gynaecology of the British Commonwealth, V76, P586
   JACKSON W. P. U., 1953, S AFRICAN MED JOUR, V27, P795
   JACKSON WPU, 1960, DIABETES, V9, P373, DOI 10.2337/diab.9.5.373
   JONES WS, 1958, DIABETES, V7, P439, DOI 10.2337/diab.7.6.439
   KARLSSON K, 1972, AM J OBSTET GYNECOL, V112, P213, DOI 10.1016/0002-9378(72)90118-4
   KEMBALL ML, 1970, ARCH DIS CHILD, V45, P696, DOI 10.1136/adc.45.243.696
   KOENIG RJ, 1976, DIABETES, V25, P230, DOI 10.2337/diabetes.25.3.230
   KUBLI FW, 1969, FOETO PLACENTAL UNIT, P323
   Lambie CG, 1926, J OBSTET GYN BR EMP, V33, P563
   Langer O, 2000, NEW ENGL J MED, V343, P1134, DOI 10.1056/NEJM200010193431601
   LAWRENCE RD, 1927, P ROY SOC MED, V21, P9
   LECORCHE, 1885, ANN GYNEC, V24, P257
   LEVER JCW, 1847, GUYS HOSP REPORT, V3
   MANNING F, 1980, AM J OBSTET GYNECOL, V136, P878
   MESTMAN JH, 1971, AM J OBSTET GYNECOL, V109, P41, DOI 10.1016/0002-9378(71)90831-3
   MESTMAN JH, 1964, DIABETES, V13, P383, DOI 10.2337/diab.13.4.383
   METZGER BE, 1980, DIABETES CARE, V3, P402, DOI 10.2337/diacare.3.3.402
   METZGER BE, 1998, DIABETES CARE S2, V21, pB1
   MILLER E, 1981, NEW ENGL J MED, V304, P1331, DOI 10.1056/NEJM198105283042204
   MILLER HC, 1945, NEW ENGL J MED, V233, P376, DOI 10.1056/NEJM194509272331302
   Miller HC, 1943, J PEDIATR-US, V23, P251, DOI 10.1016/S0022-3476(43)80001-9
   MOSS JM, 1951, ANN INTERN MED, V34, P678, DOI 10.7326/0003-4819-34-3-678
   NELSON DH, 1963, J CLIN ENDOCR METAB, V23, P261, DOI 10.1210/jcem-23-3-261
   NELSON HB, 1953, OBSTET GYNECOL, V1, P219
   OAKLEY W, 1953, BRIT MED J, V1, P1413, DOI 10.1136/bmj.1.4825.1413
   OSULLIVAN J, 1961, NEW ENGL J MED, V264, P1082, DOI 10.1056/NEJM196105252642104
   OSULLIVAN JB, 1964, DIABETES, V13, P278
   PARTRIDGE, 1895, MED RECORD, V17, P109
   PEDERSEN J, 1965, ACTA ENDOCRINOL-COP, V50, P70, DOI 10.1530/acta.0.0500070
   PEDERSEN J, 1954, ACTA ENDOCRINOL-COP, V15, P282, DOI 10.1530/acta.0.0150282
   PEDERSEN J, 1956, LANCET, V27, P607
   PEEL J, 1962, AM J OBSTET GYNECOL, V83, P847
   PEEL J, 1972, J OBSTET GYN BR COMM, V79, P385
   PERSSON B, 1975, CARBOHYD METABOL, P232
   PIRAT J, 1955, ACTA ENDOCRINOL-COP, V10, P192
   QUINN JS, 1930, IRISH J MED SCI DUBL, P612
   RAY M, 1972, AM J OBSTET GYNECOL, V114, P1
   REID DD, 1955, LANCET, V2, P833
   Reveno WS, 1923, J AMER MED ASSOC, V81, P2101, DOI 10.1001/jama.1923.02650250029007
   RIVLIN ME, 1970, AM J OBSTET GYNECOL, V106, P875, DOI 10.1016/0002-9378(70)90482-5
   ROVERSI GD, 1979, AM J OBSTET GYNECOL, V135, P567, DOI 10.1016/S0002-9378(16)32978-7
   RUBIN BL, 1946, J CLIN ENDOCR METAB, V6, P347, DOI 10.1210/jcem-6-5-347
   SKIPPER E, 1933, QJM, V7, P353
   SMITH, 1947, J SURG, V55, P288
   SONKSEN PH, 1978, LANCET, V1, P729
   SUTHERLAND HW, 1973, BRIT MED J, V20, P9
   TOWNER D, 1995, DIABETES CARE, V18, P1446, DOI 10.2337/diacare.18.11.1446
   UNGER RH, 1958, DIABETES, V7, P455, DOI 10.2337/diab.7.6.455
   VONNOORDEN C, 1917, ZUCKERKRANKHEIT
   WALFORD S, 1978, LANCET, V1, P732
   Walker A, 1927, P ROY SOC MED, Vxxi, P13
   WHITE P, 1965, MED CLIN N AM, V49, P1015, DOI 10.1016/S0025-7125(16)33292-8
   White P, 1943, J CLIN ENDOCRINOL, V3, P500, DOI 10.1210/jcem-3-9-500
   WHITE P, 1949, AM J MED, V7, P609, DOI 10.1016/0002-9343(49)90382-4
   Wilder RM, 1928, COLORADO MED, V25, P372
   WILKERSON HLC, 1957, DIABETES, V6, P324, DOI 10.2337/diab.6.4.324
   Williams JW, 1909, AM J MED SCI, V137, P1
   1987, HOFMEISTER Z F, V1, P101
   1985, DIABETES, V34
NR 96
TC 11
Z9 11
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1051-2144
J9 ENDOCRINOLOGIST
JI Endocrinologist
PD MAY-JUN
PY 2002
VL 12
IS 3
AR UNSP 0021-972X/2002/1203-0224
DI 10.1097/00019616-200205000-00010
PG 19
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 562EB
UT WOS:000176183500009
DA 2019-01-08
ER

PT J
AU De Berardis, G
   Franciosi, M
   Belfiglio, M
   Di Nardo, B
   Greenfield, S
   Kaplan, SH
   Pellegrini, F
   Sacco, M
   Tognoni, G
   Valentini, M
   Nicolucci, A
AF De Berardis, G
   Franciosi, M
   Belfiglio, M
   Di Nardo, B
   Greenfield, S
   Kaplan, SH
   Pellegrini, F
   Sacco, M
   Tognoni, G
   Valentini, M
   Nicolucci, A
CA QuED Study Grp
TI Erectile dysfunction and quality of life in type 2 diabetic patients - A
   serious problem too often overlooked
SO DIABETES CARE
LA English
DT Article
ID CORONARY HEART-DISEASE; DEPRESSIVE SYMPTOMS; OF-LIFE; ALPROSTADIL
   THERAPY; SILDENAFIL CITRATE; PREVALENCE; MEN; IMPOTENCE; HEALTH; ADULTS
AB OBJECTIVE - Within the context of a large, nationwide outcomes research program in type 2 diabetes, we assess the prevalence of self-reported erectile dysfunction and evaluate its impact on quality of life.
   RESEARCH DESIGN AND METHODS - The study involved 1,460 patients enrolled by 114 diabetes outpatient clinics and 112 general practitioners. Patients were asked to complete a questionnaire investigating their ability to achieve and maintain an erection. Various aspects of quality of life were also assessed depressive using the following instruments: SF-36 Health Survey, diabetes health distress, psychological adaptation to diabetes, depressive symptoms (CES-D scale), and quality of sexual life.
   RESULTS - Overall, 34% of the patients reported frequent erectile problems, 24% reported occasional problems, and 42% reported no erectile problems. After adjusting for patient characteristics, erectile dysfunction was associated with higher levels of diabetes-specific health distress and worse psychological adaptation to diabetes, which were, in turn, related to worse metabolic control. Erectile problems were also associated With a dramatic increase in the prevalence of severe depressive symptoms, lower scores in the mental components of the SF-36, and a less satisfactory sexual life. A total of 63% of the patients reported that their physicians had never investigated their sexual problems.
   CONCLUSIONS - Erectile dysfunction is extremely common among type 2 diabetic patients and is associated With poorer quality of life, as measured with generic and diabetes-specific instruments. Despite their relevance, sexual problems are seldom investigated by general practitioners and specialists.
C1 Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Dept Clin Pharmacol & Epidemiol, I-66030 Santa Maria Imbaro, Italy.
   Tufts Univ, Sch Med, Boston, MA 02111 USA.
RP Nicolucci, A (reprint author), Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Dept Clin Pharmacol & Epidemiol, Via Nazl, I-66030 Santa Maria Imbaro, Italy.
EM nicolucc@cmns.mnegri.it
OI Greenfield, Sheldon/0000-0003-4628-1998; Valentini,
   Miriam/0000-0002-1421-6975
CR Amato L, 1996, DIABETES METAB, V22, P314
   Ansong KS, 1998, UROLOGY, V52, P834, DOI 10.1016/S0090-4295(98)00397-5
   Apolone G, 1998, J CLIN EPIDEMIOL, V51, P1025, DOI 10.1016/S0895-4356(98)00094-8
   Araujo AB, 1998, PSYCHOSOM MED, V60, P458, DOI 10.1097/00006842-199807000-00011
   Ariyo AA, 2000, CIRCULATION, V102, P1773
   BRAUNSTEIN GD, 1987, MT SINAI J MED, V54, P236
   Chew KK, 2000, INT J IMPOT RES, V12, P41, DOI 10.1038/sj.ijir.3900457
   COMSTOCK GW, 1976, PSYCHOL MED, V6, P551
   de Leon CFM, 1998, ARCH INTERN MED, V158, P2341
   DETEJADA IS, 1988, UROL CLIN N AM, V15, P17
   DROLLER MJ, 1993, JAMA-J AM MED ASSOC, V270, P83
   DUNN SM, 1986, DIABETES CARE, V9, P480, DOI 10.2337/diacare.9.5.480
   Fedele D, 1998, DIABETES CARE, V21, P1973, DOI 10.2337/diacare.21.11.1973
   Fedele D, 2000, INT J EPIDEMIOL, V29, P524, DOI 10.1093/ije/29.3.524
   FELDMAN HA, 1994, J UROLOGY, V151, P54, DOI 10.1016/S0022-5347(17)34871-1
   Ferketich AK, 2000, ARCH INTERN MED, V160, P1261, DOI 10.1001/archinte.160.9.1261
   Franciosi M, 2001, DIABETES CARE, V24, P1870, DOI 10.2337/diacare.24.11.1870
   Gary TL, 2000, DIABETES CARE, V23, P23, DOI 10.2337/diacare.23.1.23
   GAVARD JA, 1993, DIABETES CARE, V16, P1167, DOI 10.2337/diacare.16.8.1167
   Goldstein I, 2000, AM J CARDIOL, V86, p41F
   GREENFIELD S, 1994, DIABETES CARE, V17, P32
   GREENFIELD S, 1995, MED CARE, V33, pAS47
   Hakim LS, 1996, ENDOCRIN METAB CLIN, V25, P379, DOI 10.1016/S0889-8529(05)70329-7
   Jarow JP, 1999, J UROLOGY, V162, P722, DOI 10.1097/00005392-199909010-00024
   Jonas BS, 1997, ARCH FAM MED, V6, P43, DOI 10.1001/archfami.6.1.43
   Klein R, 1996, DIABETES CARE, V19, P135, DOI 10.2337/diacare.19.2.135
   Langtry HD, 1999, DRUGS, V57, P967, DOI 10.2165/00003495-199957060-00015
   Laumann EO, 1999, JAMA-J AM MED ASSOC, V281, P537, DOI 10.1001/jama.281.6.537
   Lyness JM, 1997, ARCH INTERN MED, V157, P449, DOI 10.1001/archinte.157.4.449
   MCCULLOCH DK, 1980, DIABETOLOGIA, V18, P279
   McMahon CG, 2000, J UROLOGY, V164, P1192, DOI 10.1016/S0022-5347(05)67139-X
   Nunnally J. C., 1978, PSYCHOMETRIC THEORY
   Perttula E, 1999, POSTGRAD MED J, V75, P83, DOI 10.1136/pgmj.75.880.83
   Peyrot M, 1997, DIABETES CARE, V20, P585, DOI 10.2337/diacare.20.4.585
   RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306
   Rendell MS, 1999, JAMA-J AM MED ASSOC, V281, P421, DOI 10.1001/jama.281.5.421
   RUBIN A, 1958, JAMA-J AM MED ASSOC, V168, P498, DOI 10.1001/jama.1958.03000050010003
   Schein RL, 1997, INT J GERIATR PSYCH, V12, P436
   Schiel R, 1999, DIABETES RES CLIN PR, V44, P115, DOI 10.1016/S0168-8227(99)00012-1
   Schulz R, 2000, ARCH INTERN MED, V160, P1761, DOI 10.1001/archinte.160.12.1761
   Smith KJ, 2000, ANN INTERN MED, V132, P933, DOI 10.7326/0003-4819-132-12-200006200-00002
   Tan HL, 2000, PHARMACOECONOMICS, V17, P77, DOI 10.2165/00019053-200017010-00006
   Ware JE, 1993, SF 36 HLTH SURVEY MA
   WARE JE, 1997, MAP R WINDOWS MULTIT
   WassertheilSmoller S, 1996, ARCH INTERN MED, V156, P553, DOI 10.1001/archinte.156.5.553
   Whitehead E D, 1990, Clin Geriatr Med, V6, P771
   Williams G, 1998, BRIT J UROL, V82, P847
   Willke RJ, 1998, INT J IMPOT RES, V10, P239
   Willke RJ, 1997, J UROLOGY, V157, P2124, DOI 10.1016/S0022-5347(01)64692-5
   ZEMEL P, 1988, AM J CARDIOL, V61, pH27, DOI 10.1016/0002-9149(88)91102-2
NR 50
TC 157
Z9 161
U1 0
U2 4
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
EI 1935-5548
J9 DIABETES CARE
JI Diabetes Care
PD FEB
PY 2002
VL 25
IS 2
BP 284
EP 291
DI 10.2337/diacare.25.2.284
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 515XU
UT WOS:000173522600005
PM 11815497
OA Other Gold
DA 2019-01-08
ER

PT J
AU Kiecolt-Glaser, JK
   McGuire, L
   Robles, TF
   Glaser, R
AF Kiecolt-Glaser, JK
   McGuire, L
   Robles, TF
   Glaser, R
TI Emotions, morbidity, and mortality: New perspectives from
   psychoneuroimmunology
SO ANNUAL REVIEW OF PSYCHOLOGY
LA English
DT Review
DE depression; immune function; social support; interleukin 6
ID CORONARY-HEART-DISEASE; KILLER-CELL ACTIVITY;
   POSTTRAUMATIC-STRESS-DISORDER; BEHAVIORAL RISK-FACTORS; TO-BRAIN
   COMMUNICATION; C-REACTIVE PROTEIN; POSITIVE GAY MEN; OLDER-ADULTS;
   MYOCARDIAL-INFARCTION; MARITAL CONFLICT
AB Negative emotions can intensify a variety of health threats. We provide a broad framework relating negative emotions to a range of diseases whose onset and course may be influenced by the immune system; inflammation has been linked to a spectrum of conditions associated with aging, including cardiovascular disease, osteoporosis, arthritis, type 2 diabetes, certain cancers, Alzheimer's disease, frailty and functional decline, and periodontal disease. Production of proinflammatory cytokines that influence these and other conditions can be directly stimulated by negative emotions and stressful experiences. Additionally, negative emotions also contribute to prolonged infection and delayed wound healing, processes that fuel sustained proinflammatory cytokine production. Accordingly, we argue that distress-related immune dysregulation may be one core mechanism behind a large and diverse set of health risks associated with negative emotions. Resources such as close personal relationships that diminish negative emotions enhance health in part through their positive impact on immune and endocrine regulation.
C1 Ohio State Univ, Dept Psychiat, Coll Med, Columbus, OH 43210 USA.
   Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Coll Med, Columbus, OH 43210 USA.
   Ohio State Univ, Dept Psychol, Columbus, OH 43210 USA.
RP Kiecolt-Glaser, JK (reprint author), Ohio State Univ, Dept Psychiat, Coll Med, 1670 Upham Dr, Columbus, OH 43210 USA.
EM Kiecolt-Glaser.1@osu.edu; robles.8@osu.edu
RI foster, kylie/A-9248-2012; Kiecolt-Glaser, Janice/A-3236-2009; Glaser,
   Ronald/E-3124-2011
OI Kiecolt-Glaser, Janice/0000-0003-4900-9578; 
FU NIMH NIH HHS [R37 MH42096, T32 MH18831, K02 MH01467]; NIDCR NIH HHS [P50
   DE17811]; NIA NIH HHS [P01 AG16321]
CR ADLER NE, 1994, AM PSYCHOL, V49, P15, DOI 10.1037//0003-066X.49.1.15
   AFFLECK G, 1987, J CONSULT CLIN PSYCH, V55, P29, DOI 10.1037//0022-006X.55.1.29
   ARNETZ BB, 1991, PSYCHOTHER PSYCHOSOM, V55, P76, DOI 10.1159/000288412
   Aspinwall LG, 1996, PERS SOC PSYCHOL B, V22, P993, DOI 10.1177/01461672962210002
   BARON RS, 1990, J PERS SOC PSYCHOL, V59, P344, DOI 10.1037/0022-3514.59.2.344
   BAUM A, 1993, PSYCHOSOM MED, V55, P274, DOI 10.1097/00006842-199305000-00005
   Beach SRH, 1998, CLIN PSYCHOL REV, V18, P635, DOI 10.1016/S0272-7358(98)00023-3
   Bower JE, 1998, J CONSULT CLIN PSYCH, V66, P979, DOI 10.1037/0022-006X.66.6.979
   BURNS EA, 1990, GERIATRIC MED, P312
   BURTON R, 1893, ANATOMY MELANCHOLY, V1
   CANNON JG, 1995, J GERONTOL A-BIOL, V50, P120
   CARSTENSEN LL, 1992, PSYCHOL AGING, V7, P331, DOI 10.1037/0882-7974.7.3.331
   CASTLE S, 1995, CLIN EXP IMMUNOL, V101, P487
   Catania A, 1997, J GERONTOL A-BIOL, V52, pB93, DOI 10.1093/gerona/52A.2.B93
   Christensen AJ, 1996, PSYCHOSOM MED, V58, P150, DOI 10.1097/00006842-199603000-00009
   COE CL, 1993, PSYCHOSOM MED, V55, P298, DOI 10.1097/00006842-199305000-00007
   Cohen HJ, 1997, J GERONTOL A-BIOL, V52, pM201, DOI 10.1093/gerona/52A.4.M201
   Cohen HJ, 2000, J GERONTOL A-BIOL, V55, pM706, DOI 10.1093/gerona/55.12.M706
   Cohen S, 1998, HEALTH PSYCHOL, V17, P214, DOI 10.1037/0278-6133.17.3.214
   Cohen Sheldon, 1997, JAMA (Journal of the American Medical Association), V277, P1940, DOI 10.1001/jama.277.24.1940
   Cole SW, 1997, J PERS SOC PSYCHOL, V72, P320, DOI 10.1037/0022-3514.72.2.320
   COLE SW, 1996, PSYCHOSOM MED, V58, P1
   Coplan JD, 2000, BIOL PSYCHIAT, V47, P594, DOI 10.1016/S0006-3223(00)00226-2
   Costello NL, 1998, PSYCHOSOM MED, V60, P121, DOI 10.1097/00006842-199801000-00140
   Croyle RT, 1998, J NATL CANCER I, V90, P1856, DOI 10.1093/jnci/90.24.1856
   Davidson RJ, 2002, ANNU REV PSYCHOL, V53, P545, DOI 10.1146/annurev.psych.53.100901.135148
   DeBellis MD, 1996, J TRAUMA STRESS, V9, P369, DOI 10.1002/jts.2490090218
   Denollet J, 1998, CIRCULATION, V97, P167, DOI 10.1161/01.CIR.97.2.167
   Denollet J, 1996, LANCET, V347, P417, DOI 10.1016/S0140-6736(96)90007-0
   Dentino AN, 1999, J AM GERIATR SOC, V47, P6, DOI 10.1111/j.1532-5415.1999.tb01894.x
   DeRijk R, 1997, J CLIN ENDOCR METAB, V82, P2182, DOI 10.1210/jc.82.7.2182
   Dhabhar FS, 1997, BRAIN BEHAV IMMUN, V11, P286, DOI 10.1006/brbi.1997.0508
   Dinan TG, 1998, PSYCHIAT CLIN N AM, V21, P325, DOI 10.1016/S0193-953X(05)70008-3
   DURA JR, 1990, J ABNORM PSYCHOL, V99, P284, DOI 10.1037//0021-843X.99.3.284
   EAKER ED, 1992, AM J EPIDEMIOL, V135, P854, DOI 10.1093/oxfordjournals.aje.a116381
   ELLSWORTH PC, 1988, COGNITION EMOTION, V2, P301, DOI DOI 10.1080/02699938808412702
   Ershler WB, 2000, ANNU REV MED, V51, P245, DOI 10.1146/annurev.med.51.1.245
   ESTERLING BA, 1990, PSYCHOSOM MED, V52, P397, DOI 10.1097/00006842-199007000-00002
   ESTERLING BA, 1994, HEALTH PSYCHOL, V13, P291, DOI 10.1037/0278-6133.13.4.291
   Esterling BA, 1996, PSYCHOSOM MED, V58, P264, DOI 10.1097/00006842-199605000-00010
   Everson SA, 1997, AM J EPIDEMIOL, V146, P142
   Ferrucci L, 1999, J AM GERIATR SOC, V47, P639, DOI 10.1111/j.1532-5415.1999.tb01583.x
   Fincham FD, 1999, ANNU REV PSYCHOL, V50, P47, DOI 10.1146/annurev.psych.50.1.47
   Folkman S, 2000, AM PSYCHOL, V55, P647, DOI 10.1037/0003-066X.55.6.647
   FRANKENHAEUSER M, 1991, PL S STRESS, P39
   Frankenhaeuser M, 1986, DYNAMICS STRESS, P101, DOI DOI 10.1007/978-1-4684-5122-1_
   FRASURESMITH N, 1993, JAMA-J AM MED ASSOC, V270, P1819, DOI 10.1001/jama.270.15.1819
   FREDRICKSON BL, 1998, REV GEN PSYCHOL, V2, P271
   Glaser R, 1999, JAMA-J AM MED ASSOC, V281, P2268, DOI 10.1001/jama.281.24.2268
   Glaser R, 1999, ARCH GEN PSYCHIAT, V56, P450, DOI 10.1001/archpsyc.56.5.450
   GLASER R, 1992, PSYCHOSOM MED, V54, P22, DOI 10.1097/00006842-199201000-00005
   Glaser R, 2000, PSYCHOSOM MED, V62, P804, DOI 10.1097/00006842-200011000-00010
   GLASER R, 1994, HDB HUMAN STRESS IMM
   Glassman AH, 1998, AM J PSYCHIAT, V155, P4, DOI 10.1176/ajp.155.1.4
   HAINES AP, 1987, BRIT MED J, V295, P297, DOI 10.1136/bmj.295.6593.297
   Hamerman D, 1999, ANN INTERN MED, V130, P945, DOI 10.7326/0003-4819-130-11-199906010-00022
   Harris TB, 1999, AM J MED, V106, P506, DOI 10.1016/S0002-9343(99)00066-2
   Heim C, 2000, PSYCHONEUROENDOCRINO, V25, P1, DOI 10.1016/S0306-4530(99)00035-9
   HERBERT TB, 1993, PSYCHOL BULL, V113, P472, DOI 10.1037//0033-2909.113.3.472
   Herrmann C, 1998, PSYCHOSOM MED, V60, P570, DOI 10.1097/00006842-199809000-00011
   Hess Evelyn V., 1994, Current Opinion in Rheumatology, V6, P474, DOI 10.1097/00002281-199409000-00004
   HOLSBOER F, 1995, NEUROENDOCRINOLOGY, V62, P340, DOI 10.1159/000127023
   HOUSE JS, 1988, SCIENCE, V241, P540, DOI 10.1126/science.3399889
   HU DJ, 1995, J ACQ IMMUN DEF SYND, V10, P374
   IRWIN M, 1991, FASEB J, V5, P3100
   IRWIN M, 1987, PSYCHIAT CLIN N AM, V10, P449
   Kalman B, 1999, BIOMED PHARMACOTHER, V53, P358, DOI 10.1016/S0753-3322(99)80107-3
   Katon WJ, 1998, SEMIN CLIN NEUROPSYC, V3, P82
   Katz IR, 1996, AM J GERIAT PSYCHIAT, V4, P1, DOI 10.1097/00019442-199624410-00001
   KAWACHI I, 1994, CIRCULATION, V89, P1992, DOI 10.1161/01.CIR.89.5.1992
   KAWACHI I, 1994, CIRCULATION, V90, P2225, DOI 10.1161/01.CIR.90.5.2225
   Kawakami N, 1997, PSYCHOTHER PSYCHOSOM, V66, P192, DOI 10.1159/000289134
   KEMENY ME, 1995, PSYCHOSOM MED, V57, P547, DOI 10.1097/00006842-199511000-00007
   Kiechl S, 2001, CIRCULATION, V103, P1064, DOI 10.1161/01.CIR.103.8.1064
   KIECOLT-GLASER J K, 1988, Brain Behavior and Immunity, V2, P67, DOI 10.1016/0889-1591(88)90007-4
   Kiecolt-Glaser J. K., 1987, PSYCHOSOM MED, V49, P31
   Kiecolt-Glaser JK, 1998, ANN NY ACAD SCI, V840, P656, DOI 10.1111/j.1749-6632.1998.tb09604.x
   Kiecolt-Glaser JK, 1998, AM PSYCHOL, V53, P1209, DOI 10.1037//0003-066X.53.11.1209
   KiecoltGlaser JK, 1996, J CONSULT CLIN PSYCH, V64, P324, DOI 10.1037/0022-006X.64.2.324
   KIECOLTGLASER JK, 1988, PSYCHOSOM MED, V50, P213, DOI 10.1097/00006842-198805000-00001
   KIECOLTGLASER JK, 1995, LANCET, V346, P1194, DOI 10.1016/S0140-6736(95)92899-5
   KIECOLTGLASER JK, 1993, PSYCHOSOM MED, V55, P395, DOI 10.1097/00006842-199309000-00001
   KiecoltGlaser JK, 1996, P NATL ACAD SCI USA, V93, P3043, DOI 10.1073/pnas.93.7.3043
   KIECOLTGLASER JK, 1991, PSYCHOSOM MED, V53, P345, DOI 10.1097/00006842-199107000-00001
   KiecoltGlaser JK, 1997, PSYCHOSOM MED, V59, P339, DOI 10.1097/00006842-199707000-00001
   KIECOLTGLASER JK, 2001, IN PRESS PSYCHOL B
   Koenig HG, 1997, INT J PSYCHIAT MED, V27, P233, DOI 10.2190/40NF-Q9Y2-0GG7-4WH6
   Krantz DS, 2002, ANNU REV PSYCHOL, V53, P341, DOI 10.1146/annurev.psych.53.100901.135208
   Kronfol Z, 2000, AM J PSYCHIAT, V157, P683, DOI 10.1176/appi.ajp.157.5.683
   LEMIEUX AM, 1995, PSYCHOSOM MED, V57, P105, DOI 10.1097/00006842-199503000-00002
   Leproult R, 1997, SLEEP, V20, P865
   Lerman Y, 1999, PSYCHOSOM MED, V61, P828, DOI 10.1097/00006842-199911000-00017
   Leventhal H, 1998, ANN REV GERONTOLOGY, V17, P138
   LIEBESKIND JC, 1991, PAIN, V44, P3, DOI 10.1016/0304-3959(91)90141-J
   Lutgendorf SK, 1999, J GERONTOL A-BIOL, V54, pM434, DOI 10.1093/gerona/54.9.M434
   Maes M, 1997, CYTOKINE, V9, P853, DOI 10.1006/cyto.1997.0238
   Maes M, 1998, CYTOKINE, V10, P313, DOI 10.1006/cyto.1997.0290
   Maes M, 1999, BIOL PSYCHIAT, V45, P833, DOI 10.1016/S0006-3223(98)00131-0
   Maier SF, 1998, PSYCHOL REV, V105, P83, DOI 10.1037/0033-295X.105.1.83
   MALARKEY WB, 1994, PSYCHOSOM MED, V56, P41, DOI 10.1097/00006842-199401000-00006
   Malarkey WB, 1996, ENDOCRINE, V5, P33, DOI 10.1007/BF02738653
   Marucha PT, 1998, PSYCHOSOM MED, V60, P362, DOI 10.1097/00006842-199805000-00025
   Maruta T, 2000, MAYO CLIN PROC, V75, P140
   McEwen BS, 1998, NEW ENGL J MED, V338, P171, DOI 10.1056/NEJM199801153380307
   Meyerowitz BE, 1998, PSYCHOL BULL, V123, P47, DOI 10.1037/0033-2909.123.1.47
   Michelson D, 1996, NEW ENGL J MED, V335, P1176, DOI 10.1056/NEJM199610173351602
   Miller AH, 1998, PSYCHIAT CLIN N AM, V21, P443, DOI 10.1016/S0193-953X(05)70015-0
   Miller TQ, 1996, PSYCHOL BULL, V119, P322, DOI 10.1037/0033-2909.119.2.322
   Mills PJ, 1999, PSYCHOSOM MED, V61, P168, DOI 10.1097/00006842-199903000-00008
   Molassiotis A, 1997, J PSYCHOSOM RES, V42, P275, DOI 10.1016/S0022-3999(96)00298-X
   Morag M, 1999, J PSYCHIAT RES, V33, P389, DOI 10.1016/S0022-3956(99)00010-2
   Myers HF, 1995, HEALTH PSYCHOL, V14, P613, DOI 10.1037//0278-6133.14.7.613
   Nolen-Hoeksema S, 1999, J PERS SOC PSYCHOL, V77, P1061, DOI 10.1037//0022-3514.77.5.1061
   NOLENHOEKSEMA S, 1999, WELL BEING FDN HEDON, P330
   Padgett DA, 1998, BRAIN BEHAV IMMUN, V12, P64, DOI 10.1006/brbi.1997.0512
   Papanicolaou DA, 1998, ANN INTERN MED, V128, P127, DOI 10.7326/0003-4819-128-2-199801150-00009
   PATRIARCA PA, 1994, JAMA-J AM MED ASSOC, V272, P1700, DOI 10.1001/jama.272.21.1700
   PENNEBAKER JW, 1988, J CONSULT CLIN PSYCH, V56, P239, DOI 10.1037/0022-006X.56.2.239
   Penninx BWJH, 1998, J NATL CANCER I, V90, P1888, DOI 10.1093/jnci/90.24.1888
   Penninx BWJH, 1998, JAMA-J AM MED ASSOC, V279, P1720, DOI 10.1001/jama.279.21.1720
   Penninx BWJH, 1999, AM J PUBLIC HEALTH, V89, P1346, DOI 10.2105/AJPH.89.9.1346
   PETERSON C, 1988, J PERS SOC PSYCHOL, V55, P23, DOI 10.1037/0022-3514.55.1.23
   PETRIE KJ, 1995, J CONSULT CLIN PSYCH, V63, P787, DOI 10.1037/0022-006X.63.5.787
   Philibert RA, 1997, J CLIN PSYCHIAT, V58, P355, DOI 10.4088/JCP.v58n0805
   Phinney JS, 1996, AM PSYCHOL, V51, P918, DOI 10.1037/0003-066X.51.9.918
   Pratt LA, 1996, CIRCULATION, V94, P3123, DOI 10.1161/01.CIR.94.12.3123
   Rabin B.S., 1999, STRESS IMMUNE FUNCTI
   Rantanen T, 2000, J AM GERIATR SOC, V48, P613, DOI 10.1111/j.1532-5415.2000.tb04717.x
   Reed GM, 1999, HEALTH PSYCHOL, V18, P354, DOI 10.1037//0278-6133.18.4.354
   Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401
   ROJAS I, 2001, IN PRESS BRAIN BEHAV
   Rozanski A, 1999, CIRCULATION, V99, P2192, DOI 10.1161/01.CIR.99.16.2192
   Ryff CD, 1998, PSYCHOL INQ, V9, P1, DOI 10.1207/s15327965pli0901_1
   Scheier MF, 1999, ARCH INTERN MED, V159, P829, DOI 10.1001/archinte.159.8.829
   SCHEIER MF, 1992, COGNITIVE THER RES, V16, P201, DOI 10.1007/BF01173489
   SCHEIER MF, 1995, PSYCHOSOM MED, V57, P255, DOI 10.1097/00006842-199505000-00007
   SCHLEIFER SJ, 1989, ARCH GEN PSYCHIAT, V46, P81
   SCHLEIFER SJ, 1983, JAMA-J AM MED ASSOC, V250, P374, DOI 10.1001/jama.250.3.374
   Schoevers RA, 2000, BRIT J PSYCHIAT, V177, P336, DOI 10.1192/bjp.177.4.336
   Schulz R, 2000, ARCH INTERN MED, V160, P1761, DOI 10.1001/archinte.160.12.1761
   Seeman Teresa E., 1997, Archives of Internal Medicine, V157, P2259, DOI 10.1001/archinte.157.19.2259
   Segerstrom SC, 2000, ANN BEHAV MED, V22, P180, DOI 10.1007/BF02895112
   Shepperd JA, 1996, J RES PERS, V30, P517, DOI 10.1006/jrpe.1996.0038
   SHERIDAN JF, 1991, J NEUROIMMUNOL, V31, P245, DOI 10.1016/0165-5728(91)90046-A
   Sluzewska A, 1995, ANN NY ACAD SCI, V762, P474
   Staats PS, 1999, AM FAM PHYSICIAN, V60, P42
   Sternberg EM, 1997, NAT MED, V3, P264, DOI 10.1038/nm0397-264
   STERNBERG EM, 1992, ANN INTERN MED, V117, P854, DOI 10.7326/0003-4819-117-10-854
   STONEY CM, 1987, PSYCHOPHYSIOLOGY, V24, P127, DOI 10.1111/j.1469-8986.1987.tb00264.x
   Taaffe DR, 2000, J GERONTOL A-BIOL, V55, pM709, DOI 10.1093/gerona/55.12.M709
   Taylor S. E, 1989, POSITIVE ILLUSIONS C
   Taylor SE, 1997, ANNU REV PSYCHOL, V48, P411, DOI 10.1146/annurev.psych.48.1.411
   TAYLOR SE, 1983, AM PSYCHOL, V38, P1161, DOI 10.1037/0003-066X.38.11.1161
   Taylor SE, 2000, PSYCHOL REV, V107, P411, DOI 10.1037/0033-295X.107.3.411
   Taylor SE, 2000, AM PSYCHOL, V55, P99, DOI 10.1037//0003-066X.55.1.99
   Turk DC, 1992, HDB PAIN ASSESSMENT, P3
   Uchino BN, 1996, PSYCHOL BULL, V119, P488, DOI 10.1037/0033-2909.119.3.488
   US Department of Health and Human Services, 1999, MENT HLTH REP SURG G
   Vahtera J, 1997, PSYCHOL MED, V27, P693, DOI 10.1017/S0033291797004832
   Vedhara K, 1999, LANCET, V353, P627, DOI 10.1016/S0140-6736(98)06098-X
   Veldhuis JD, 1996, SLEEP, V19, pS221, DOI 10.1093/sleep/19.suppl_10.S221
   VERBRUGGE LM, 1982, PUBLIC HEALTH REP, V97, P417
   Watkins LR, 2000, ANNU REV PSYCHOL, V51, P29, DOI 10.1146/annurev.psych.51.1.29
   WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI 10.1001/jama.262.7.914
   Whooley MA, 1998, ARCH INTERN MED, V158, P2129, DOI 10.1001/archinte.158.19.2129
   Williams DR, 1997, ANN EPIDEMIOL, V7, P322, DOI 10.1016/S1047-2797(97)00051-3
   WILLIAMS DR, 1995, ANNU REV SOCIOL, V21, P349, DOI 10.1146/annurev.so.21.080195.002025
   Wolkowitz OM, 1999, PSYCHOSOM MED, V61, P698, DOI 10.1097/00006842-199909000-00011
   Wu H, 1999, J GERONTOL A-BIOL, V54, pM212, DOI 10.1093/gerona/54.4.M212
   Wulsin LR, 1999, PSYCHOSOM MED, V61, P6, DOI 10.1097/00006842-199901000-00003
   YOSHIKAWA TT, 1983, J AM GERIATR SOC, V31, P34, DOI 10.1111/j.1532-5415.1983.tb06285.x
   Zautra AJ, 1998, ARTHRIT CARE RES, V11, P271, DOI 10.1002/art.1790110408
   ZHOU DH, 1993, ENDOCRINOLOGY, V133, P2523, DOI 10.1210/en.133.6.2523
NR 173
TC 554
Z9 562
U1 4
U2 111
PU ANNUAL REVIEWS
PI PALO ALTO
PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0139 USA
SN 0066-4308
EI 1545-2085
J9 ANNU REV PSYCHOL
JI Annu. Rev. Psychol.
PY 2002
VL 53
BP 83
EP 107
DI 10.1146/annurev.psych.53.100901.135217
PG 25
WC Psychology; Psychology, Multidisciplinary
SC Psychology
GA 524XY
UT WOS:000174039200005
PM 11752480
DA 2019-01-08
ER

PT J
AU Franciosi, M
   Pellegrini, F
   De Berardis, G
   Belfiglio, M
   Cavaliere, D
   Di Nardo, B
   Greenfield, S
   Kaplan, SH
   Sacco, M
   Tognoni, G
   Valentini, M
   Nicolucci, A
AF Franciosi, M
   Pellegrini, F
   De Berardis, G
   Belfiglio, M
   Cavaliere, D
   Di Nardo, B
   Greenfield, S
   Kaplan, SH
   Sacco, M
   Tognoni, G
   Valentini, M
   Nicolucci, A
CA QuED Study Group
TI The impact of blood glucose self-monitoring on metabolic control and
   quality of life in type 2 diabetic patients - An urgent need for better
   educational strategies
SO DIABETES CARE
LA English
DT Article; Proceedings Paper
CT Annual Meeting of the American-Diabetes-Association
CY JUN 22-26, 2001
CL PHILADELPHIA, PENNSYLVANIA
SP Amer Diabetes Assoc
AB OBJECTIVE - The role of self-monitoring of blood glucose (SMBG) in type 2 diabetes is still a matter of debate. in the framework of a nationwide outcomes research program, we investigated the frequency of SMBG and its association with metabolic control and quality of life (QoL).
   RESEARCH DESIGN AND METHODS - The study involved 3,567 patients with type 2 diabetes who were recruited by 101 outpatient diabetes clinics and 103 general practitioners. Patients completed a questionnaire investigating SMBG practice and QoL (diabetes-related stress, diabetes health distress, diabetes-related worries, and Centers for Epidemiologic Studies-Depression scale).
   RESULTS - Data on SMBG were available for 2,855 subjects (80% of the entire study population). Overall, 471 patients (17%) stated that they tested their blood glucose levels at home I time per day, 899 patients (31%) tested their blood glucose levels : I time per week, and 414 patients (14%) tested their blood whereas 1,071 patients (38%) stated that the never practiced SMBG. A higher frequency of SMBG was associated with better, metabolic control among subjects who were able to adjust insulin doses, whereas no relationship was found in all other patients, irrespective of the kind of treatment. Multivariate analyses showed that an SMBG Frequency ! 1 Lime per day was significantly related to higher levels of distress, worries, and depressive symptoms in non-insulin-treated patients.
   CONCLUSIONS - our findings suggest that SMBG can have an important role in improving metabolic control if it is an integral part of a wider educational strategy devoted to the promotion of patient autonomy. In patients not treated with insulin, self-monitoring is associated with higher HbA(1c) levels and psychological burden. Our data do not support the extension of SMBG to this group.
C1 Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Dept Clin Pharmacol & Epidemiol, I-66030 Santa Maria Imbaro, CH, Italy.
   Tufts Univ, Sch Med, Boston, MA 02111 USA.
RP Nicolucci, A (reprint author), Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Dept Clin Pharmacol & Epidemiol, Via Nazl, I-66030 Santa Maria Imbaro, CH, Italy.
OI Valentini, Miriam/0000-0002-1421-6975; Greenfield,
   Sheldon/0000-0003-4628-1998
CR *AM DIAB ASS, 2000, DIABETES CARE S1, V24, pS80
   CAMPBELL DT, 1959, PSYCHOL BULL, V56, P81, DOI 10.1037/h0046016
   CRONBACH LJ, 1951, PSYCHOMETRIKA, V16, P297, DOI DOI 10.1007/BF02310555
   DUNN SM, 1986, DIABETES CARE, V9, P480, DOI 10.2337/diacare.9.5.480
   Evans JMM, 1999, BRIT MED J, V319, P83, DOI 10.1136/bmj.319.7202.83
   Faas A, 1997, DIABETES CARE, V20, P1482, DOI 10.2337/diacare.20.9.1482
   Gallichan M, 1997, BRIT MED J, V314, P964, DOI 10.1136/bmj.314.7085.964
   GREENFIELD S, 1994, DIABETES CARE, V17, P32
   GREENFIELD S, 1995, MED CARE, V33, pAS47
   Harris MI, 2001, DIABETES CARE, V24, P979, DOI 10.2337/diacare.24.6.979
   HOWARD KI, 1962, EDUC PSYCHOL MEAS, V22, P731, DOI 10.1177/001316446202200407
   RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306
   *SAS I, 2000, SAS LANG VERS 8 1
   Scorpiglione N, 1996, DIABETES RES CLIN PR, V34, P115, DOI 10.1016/S0168-8227(96)01343-5
   Snijders T, 1999, MULTILEVEL ANAL INTR
   SPILKER B, 1996, QUALITY LIFE PHARMAC, P681
   Sullivan LM, 1999, STAT MED, V18, P855, DOI 10.1002/(SICI)1097-0258(19990415)18:7<855::AID-SIM117>3.0.CO;2-7
   WARE JE, 1997, MAP R WINDOWS MULTIT
NR 18
TC 180
Z9 187
U1 0
U2 23
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1660 DUKE ST, ALEXANDRIA, VA 22314 USA
SN 0149-5992
J9 DIABETES CARE
JI Diabetes Care
PD NOV
PY 2001
VL 24
IS 11
BP 1870
EP 1877
DI 10.2337/diacare.24.11.1870
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 488LZ
UT WOS:000171937800004
PM 11679449
OA Bronze
DA 2019-01-08
ER

PT J
AU Mollema, ED
   Snoek, FJ
   Ader, HJ
   Heine, RJ
   van der Ploeg, HM
AF Mollema, ED
   Snoek, FJ
   Ader, HJ
   Heine, RJ
   van der Ploeg, HM
TI Insulin-treated diabetes patients with fear of self-injecting or fear of
   self-testing - Psychological comorbidity and general well-being
SO JOURNAL OF PSYCHOSOMATIC RESEARCH
LA English
DT Article
DE adults; diabetes mellitus; fear of self-injecting; fear of self-testing;
   psychological functioning
ID GLYCEMIC CONTROL; DEPRESSION INVENTORY; PROBLEM AREAS; QUESTIONNAIRE;
   POPULATION; DISTRESS; ANXIETY; BLOOD; SCALE; EXPERIENCES
AB Objective: To examine psychological functioning and selfmanagement behaviours of Dutch adult patients with insulin-requiring diabetes mellitus suffering from extreme fear of self-injecting (FSI) and/or fear of self-testing (FST). Methods: A cross-sectional survey was performed in a sample of insulin-treated diabetes patients (n=1275; 51.1% male; age 49.7 +/- 15.8 years; 58.0% Type 1 diabetes), assessing FSI and FST. Patients completed the questionnaires concerning trait/state anxiety, depression, fear of hypoglycemia, diabetes-related distress, diabetes self-care activities, and general well-being. Comparisons were made on these measures between patients with extremely high scores on FSI and/or FST (greater than or equal to 95th percentile) and the other patients. Patients with extreme scores on FSI and/or FST were invited to take part in a second survey to assess the prevalence of major depression, common fears/phobias, and psychoneuroticism. Results: People with extreme FSI/FST scores, as compared to the other patients, reported higher levels of trait/state anxiety and depression. This group also reported more fear of hypoglycaemia. and diabetes-related distress, had lower levels of general wellbeing, and reported less frequent self-monitoring of blood glucose. The second survey showed 11.1% of patients with extreme FSI/ FST reporting scores indicating major depression. Prevalence of scores greater than or equal to the high scores on phobias (38.063.3%) and psychoneuroticism (27.8%) were consistently higher than norm group prevalences. Discussion: Extreme levels of FSI and/or FST are associated with high diabetes-related distress, poor general well-being, and psychological comorbidity, as well as poorer adherence to the diabetes treatment regimen. It is concluded that patients with extreme FSI/FST are often burdened with more than this specific phobia. (C) 2001 Elsevier Science Inc. All rights reserved.
C1 Free Univ Amsterdam, Med Ctr, Dept Psychol Med, EMGO Inst,Fac Med,Inst Res Extramural Med, NL-1081 BT Amsterdam, Netherlands.
   Vrije Univ Amsterdam, Ctr Med, Dept Psychol Med, Amsterdam, Netherlands.
   Vrije Univ Amsterdam, Dept Clin Epidemiol & Biostat, Med Ctr, NL-1081 HV Amsterdam, Netherlands.
   Vrije Univ Amsterdam, Med Ctr, Dept Endocrinol, Amsterdam, Netherlands.
RP Mollema, ED (reprint author), Free Univ Amsterdam, Med Ctr, Dept Psychol Med, EMGO Inst,Fac Med,Inst Res Extramural Med, Van der Boechorststr 7, NL-1081 BT Amsterdam, Netherlands.
EM ed.mollema.emgo@med.vu.nl
CR ARRINDELL WA, 1980, BEHAV RES THER, V18, P229, DOI 10.1016/0005-7967(80)90080-7
   ARRINDELL WA, 1986, SCL90 MANUAL MULTI D
   BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561
   BELL DSH, 1983, DIABETES CARE, V6, P622, DOI 10.2337/diacare.6.6.622a
   Berlin I, 1997, DIABETES CARE, V20, P176, DOI 10.2337/diacare.20.2.176
   Bienvenu OJ, 1998, PSYCHOL MED, V28, P1129, DOI 10.1017/S0033291798007144
   Bodzin B, 1996, Home Healthc Nurse, V14, P378, DOI 10.1097/00004045-199605000-00009
   BOUMAN TK, 1985, GEDRAG GEZOND, V13, P13
   BOUMAN TK, 1987, MEASUREMENT DEPRESSI
   BRADLEY C, 1994, HDB PSYCHOL DIABETES, P89
   Derogatis L. R., 1977, SCL90 ADM SCORING PR
   *EUR IDDM POL GROU, 1993, CONS GUID MAN INS DE
   Evans JMM, 1999, BRIT MED J, V319, P83, DOI 10.1136/bmj.319.7202.83
   Herrmann C, 1997, J PSYCHOSOM RES, V42, P17, DOI 10.1016/S0022-3999(96)00216-4
   *INT DIAB FED, 1999, DIABETIC MED, V16, P1
   Irvin A, 1994, HDB PSYCHOL DIABETES, P133
   KOLKO DJ, 1980, J BEHAV THER EXP PSY, V11, P273, DOI 10.1016/0005-7916(80)90070-1
   Lustman PJ, 1997, PSYCHOSOM MED, V59, P24, DOI 10.1097/00006842-199701000-00004
   METSCH J, 1995, INT J BEHAV MED, V2, P104, DOI 10.1207/s15327558ijbm0202_2
   Mollema ED, 2000, DIABETES CARE, V23, P765, DOI 10.2337/diacare.23.6.765
   Morris AD, 1997, LANCET, V350, P1505, DOI 10.1016/S0140-6736(97)06234-X
   Peyrot M, 1997, DIABETES CARE, V20, P585, DOI 10.2337/diacare.20.4.585
   POLONSKY WH, 1995, DIABETES CARE, V18, P754, DOI 10.2337/diacare.18.6.754
   Pouwer F, 1999, DIABETES CARE, V22, P2004, DOI 10.2337/diacare.22.12.2004
   Ruggiero L, 1997, DIABETES CARE, V20, P568, DOI 10.2337/diacare.20.4.568
   Snaith RP, 1994, HOSP ANXIETY DEPRESS
   Snoek F, 1996, GEDRAG GEZONDHEID, V24, P287
   Snoek FJ, 1997, DIABETIC MED, V14, P871, DOI 10.1002/(SICI)1096-9136(199710)14:10<871::AID-DIA457>3.3.CO;2-P
   Snoek FJ, 2000, DIABETES CARE, V23, P1305, DOI 10.2337/diacare.23.9.1305
   *SPSS, 1997, SPSS BAS 7 5 WIND US
   van den Akker M, 1998, FAM PRACT, V15, P261, DOI 10.1093/fampra/15.3.261
   VANDERPLOEG HM, 2000, MAN DUTCH VERS STAI
   Welch GW, 1997, DIABETES CARE, V20, P760, DOI 10.2337/diacare.20.5.760
   WOLPE J, 1964, BEHAV RES THER, V2, P27, DOI 10.1016/0005-7967(64)90051-8
   Zambanini A, 1999, DIABETES RES CLIN PR, V46, P239, DOI 10.1016/S0168-8227(99)00099-6
   Zambanini A, 1997, DIABETIC MED, V14, P321, DOI 10.1002/(SICI)1096-9136(199704)14:4<321::AID-DIA356>3.0.CO;2-H
NR 36
TC 68
Z9 70
U1 0
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0022-3999
EI 1879-1360
J9 J PSYCHOSOM RES
JI J. Psychosomat. Res.
PD NOV
PY 2001
VL 51
IS 5
BP 665
EP 672
DI 10.1016/S0022-3999(01)00229-X
PG 8
WC Psychiatry
SC Psychiatry
GA 500RL
UT WOS:000172640500006
PM 11728507
DA 2019-01-08
ER

PT J
AU Herpertz, S
   Albus, C
   Kielmann, R
   Hagemann-Patt, H
   Lichtblau, K
   Kohle, K
   Mann, K
   Senf, W
AF Herpertz, S
   Albus, C
   Kielmann, R
   Hagemann-Patt, H
   Lichtblau, K
   Kohle, K
   Mann, K
   Senf, W
TI Comorbidity of diabetes mellitus and eating disorders - A follow-up
   study
SO JOURNAL OF PSYCHOSOMATIC RESEARCH
LA English
DT Article; Proceedings Paper
CT 23rd European Conference on Psychosomatic Research/EACLPP
CY JUN 16-21, 2000
CL OSLO, NORWAY
DE diabetes mellitus; eating disorder; follow-up
ID BECK DEPRESSION INVENTORY; ANOREXIA-NERVOSA; BULIMIA-NERVOSA; STRUCTURED
   INTERVIEW; ADOLESCENT GIRLS; INSULIN OMISSION; YOUNG-ADULTS;
   BODY-WEIGHT; WOMEN; BEHAVIOR
AB Objective: There is increasing evidence that the coexistence of diabetes and eating disorders (ED) leads to poor glycemic control and an increased risk of long-term complications. Methods: In a questionnaire- and interview-based study, a sample of 36 out of originally 38 (94.7%) diabetic patients with an ED (type-1: n = 13, type-2: n = 23) was assessed after a period of about 2 years in order to determine the course of EDs, body mass index (BMI), glycemic control, and psychiatric symptomatology. Results: Five patients (13.9%) of the total sample showed full remission for at least 12 consecutive weeks. Twenty-two patients (61.6%) showed no change in the diagnosis of the ED. Four patients (11.1%) shifted from subclinical to clinical EDs and five patients (13.9%) vice versa. Of the eight patients who went on to psychotherapy, only one patient (12.5%) showed full remission. Emotional distress of type-2 diabetics was considerably higher compared to type-1 diabetics, which was rather low at baseline. Except interpersonal distrust as one ED-related variable, no significant change of any psychological variable could be observed in the type-1 diabetic sample during follow-up. Of the 13 type-1 diabetic patients with an ED, five patients deliberately omitted insulin in order to lose weight. These patients showed a more serious psychopathology with regard to each measured psychological variable, a higher BMI, and worse metabolic control compared to those without insulin omission. Type-2 diabetics showed a significant increase in drive for thinness and body dissatisfaction. No considerable change could be observed with regard to BMI, glycemic control, and depressive and global psychiatric symptomatology in either diabetic subsample during follow-up. Conclusion: EDs tended to persist over time with a considerable shift within the different types of EDs. Insulin-purging in type-1 diabetics was associated with enhanced psychopathology, higher BMI, and worse metabolic control. Both mean body mass and ED-related symptoms such as ''drive for thinness'' and ''body dissatisfaction'' increased in the average obese type-2 diabetic sample, illustrating the vicious circle of low self-esteem, enhanced restraint eating, and binge eating in weight control measures, (C) 2001 Elsevier Science Inc. All rights reserved.
C1 Univ Essen Gesamthsch, Clin Psychotherapy & Psychosomat, D-45030 Essen, Germany.
   Univ Cologne, Dept Psychosomat & Psychotherapy, Cologne, Germany.
   Univ Essen Gesamthsch, Med Clin, Dept Endocrinol, Essen, Germany.
RP Herpertz, S (reprint author), Univ Essen Gesamthsch, Clin Psychotherapy & Psychosomat, Postfach 103043, D-45030 Essen, Germany.
RI Albus, Christian/C-1701-2015
CR Affenito SG, 1997, DIABETES CARE, V20, P182, DOI 10.2337/diacare.20.2.182
   BECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5
   BIGGS MM, 1994, DIABETES CARE, V17, P1186, DOI 10.2337/diacare.17.10.1186
   Brown SA, 1996, DIABETES CARE, V19, P613, DOI 10.2337/diacare.19.6.613
   Bryden KS, 1999, DIABETES CARE, V22, P1956, DOI 10.2337/diacare.22.12.1956
   Carroll P, 1999, J BEHAV MED, V22, P59, DOI 10.1023/A:1018799618864
   COLAS C, 1991, DIABETOLOGIA, V34, P288, DOI 10.1007/BF00405092
   COOPER A, 1997, INT J EAT DISORDER, V6, P1
   COPELAND PM, 1995, HARVARD REV PSYCHIAT, V3, P46
   Crow SJ, 1998, PSYCHOSOMATICS, V39, P233, DOI 10.1016/S0033-3182(98)71340-4
   DEROGATIS LR, 1977, J CLIN PSYCHOL, V33, P981, DOI 10.1002/1097-4679(197710)33:4<981::AID-JCLP2270330412>3.0.CO;2-0
   DEROGATIS LR, 1970, SCL90 ADM SCORING PR
   Engstrom I, 1999, ACTA PAEDIATR, V88, P175, DOI 10.1080/08035259950170358
   FAIRBURN CG, 1991, BRIT MED J, V303, P17, DOI 10.1136/bmj.303.6793.17
   FICHTER MM, 1991, INT J EAT DISORDER, V10, P571, DOI 10.1002/1098-108X(199109)10:5<571::AID-EAT2260100510>3.0.CO;2-J
   Fichter MM, 1998, INT J EAT DISORDER, V24, P227, DOI 10.1002/(SICI)1098-108X(199811)24:3<227::AID-EAT1>3.0.CO;2-O
   FRIEDMAN S, 1994, ANN MED-PSYCHOL, V153, P282
   GARNER DM, 1991, CLIN PSYCHOL REV, V11, P729, DOI 10.1016/0272-7358(91)90128-H
   GARNER DM, 1983, INT J EAT DISORDER, V2, P15, DOI 10.1002/1098-108X(198321)2:2<15::AID-EAT2260020203>3.0.CO;2-6
   GORTMAKER SL, 1993, NEW ENGL J MED, V329, P1008, DOI 10.1056/NEJM199309303291406
   Hautzinger M, 1995, BECK DEPRESSIONS INV
   Herpertz S, 2000, PSYCHOTHER PSYCH MED, V50, P161, DOI 10.1055/s-2000-13242
   Herpertz S, 1998, DIABETES CARE, V21, P1110, DOI 10.2337/diacare.21.7.1110
   Herpertz S, 1998, J PSYCHOSOM RES, V44, P503, DOI 10.1016/S0022-3999(97)00274-2
   Herpertz S, 2000, INT J EAT DISORDER, V28, P68, DOI 10.1002/(SICI)1098-108X(200007)28:1<68::AID-EAT8>3.0.CO;2-R
   HERPERTZ S, IN PRESS HDB EATING
   Jones JM, 2000, BMJ-BRIT MED J, V320, P1563, DOI 10.1136/bmj.320.7249.1563
   KENARDY J, 1994, DIABETES CARE, V17, P1197, DOI 10.2337/diacare.17.10.1197
   LLOYD GG, 1987, PSYCHOTHER PSYCHOSOM, V48, P189, DOI 10.1159/000288052
   Lustman PJ, 1997, PSYCHOSOM MED, V59, P24, DOI 10.1097/00006842-199701000-00004
   LUSTMAN PJ, 1992, PSYCHOSOM MED, V54, P602, DOI 10.1097/00006842-199209000-00007
   MULLER UA, 1996, FORDERUNGEN ST VINCE, P119
   Nielsen S, 1998, EUR EAT DISORD REV, V6, P1
   PEVELER RC, 1989, BEHAV RES THER, V27, P95, DOI 10.1016/0005-7967(89)90125-3
   PEVELER RC, 1992, INT J EAT DISORDER, V11, P45
   POLIVY J, 1995, AM PSYCHOL, V40, P191
   POLLOCK M, 1995, J AM ACAD CHILD PSY, V34, P291, DOI 10.1097/00004583-199503000-00012
   POLONSKY WH, 1994, DIABETES CARE, V17, P1178, DOI 10.2337/diacare.17.10.1178
   POPKIN MK, 1988, ARCH GEN PSYCHIAT, V45, P64
   RIEF W, 1992, PSYCHOPATHOLOGY, V25, P128, DOI 10.1159/000284763
   ROBERTSON P, 1990, J PSYCHOSOM RES, V34, P535, DOI 10.1016/0022-3999(90)90028-3
   ROUGHAN P, 1990, INT J OBESITY, V14, P135
   Rydall AC, 1997, NEW ENGL J MED, V336, P1849, DOI 10.1056/NEJM199706263362601
   STEEL JM, 1989, BRIT J PSYCHIAT, V155, P515, DOI 10.1192/bjp.155.4.515
   STRIEGELMOORE RH, 1992, DIABETES CARE, V15, P1361, DOI 10.2337/diacare.15.10.1361
   Takii M, 1999, J PSYCHOSOM RES, V47, P221, DOI 10.1016/S0022-3999(99)00031-8
   THIEL A, 1988, Z DIFFERENTIELLE DIA, V9, P267
   Vila G, 1995, EUR CHILD ADOLES PSY, V4, P270, DOI 10.1007/BF01980491
   WING RR, 1989, INT J EAT DISORDER, V8, P671, DOI 10.1002/1098-108X(198911)8:6<671::AID-EAT2260080608>3.0.CO;2-5
NR 49
TC 29
Z9 30
U1 0
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0022-3999
J9 J PSYCHOSOM RES
JI J. Psychosomat. Res.
PD NOV
PY 2001
VL 51
IS 5
BP 673
EP 678
DI 10.1016/S0022-3999(01)00246-X
PG 6
WC Psychiatry
SC Psychiatry
GA 500RL
UT WOS:000172640500007
PM 11728508
DA 2019-01-08
ER

PT J
AU Elia, M
AF Elia, M
TI Obesity in the elderly
SO OBESITY RESEARCH
LA English
DT Article; Proceedings Paper
CT Symposium on Dietary Patterns in Weight Management and Health
CY APR 27-29, 2001
CL DALLAS, TEXAS
SP Slim Fast Foods Co
DE elderly; mortality; body mass index; basal metabolic rate; energy
   expenditure
ID BODY-MASS INDEX; WESTERN ELECTRIC COMPANY; INTENTIONAL WEIGHT-LOSS; AGED
   40-64 YEARS; PHYSICAL-ACTIVITY; RISK-FACTORS; OLDER WOMEN; MORTALITY;
   MEN; HEALTH
AB In developed countries, there is a general increase in body weight and body mass index (BMI) with age, until similar to 60 years of age, when body weight and BMI begin to decline. The proportion of intra-abdominal fat, which is related to increased morbidity and mortality, progressively increases with age. There is also a progressive decline in energy intake and daily total energy expenditure (165 kcal/decade in men and 103 kcal/decade in women in developed countries), which is primarily due to a decrease in physical activity, and to a lesser extent, a decrease in basal metabolic rate. The decrease in physical activity is more pronounced in those with chronic disabilities and diseases. The BMI-mortality curves have been reported to move upward (greater overall mortality), become flatter (less effect of BMI on mortality), and in some cases shift to the right (minimum mortality occurs at a higher BMI), for a variety of possible reasons. Weight loss in the elderly has been reported to increase, decrease, or not alter mortality, but the studies are confounded by numerous methodological problems. It has been argued that there may be little benefit in encouraging weight loss in extreme old age (short life expectancy), especially when there are no obesity-related complications or biochemical risk factors and when strong resistance and distress arise from changes in lifelong habits of eating and exercise. In contrast, weight loss in the elderly can reduce morbidity from arthritis, diabetes and other conditions, reduce cardiovascular risk factors, and improve well-being. BMI also predicts morbidity in those without disease. Furthermore, increased physical activity in the elderly, which is an important component of weight management, can produce beneficial effects on muscle strength, endurance, and well-being.
C1 Univ Southampton, Southampton, Hants, England.
RP Elia, M (reprint author), Southampton Gen Hosp MP113, Inst Human Nutr, Tremona Rd, Southampton SO16 GYD, Hants, England.
CR ANDERSON JJ, 1988, AM J EPIDEMIOL, V128, P179, DOI 10.1093/oxfordjournals.aje.a114939
   ANDRES R, 1985, ANN INTERN MED, V103, P1030, DOI 10.7326/0003-4819-103-6-1030
   Andrews GR, 2001, BRIT MED J, V322, P728, DOI 10.1136/bmj.322.7288.728
   BAUFRERE B, 2000, EUR J CLIN NUTR, V54, pS48
   BAUMGARTNER RN, 1995, OBES RES, V3, P73, DOI 10.1002/j.1550-8528.1995.tb00124.x
   BJORNTORP P, 1990, ARTERIOSCLEROSIS, V10, P493, DOI 10.1161/01.ATV.10.4.493
   BRIERLEY EJ, 1995, QJM-MON J ASSOC PHYS, V88, P439
   Burger H, 1998, AM J EPIDEMIOL, V147, P871, DOI 10.1093/oxfordjournals.aje.a009541
   CAMPBELL AJ, 1990, AGE AGEING, V19, P131, DOI 10.1093/ageing/19.2.131
   Campbell AJ, 1997, BRIT MED J, V315, P1065, DOI 10.1136/bmj.315.7115.1065
   Dyer AR, 2000, AM J EPIDEMIOL, V152, P324, DOI 10.1093/aje/152.4.324
   Elia M, 2000, EUR J CLIN NUTR, V54, pS92, DOI 10.1038/sj.ejcn.1601030
   ELIA M, 1992, ENERGY METABOLISM TI, P92
   ERENS B, 1999, HLTH SURVEY ENGLAND
   FIATARONE MA, 1990, JAMA-J AM MED ASSOC, V263, P3029, DOI 10.1001/jama.263.22.3029
   French SA, 1999, AM J EPIDEMIOL, V149, P504
   GALANOS AN, 1994, J AM GERIATR SOC, V42, P368, DOI 10.1111/j.1532-5415.1994.tb07483.x
   HORBER FF, 1997, NUTRITION, V13, P424
   KINSELLA K, 1996, EPIDEMIOLOGY OLD AGE, P32
   LACROIX AZ, 1993, AM J EPIDEMIOL, V137, P858, DOI 10.1093/oxfordjournals.aje.a116747
   LAUNER LJ, 1994, JAMA-J AM MED ASSOC, V271, P1093, DOI 10.1001/jama.271.14.1093
   Lehmann AB, 1996, EUR J CLIN NUTR, V50, P6
   Lindsted KD, 1997, AM J EPIDEMIOL, V146, P1
   MacRae PG, 1996, J AM GERIATR SOC, V44, P175, DOI 10.1111/j.1532-5415.1996.tb02435.x
   Malbut-Shennan K, 1999, CORONARY ARTERY DIS, V10, P37
   McMurdo MET, 2000, BRIT MED J, V321, P1149, DOI 10.1136/bmj.321.7269.1149
   MORIGUTI JC, 1999, OBES RES S1, V7, P1035
   *NAT RES COUNC, 1989, DIT HLTH
   OSTMAN J, 1969, ACTA MED SCAND, V186, P241
   PETITT DJ, 1982, AM J EPIDEMIOL, V115, P359
   RISSANEN A, 1989, J CLIN EPIDEMIOL, V42, P781, DOI 10.1016/0895-4356(89)90076-0
   ROBERTS SB, 1994, JAMA-J AM MED ASSOC, V272, P1601, DOI 10.1001/jama.272.20.1601
   Roubenoff R, 2000, EUR J CLIN NUTR, V54, pS40, DOI 10.1038/sj.ejcn.1601024
   RUUSKANEN JM, 1995, AGE AGEING, V24, P292, DOI 10.1093/ageing/24.4.292
   Seidell JC, 2000, EUR J CLIN NUTR, V54, pS33, DOI 10.1038/sj.ejcn.1601023
   Spataro JA, 1996, J CLIN EPIDEMIOL, V49, P849, DOI 10.1016/0895-4356(96)00067-4
   Stevens J, 1998, NEW ENGL J MED, V338, P1, DOI 10.1056/NEJM199801013380101
   Stevens J, 1998, OBES RES, V6, P268, DOI 10.1002/j.1550-8528.1998.tb00349.x
   TAYBACK M, 1990, ARCH INTERN MED, V150, P1065, DOI 10.1001/archinte.150.5.1065
   Visscher TLS, 2000, AM J EPIDEMIOL, V151, P660
   Visser M, 1998, AM J CLIN NUTR, V68, P584
   Waaler H T, 1988, Acta Med Scand Suppl, V723, P17
   WILLERY WC, 1991, AM J CLIN NUTR, V153, P1102
   Williamson DF, 1999, AM J EPIDEMIOL, V149, P491
   WILLIAMSON DF, 1995, AM J EPIDEMIOL, V141, P1128, DOI 10.1093/oxfordjournals.aje.a117386
   Zamboni M, 1997, AM J CLIN NUTR, V66, P111
   1990, DIETARY GUIDELINES A, P261
   1995, DIETARY GUIDELINES A
NR 48
TC 133
Z9 140
U1 0
U2 9
PU NORTH AMER ASSOC STUDY OBESITY
PI ROCHESTER
PA C/O DR MICHAEL JENSEN, MAYO MEDICAL CENTER, MAYO CLIN 200 FIRST ST, SW,
   ROCHESTER, MN 55905 USA
SN 1071-7323
J9 OBES RES
JI Obes. Res.
PD NOV
PY 2001
VL 9
SU 4
BP 244S
EP 248S
DI 10.1038/oby.2001.126
PG 5
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA 496AC
UT WOS:000172371700006
PM 11707549
OA Bronze
DA 2019-01-08
ER

PT J
AU Snoek, FJ
   van der Ven, NCW
   Lubach, CHC
   Chatrou, M
   Ader, HJ
   Heine, RJ
   Jacobson, AM
AF Snoek, FJ
   van der Ven, NCW
   Lubach, CHC
   Chatrou, M
   Ader, HJ
   Heine, RJ
   Jacobson, AM
TI Effects of cognitive behavioural group training (CBGT) in adult patients
   with poorly controlled insulin-dependent (type 1) diabetes: a pilot
   study
SO PATIENT EDUCATION AND COUNSELING
LA English
DT Article
DE cognitive behaviour therapy; group training; type 1 diabetes; coping;
   glycaemic control; well-being
ID SELF-CARE; METABOLIC CONTROL; CONTROLLED TRIAL; MELLITUS; EDUCATION;
   VALIDITY; DUTCH
AB A substantial group of patients with type 1 diabetes has difficulty adhering to the treatment regimen, and as a consequence is at increased risk of developing microvascular complications. Cognitive behavioural interventions may help these patients to cope more effectively with their diabetes. We developed a 4 weeks cognitive behavioural. group training (CBGT) for patients with type I (insulin-dependent) diabetes in persistent poor glycaemic control, to help them overcome negative beliefs and attitudes towards diabetes and improve their self-care behaviours. Feasibility and efficacy of CBGT were tested in a non-randomised prospective study in 24 poorly-controlled type I diabetes patients (mean age 35.2 +/- 11.1 years; 15 female; mean HbA(1c) 9.3% (+/-1.2)), with assessments at 3 and 6 months follow-up. The program-me was delivered in small groups (n = 6-8), by a team of a diabetes nurse specialist and a psychologist. Primary outcome measures were glycosylated haemoglobin (HbA1(c)), diabetes-related emotional distress (PAID) and psychological well-being (WBQ-12). Chang diabetes self-care activities (DSCI) were documented, along with perceived barriers in diabetes questionniare (BDQ) and fear of hypoglycaemia survey (HFS). Data were analysed using repeated measures analysis of variance. The CBGT proved to be feasible in this selected group of patients and was well appreciated. Following CBGT, mean HbA(1c) dropped by 0.8% at 6 months from baseline, while emotional well-being was preserved, It is concluded that CBGT is a promising intervention that deserves further evaluation in randomised controlled trials. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.
C1 Vrije Univ Amsterdam, Med Ctr, Dept Med Psychol, Amsterdam, Netherlands.
   Vrije Univ Amsterdam, Med Ctr, Dept Endocrinol, Amsterdam, Netherlands.
   Vrije Univ Amsterdam, Med Ctr, Dept Clin Epidemiol & Biostat, Amsterdam, Netherlands.
   Joslin Diabet Ctr, Sect Behav Res, Boston, MA 02215 USA.
   Joslin Diabet Ctr, Mental Hlth Unit, Boston, MA 02215 USA.
RP Snoek, FJ (reprint author), Vrije Univ Amsterdam, Med Ctr, Dept Med Psychol, Amsterdam, Netherlands.
CR ANDERSON RM, 1995, DIABETES CARE, V18, P943, DOI 10.2337/diacare.18.7.943
   Arrindell W, 1986, SCL 90 MANUAL MULTID
   BECK A, 1980, COGNITIVE THERAPY DE
   Becker M. H., 1974, HLTH ED MONOGRAPHS, V2, P324, DOI DOI 10.1177/109019817400200401
   BROWNLEEDUFFECK M, 1987, J CONSULT CLIN PSYCH, V55, P139, DOI 10.1037//0022-006X.55.2.139
   DEWEERDT I, 1990, SOC SCI MED, V30, P605, DOI 10.1016/0277-9536(90)90159-P
   Ellis A., 1994, REASON EMOTION PSYCH
   EMMELKAMP PMG, 1993, PSYCHOTHER PSYCHOSOM, V59, P116, DOI 10.1159/000288656
   Fosbury JA, 1997, DIABETES CARE, V20, P959, DOI 10.2337/diacare.20.6.959
   Glasgow RE, 1999, DIABETES CARE, V22, P832, DOI 10.2337/diacare.22.5.832
   KRAAINAAR FW, 1998, BEHAV RES THER, V29, P19
   Lustman PJ, 1998, ANN INTERN MED, V129, P613, DOI 10.7326/0003-4819-129-8-199810150-00005
   Mollem ED, 1996, PATIENT EDUC COUNS, V29, P277, DOI 10.1016/S0738-3991(96)00926-3
   Pouwer F, 1999, DIABETES CARE, V22, P2004, DOI 10.2337/diacare.22.12.2004
   RUBIN RR, 1989, DIABETES CARE, V12, P673, DOI 10.2337/diacare.12.10.673
   Ruggiero L, 1997, DIABETES CARE, V20, P568, DOI 10.2337/diacare.20.4.568
   SALKOVSKIS PM, 1996, FRONTIERS COGNTIIVE
   SHAMOON H, 1993, NEW ENGL J MED, V329, P977
   Snoek F, 1996, GEDRAG GEZONDHEID, V24, P287
   Snoek F. J., 1999, DIABETES SPECTRUM, V12, P147
   Snoek FJ, 1999, DIABETES, V48, pA9
   Snoek FJ, 2000, DIABETES CARE, V23, P1305, DOI 10.2337/diacare.23.9.1305
   SPEERS MA, 1982, PAT COUNS HLTH ED, V4, P144
   *SPSS INC, 2000, SPSS BAS 9 0 WIND US
   VANDERVEN, 2000, PSYCHOL DIABETES CAR, P207
   ZETTLER A, 1995, PSYCHOTHER PSYCHOSOM, V64, P178, DOI 10.1159/000289009
NR 26
TC 42
Z9 44
U1 0
U2 6
PU ELSEVIER SCI IRELAND LTD
PI CLARE
PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE,
   IRELAND
SN 0738-3991
J9 PATIENT EDUC COUNS
JI Patient Educ. Couns.
PD NOV
PY 2001
VL 45
IS 2
BP 143
EP 148
DI 10.1016/S0738-3991(01)00113-6
PG 6
WC Public, Environmental & Occupational Health; Social Sciences,
   Interdisciplinary
SC Public, Environmental & Occupational Health; Social Sciences - Other
   Topics
GA 493YM
UT WOS:000172251100009
PM 11687328
DA 2019-01-08
ER

PT J
AU Johnson, JG
   Spitzer, RL
   Williams, JBW
AF Johnson, JG
   Spitzer, RL
   Williams, JBW
TI Health problems, impairment and illnesses associated with bulimia
   nervosa and binge eating disorder among primary care and obstetric
   gynaecology patients
SO PSYCHOLOGICAL MEDICINE
LA English
DT Article
ID PSYCHIATRIC COMORBIDITY; ANOREXIA-NERVOSA; LONG-TERM; MAJOR DEPRESSION;
   MENTAL-DISORDERS; SUICIDE ATTEMPTS; AXIS-I; DSM-IV; PREVALENCE; SYMPTOMS
AB Background. Although psychiatric patients with eating disorders are known to be at risk for a variety of health problems, relatively little is known about eating disorders and associated health problems in other populations. An epidemiological study was conducted to investigate health problems and impairment associated with bulimia nervosa (BN) and binge eating disorder (BED) among female primary care and obstetric gynaecology patients.
   Methods. Psychiatric disorders, physical illnesses, disabilities, functional status and stress were assessed among 4651 female patients (age range:18 to 99 years) at 8 primary care and 7 obstetric gynaecology clinics throughout the United States.
   Results. Two hundred eighty-nine women (6(.)2 %) were diagnosed with BN or BED. The prevalence of BN was approximately 1 % among young and middle-aged women. The prevalence of BED increased steadily from early (3(.)3 %) through middle (8(.)5 %) adulthood. Anxiety disorders, mood disorders and diabetes were much more common among women with BN or BED than among women without these eating disorders. Women with BN or BED reported markedly poorer functioning and much higher levels of disability, health problems, insomnia, psychosocial stress and suicidal thoughts than did women without BN or BED, after co-occurring psychiatric disorders were controlled statistically. Yet, fewer than one of ten cases of BN or BED was recognized by the patients' physicians.
   Conclusions. Patients with BN or BED often experience considerable disability, impairment, distress and co-occurring illnesses. Increased recognition of eating disorders may be a crucial step towards encouraging more patients to seek treatment for these disabling conditions.
C1 New York State Psychiat Inst & Hosp, Biometr Res Unit, New York, NY 10032 USA.
   Columbia Univ, New York, NY 10027 USA.
RP Johnson, JG (reprint author), New York State Psychiat Inst & Hosp, Biometr Res Unit, Unit 60,1051 Riverside Dr, New York, NY 10032 USA.
CR American Psychiatric Association, 1994, DIAGN STAT MAN MENT
   BARRETT JE, 1988, ARCH GEN PSYCHIAT, V45, P1100
   BRAUN DL, 1994, PSYCHOL MED, V24, P859, DOI 10.1017/S0033291700028956
   BREWERTON TD, 1995, J CLIN PSYCHIAT, V56, P77
   Buekens P, 1998, EUR J OBSTET GYN R B, V81, P43, DOI 10.1016/S0301-2115(98)00134-1
   Bulik CM, 1997, ACTA PSYCHIAT SCAND, V96, P101, DOI 10.1111/j.1600-0447.1997.tb09913.x
   Bulik CM, 1999, ACTA PSYCHIAT SCAND, V100, P27, DOI 10.1111/j.1600-0447.1999.tb10910.x
   BYRNE P, 1984, BRIT J PSYCHIAT, V144, P28, DOI 10.1192/bjp.144.1.28
   Carpenter KM, 2000, AM J PUBLIC HEALTH, V90, P251, DOI 10.2105/AJPH.90.2.251
   Carter JC, 1995, ADDICT BEHAV, V20, P765, DOI 10.1016/0306-4603(95)00096-8
   COOPER Z, 1987, INT J EAT DISORDER, V6, P1, DOI 10.1002/1098-108X(198701)6:1<1::AID-EAT2260060102>3.0.CO;2-9
   Crow SJ, 1998, PSYCHOSOMATICS, V39, P233, DOI 10.1016/S0033-3182(98)71340-4
   DEEP AL, 1995, INT J EAT DISORDER, V17, P291
   DEVLIN MJ, 1990, ARCH GEN PSYCHIAT, V47, P144
   DEZWAAN M, 1994, HARVARD REV PSYCHIAT, V1, P310, DOI 10.3109/10673229409017098
   Fairburn CG, 1997, ARCH GEN PSYCHIAT, V54, P509
   FAIRBURN CG, 1985, J PSYCHIAT RES, V19, P135, DOI 10.1016/0022-3956(85)90009-3
   Fava M, 1997, J NERV MENT DIS, V185, P140, DOI 10.1097/00005053-199703000-00002
   Favaro A, 1997, ACTA PSYCHIAT SCAND, V95, P508, DOI 10.1111/j.1600-0447.1997.tb10139.x
   FICHTER MM, 1993, INT J EAT DISORDER, V14, P1, DOI 10.1002/1098-108X(199307)14:1<1::AID-EAT2260140102>3.0.CO;2-3
   FOMBONNE F, 1998, EUROPEAN ARCH PSYCHI, V248, P1
   Franko DL, 2000, OBSTET GYNECOL, V95, P942, DOI 10.1016/S0029-7844(00)00792-4
   Grilo CM, 1996, PSYCHIATR SERV, V47, P426
   Grilo CM, 1997, PSYCHOPHARMACOL BULL, V33, P321
   Heatherton TF, 1997, J ABNORM PSYCHOL, V106, P117, DOI 10.1037/0021-843X.106.1.117
   Herpertz S, 1998, DIABETES CARE, V21, P1110, DOI 10.2337/diacare.21.7.1110
   HOLDERNESS HC, 1994, INT J EAT DISORDER, V16, P1, DOI 10.1002/1098-108X(199407)16:1<1::AID-EAT2260160102>3.0.CO;2-T
   Hsu LKG, 1996, PSYCHIAT CLIN N AM, V19, P681, DOI 10.1016/S0193-953X(05)70375-0
   KAPLAN AS, 1990, CAN J PSYCHIAT, V35, P745, DOI 10.1177/070674379003500905
   KAYE WH, 1989, BIOL PSYCHIAT, V25, P768, DOI 10.1016/0006-3223(89)90248-5
   Keel PK, 1999, ARCH GEN PSYCHIAT, V56, P63, DOI 10.1001/archpsyc.56.1.63
   Keel PK, 1997, AM J PSYCHIAT, V154, P313
   KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8
   LAESSLE RG, 1989, INT J EAT DISORDER, V8, P569, DOI 10.1002/1098-108X(198909)8:5<569::AID-EAT2260080508>3.0.CO;2-0
   Miranda J, 1998, AM J OBSTET GYNECOL, V178, P212, DOI 10.1016/S0002-9378(98)80002-1
   Mitchell JE, 1995, ADDICT BEHAV, V20, P725, DOI 10.1016/0306-4603(95)00095-X
   NELSON E, 1983, JAMA-J AM MED ASSOC, V249, P3331, DOI 10.1001/jama.249.24.3331
   PALMER EP, 1985, NEW ENGL J MED, V313, P1457, DOI 10.1056/NEJM198512053132306
   READ JL, 1987, J CHRONIC DIS S1, V40, P7
   ROBINS LN, 1991, PSYCHIAT DISORDERS A
   SCHULBERG HC, 1988, GEN HOSP PSYCHIAT, V10, P79, DOI 10.1016/0163-8343(88)90092-8
   SPITZER RL, 1993, INT J EAT DISORDER, V13, P161, DOI 10.1002/1098-108X(199303)13:2<161::AID-EAT2260130204>3.0.CO;2-R
   SPITZER RL, 1993, INT J EAT DISORDER, V13, P137
   SPITZER RL, 1992, INT J EAT DISORDER, V11, P191, DOI 10.1002/1098-108X(199204)11:3<191::AID-EAT2260110302>3.0.CO;2-S
   SPITZER RL, 1995, JAMA-J AM MED ASSOC, V274, P1511, DOI 10.1001/jama.274.19.1511
   SPITZER RL, 1994, JAMA-J AM MED ASSOC, V272, P1749, DOI 10.1001/jama.272.22.1749
   Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737
   STEWART AL, 1989, JAMA-J AM MED ASSOC, V262, P907, DOI 10.1001/jama.262.7.907
   STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007
   Striegel-Moore RH, 1999, INT J EAT DISORDER, V25, P405, DOI 10.1002/(SICI)1098-108X(199905)25:4<405::AID-EAT5>3.0.CO;2-F
   Sunday SR, 1997, PSYCHOPHARMACOL BULL, V33, P373
   Telch CF, 1998, J CONSULT CLIN PSYCH, V66, P768, DOI 10.1037/0022-006X.66.5.768
   THEANDER S, 1985, J PSYCHIATR RES, V19, P493, DOI 10.1016/0022-3956(85)90059-7
   Wiederman MW, 1996, INT J EAT DISORDER, V20, P163, DOI 10.1002/(SICI)1098-108X(199609)20:2<163::AID-EAT6>3.0.CO;2-E
   Williams M, 1999, ENVIRON HIST, V4, P103, DOI 10.2307/3985331
   Wonderlich SA, 1997, PSYCHOPHARMACOL BULL, V33, P381
   Yanovski SZ, 1995, ADDICT BEHAV, V20, P705, DOI 10.1016/0306-4603(96)00092-5
   YANOVSKI SZ, 1993, AM J PSYCHIAT, V150, P1472
   ZAIDER TI, 2000, UNPUB PROSPECTIVE LO
NR 59
TC 149
Z9 150
U1 0
U2 7
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 40 WEST 20TH ST, NEW YORK, NY 10011-4221 USA
SN 0033-2917
J9 PSYCHOL MED
JI Psychol. Med.
PD NOV
PY 2001
VL 31
IS 8
BP 1455
EP 1466
PG 12
WC Psychology, Clinical; Psychiatry; Psychology
SC Psychology; Psychiatry
GA 494HL
UT WOS:000172276000012
PM 11722160
DA 2019-01-08
ER

PT J
AU Fisher, L
   Chesla, CA
   Mullan, JT
   Skaff, MM
   Kanter, RA
AF Fisher, L
   Chesla, CA
   Mullan, JT
   Skaff, MM
   Kanter, RA
TI Contributors to depression in Latino and European-American patients with
   type 2 diabetes
SO DIABETES CARE
LA English
DT Article
ID QUALITY-OF-LIFE; GLYCEMIC CONTROL; DISEASE MANAGEMENT;
   AFRICAN-AMERICANS; METABOLIC-CONTROL; MAJOR DEPRESSION; SYMPTOMS;
   ADULTS; MELLITUS; POPULATION
AB OBJECTIVE - To deter-mine the independent and cumulative contributions of diabetes and other life stresses on depression and anxiety in Latino and European-American (EA) patients with diabetes.
   RESEARCH DESIGN AND METHODS - A total of 75 Latino and 113 EA patients with type 2 diabetes, recruited from managed care settings, were assessed regarding three groups of potential Stresses: demographics (age, sex, and education), disease status (functional impact, time since diagnosis, comorbidities, HbA(1c) and BMI), an family stress (financial stress, spouse conflict resolution, and family closeness). Dependent variables were depression (Center for Epidemiological Studies-Depression scale [CES-D]) and anxiety (Symptom Checklist [SCL-90]). Multiple regression equations assessed the independent contribution of each predictor on depression and anxiety.
   RESULTS - For both ethnic groups, education, functional impact, and financial stress significantly and independently predicted depression; poor spouse conflict resolution was a fourth significant predictor for EA patients only. The equations accounted for a high percentage of variance (43-55%). Excluding education, the same variables predicted anxiety for both ethnic groups. The disease status and family Stress variable groups significantly predicted outcomes independently. The relationships among these variables an occurred for all patients, not only for those classified as likely depressed.
   CONCLUSIONS - The findings suggest the utility of considering many life stresses, not just diabetes alone, that combine to affect depression and anxiety. We suggest that these effects are experienced cumulatively as general psychological distress for all patients with diabetes, not just those classified as likely depressed. Taken together, the findings emphasize a life-centered, patient-focused approach to the treatment of depression, rather than an exclusive disease-related perspective.
C1 Univ Calif San Francisco, Dept Family & Community Med, San Francisco, CA 94143 USA.
   No Calif Kaiser Permanente, San Francisco, CA USA.
RP Fisher, L (reprint author), Univ Calif San Francisco, Dept Family & Community Med, Box 0900, San Francisco, CA 94143 USA.
EM fisher@itsa.ucsf.edu
FU NIDDK NIH HHS [DK-49816, DK-53203]
CR BETANCOURT H, 1993, AM PSYCHOL, V48, P629, DOI 10.1037/0003-066X.48.6.629
   Black SA, 1998, J GERONTOL B-PSYCHOL, V53, pS198, DOI 10.1093/geronb/53B.4.S198
   BLACK SA, 1999, ANN EPIDEMIOL, V9, P46
   BLACK SA, 1998, J GERONTOL A-BIOL, V53, P188
   CARNEY JA, 1995, SEMIN DERMATOL, V14, P90, DOI 10.1016/S1085-5629(05)80003-3
   Ciechanowski PS, 2000, ARCH INTERN MED, V160, P3278, DOI 10.1001/archinte.160.21.3278
   CONNELL CM, 1994, HEALTH PSYCHOL, V13, P263, DOI 10.1037//0278-6133.13.3.263
   DCCT Res Grp, 1988, DIABETES CARE, V11, P725
   de Groot M, 1999, J PSYCHOSOM RES, V46, P425, DOI 10.1016/S0022-3999(99)00014-8
   De Groot M, 2000, DIABETES, V49, pA63
   De Groot M, 2001, DIABETES CARE, V24, P407, DOI 10.2337/diacare.24.2.407
   DEROGATIS L R, 1973, Psychopharmacology Bulletin, V9, P13
   EVERSON SA, 2001, C DEPR MENT DIS PAT
   FALICOV C, 1998, LATINO FAMILIES THER
   Fisher L, 2000, DIABETES CARE, V23, P267, DOI 10.2337/diacare.23.3.267
   Fisher L, 2000, FAM PROCESS, V39, P403, DOI 10.1111/j.1545-5300.2000.39402.x
   Gary TL, 2000, DIABETES CARE, V23, P23, DOI 10.2337/diacare.23.1.23
   GAVARD JA, 1993, DIABETES CARE, V16, P1167, DOI 10.2337/diacare.16.8.1167
   Hanninen JA, 1999, DIABETES CARE, V22, P997, DOI 10.2337/diacare.22.6.997
   Hodges EP, 1998, PSYCHOL REP, V83, P1081, DOI 10.2466/PR0.83.7.1081-1082
   Jackson-Triche ME, 2000, J AFFECT DISORDERS, V58, P89, DOI 10.1016/S0165-0327(99)00069-5
   JACOBSON AM, 1993, DIABETES CARE, V16, P1621, DOI 10.2337/diacare.16.12.1621
   Johnson D., 1980, BASIC DATA DEPRESSIV
   KATON W, 1990, Journal of Clinical Psychiatry, V51, P3
   Kohen D, 1998, QUAL LIFE RES, V7, P197, DOI 10.1023/A:1008817812520
   Kovacs M, 1997, DIABETES CARE, V20, P45, DOI 10.2337/diacare.20.1.45
   LEEDOM L, 1991, PSYCHOSOMATICS, V32, P280, DOI 10.1016/S0033-3182(91)72066-5
   Lewinsohn PM, 1996, J AM ACAD CHILD PSY, V35, P1120, DOI 10.1097/00004583-199609000-00009
   Lipton RB, 1998, DIABETES EDUCATOR, V24, P67, DOI 10.1177/014572179802400109
   Lloyd CE, 2000, DIABETIC MED, V17, P198, DOI 10.1046/j.1464-5491.2000.00260.x
   Lustman PJ, 1999, DIABETES, V48, pA73
   LUSTMAN PJ, 1986, J NERV MENT DIS, V174, P736, DOI 10.1097/00005053-198612000-00005
   Lustman PJ, 2000, DIABETES CARE, V23, P934, DOI 10.2337/diacare.23.7.934
   Lustman PJ, 2000, DIABETES CARE, V23, P618, DOI 10.2337/diacare.23.5.618
   LUSTMAN PJ, 1995, DIABETES AM, P507
   LYONS RA, 1994, J EPIDEMIOL COMMUN H, V48, P388, DOI 10.1136/jech.48.4.388
   MARIN G, 1991, RES HISPANIC POPULAT, V23
   Miranda J, 1996, J CONSULT CLIN PSYCH, V64, P868, DOI 10.1037/0022-006X.64.5.868
   Miyaoka Y, 1997, PSYCHIAT CLIN NEUROS, V51, P203, DOI 10.1111/j.1440-1819.1997.tb02583.x
   MOLDIN SO, 1993, PSYCHOL MED, V23, P755, DOI 10.1017/S0033291700025526
   PALINKAS LA, 1991, DIABETIC MED, V8, P532, DOI 10.1111/j.1464-5491.1991.tb01646.x
   Pearlin LI, 1981, J HEALTH SOC BEHAV, V22, P333
   Peyrot M, 1999, DIABETES CARE, V22, P448, DOI 10.2337/diacare.22.3.448
   Peyrot M, 1997, DIABETES CARE, V20, P585, DOI 10.2337/diacare.20.4.585
   Polonsky WH, 2000, DIABETES, V49, pA64
   RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306
   Rajala U, 1997, SOC PSYCH PSYCH EPID, V32, P363, DOI 10.1007/BF00805442
   ROY M, 1994, COMPR PSYCHIAT, V35, P129, DOI 10.1016/0010-440X(94)90057-O
   Talbot F, 1999, HEALTH PSYCHOL, V18, P537
   Talbot F, 2000, DIABETES CARE, V23, P1556, DOI 10.2337/diacare.23.10.1556
   Tschann JM, 1999, J MARRIAGE FAM, V61, P269, DOI 10.2307/353747
   VanderDoes FEE, 1996, DIABETES CARE, V19, P204, DOI 10.2337/diacare.19.3.204
   WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI 10.1001/jama.262.7.914
   WEYRER S, 1989, J PSYCHOSOM RES, V33, P633
   WINOCOUR PH, 1990, DIABETES RES CLIN EX, V14, P171
   Zayas L. H., 1994, FAMILY SYSTEMS MED, V12, P315, DOI 10.1037/h0089119
   Zeiss AM, 1996, PSYCHOL AGING, V11, P572, DOI 10.1037/0882-7974.11.4.572
NR 57
TC 96
Z9 101
U1 0
U2 8
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
EI 1935-5548
J9 DIABETES CARE
JI Diabetes Care
PD OCT
PY 2001
VL 24
IS 10
BP 1751
EP 1757
DI 10.2337/diacare.24.10.1751
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 478AW
UT WOS:000171321600009
PM 11574437
OA Bronze
DA 2019-01-08
ER

PT J
AU Trief, PM
   Himes, CL
   Orendorff, R
   Weinstock, RS
AF Trief, PM
   Himes, CL
   Orendorff, R
   Weinstock, RS
TI The marital relationship and psychosocial adaptation and glycemic
   control of individuals with diabetes
SO DIABETES CARE
LA English
DT Article
ID HEALTH SURVEY SF-36; SOCIAL SUPPORT; CHRONIC ILLNESS; FAMILY;
   ADJUSTMENT; MELLITUS; QUALITY; MANAGEMENT; FRAMEWORK; ADHERENCE
AB OBJECTIVE - To explore the relationship between marital relationship domains (i.e., intimacy and adjustment) and glycemic control and psychosocial adaptation to diabetes.
   RESEARCH DESIGN AND METHODS - A total of 78 insulin-treated adults with both type 1 and type 2 diabetes were assessed on a Single occasion. They completed two marital quality measures (Spanier Dyadic Adjustment Scale and Personal Assessment of Intimacy in Relationships Scale) and four quality-of-life measures (Diabetes Quality of Life Scale, Medical Outcomes Study Health Survey, Problem Areas in Diabetes Scale, and Positive and Negative Affect Scale). Glycemic control was assessed by HbA(1c). Demographic data (age, sex, type and duration of diabetes, years married, other medical conditions, family history, disability, and years of education) were gathered from the chart and questionnaires.
   RESULTS - Concerning psychosocial adaptation, both of the marital quality measures were predictors of aspects of adaptation. Better marital satisfaction was related to higher levels of diabetes-related satisfaction and less impact, as well as less diabetes-related distress and better general quality of life. Higher levels of marital intimacy were related to better diabetes-specific and general quality of life, Concerning glycemic control, there was a nonsignificant trend for marital adjustment scores to relate to HbA(1c) (P = 0.0568).
   CONCLUSIONS - For insulin-treated adults with diabetes, quality of marriage is associated with adaptation to diabetes and other aspects of health-related quality of life, The suggestive finding that marital adjustment may relate to glycemic control warrants further study. Future work should also explore the impact of couples-focused interventions on adaptation, adherence, and glycemic control.
C1 SUNY Upstate Med Univ, Dept Psychiat, Syracuse, NY 13210 USA.
   Syracuse Univ, Syracuse, NY USA.
   Joslin Diabet Ctr, Syracuse, NY USA.
   Vet Adm Med Ctr, Syracuse, NY 13210 USA.
RP Trief, PM (reprint author), SUNY Upstate Med Univ, Dept Psychiat, 750 E Adams St, Syracuse, NY 13210 USA.
OI Trief, Paula/0000-0002-2827-5722
CR BLOOM JR, 1984, SOC SCI MED, V19, P831, DOI 10.1016/0277-9536(84)90400-3
   CARDENAS L, 1987, AM J MED SCI, V293, P28, DOI 10.1097/00000441-198701000-00007
   DCCT Res Grp, 1988, DIABETES CARE, V11, P725
   EATON WW, 1992, INT J PSYCHIAT MED, V22, P105, DOI 10.2190/DF4H-9HQW-NJEC-Q54E
   Fisher L, 1998, DIABETES EDUCATOR, V24, P599, DOI 10.1177/014572179802400504
   GARAYSEVILA ME, 1995, J DIABETES COMPLICAT, V9, P81, DOI 10.1016/1056-8727(94)00021-F
   HAUSER ST, 1990, J PEDIATR PSYCHOL, V15, P527, DOI 10.1093/jpepsy/15.4.527
   JACOBSON AM, 1994, DIABETES CARE, V17, P267, DOI 10.2337/diacare.17.4.267
   KATZ AM, 1969, B MENNINGER CLIN, V33, P79
   LOCKE HJ, 1959, J MARRIAGE FAMILY LI, V21, P251
   Lyons R. F., 1995, RELATIONSHIPS CHRONI
   MCHORNEY CA, 1994, MED CARE, V32, P40, DOI 10.1097/00005650-199401000-00004
   Meadows K, 1996, QUAL LIFE RES, V5, P242, DOI 10.1007/BF00434746
   PEYROT M, 1985, PSYCHOSOM MED, V47, P542, DOI 10.1097/00006842-198511000-00004
   Pieper B A, 1990, Diabetes Educ, V16, P108, DOI 10.1177/014572179001600206
   POLONSKY WH, 1995, DIABETES CARE, V18, P754, DOI 10.2337/diacare.18.6.754
   PRIMOMO J, 1990, RES NURS HEALTH, V13, P153, DOI 10.1002/nur.4770130304
   Quittner AL, 1998, HEALTH PSYCHOL, V17, P112, DOI 10.1037/0278-6133.17.2.112
   Rissman R, 1987, FAMILY SYSTEMS MED, V5, P446
   SCHAEFER MT, 1981, J MARITAL FAM THER, V7, P47, DOI 10.1111/j.1752-0606.1981.tb01351.x
   SCHAFER LC, 1986, DIABETES CARE, V9, P179, DOI 10.2337/diacare.9.2.179
   SCHWARTZ LS, 1991, GEN HOSP PSYCHIAT, V13, P19, DOI 10.1016/0163-8343(91)90005-H
   SPANIER GB, 1976, J MARRIAGE FAM, V38, P15, DOI 10.2307/350547
   THARP RG, 1966, J CONSULT PSYCHOL, V30, P426, DOI 10.1037/h0023835
   Trief PM, 1998, DIABETES CARE, V21, P241, DOI 10.2337/diacare.21.2.241
   WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002
   WARE JE, 1994, SF 36 PHYSICAL MENTA
   WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063
   WEINGER K, 1998, ANN BEHAV MED, V20, P5118
   Welch GW, 1997, DIABETES CARE, V20, P760, DOI 10.2337/diacare.20.5.760
NR 30
TC 84
Z9 88
U1 0
U2 8
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1660 DUKE ST, ALEXANDRIA, VA 22314 USA
SN 0149-5992
J9 DIABETES CARE
JI Diabetes Care
PD AUG
PY 2001
VL 24
IS 8
BP 1384
EP 1389
DI 10.2337/diacare.24.8.1384
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 456HE
UT WOS:000170076400013
PM 11473074
OA Bronze
DA 2019-01-08
ER

PT J
AU Mollema, ED
   Snoek, FJ
   Heine, RJ
   van der Ploeg, HM
AF Mollema, ED
   Snoek, FJ
   Heine, RJ
   van der Ploeg, HM
TI Phobia of self-injecting and self-testing in insulin-treated diabetes
   patients: opportunities for screening
SO DIABETIC MEDICINE
LA English
DT Article
DE diabetes; phobia; self-injecting; self-testing; adult; prevalence
ID GLYCEMIC CONTROL; QUESTIONNAIRE; BLOOD; FEAR; MELLITUS; INJURY
AB Aims To define clinically relevant cut-off points for severe fear of self-injecting (FSI) and self-testing (FST) (phobia) in insulin-treated patients with diabetes, and to estimate the magnitude of these phobias in our research population.
   Methods FSI and FST were assessed in a cross-sectional survey using the Diabetes Fear of Injecting and Self-testing Questionnaire (D-FISQ). A sample of 24 insulin-treated adult diabetic patients was selected from the high-scorers on FSI and/or FST (greater than or equal to 95th percentile). FSI and FST were re-assessed, after which patients participated in a behavioural avoidance test (BAT), thereby determining the current level of avoidance of either self-injecting or self-testing. FSI and FST scores were linked to the outcome of the BATs. Cut-off scores for severe FSI/FST were determined and extrapolated to the total study population (n = 1275).
   Results Seven patients participated in the self-injecting BAT: two patients refused to perform an extra injection. in the self-testing BAT (n = 17) four patients declined to perform the extra blood glucose self-test. Extrapolation of FSI and FST cut-off scores to the total research population showed that 0.2-1.3% of the population scored in the severe FSI range. In FST, 0.6-0.8% of the total study population obtained scores in the cut-off range.
   Conclusions Severe FSI and FST, characterized by emotional distress and avoidance behaviour, seems to occur in a small group of insulin-treated patients with diabetes. The D-FISQ can be of use to health care professionals (physicians, nurse specialists) in quickly providing valuable information on levels of FSI and FST in diabetes patients.
C1 Free Univ Amsterdam, Med Ctr, Fac Med, Dept Med Psychol,EMGO Inst, NL-1081 BT Amsterdam, Netherlands.
   Free Univ Amsterdam, Med Ctr, Dept Endocrinol, NL-1081 BT Amsterdam, Netherlands.
RP Mollema, ED (reprint author), Free Univ Amsterdam, Med Ctr, Fac Med, Dept Med Psychol,EMGO Inst, Boechorststr 7, NL-1081 BT Amsterdam, Netherlands.
CR Berlin I, 1997, DIABETES CARE, V20, P176, DOI 10.2337/diacare.20.2.176
   Bienvenu OJ, 1998, PSYCHOL MED, V28, P1129, DOI 10.1017/S0033291798007144
   Bodzin B, 1996, Home Healthc Nurse, V14, P378, DOI 10.1097/00004045-199605000-00009
   COX DJ, 1992, J CONSULT CLIN PSYCH, V60, P628, DOI 10.1037//0022-006X.60.4.628
   Evans JMM, 1999, BRIT MED J, V319, P83, DOI 10.1136/bmj.319.7202.83
   Glasgow RE, 1999, DIABETES CARE, V22, P832, DOI 10.2337/diacare.22.5.832
   Kindt M, 1996, BEHAV RES THER, V34, P277, DOI 10.1016/0005-7967(95)00069-0
   KOLKO DJ, 1980, J BEHAV THER EXP PSY, V11, P273, DOI 10.1016/0005-7916(80)90070-1
   METSCH J, 1995, INT J BEHAV MED, V2, P104, DOI 10.1207/s15327558ijbm0202_2
   Mollem ED, 1996, PATIENT EDUC COUNS, V29, P277, DOI 10.1016/S0738-3991(96)00926-3
   Mollema ED, 2000, DIABETES CARE, V23, P765, DOI 10.2337/diacare.23.6.765
   Morris AD, 1997, LANCET, V350, P1505, DOI 10.1016/S0140-6736(97)06234-X
   OST LG, 1992, BEHAV THER, V23, P263, DOI 10.1016/S0005-7894(05)80385-5
   RAINWATER N, 1988, CHILD FAM BEHAV THER, V10, P19
   Ruggiero L, 1997, DIABETES CARE, V20, P568, DOI 10.2337/diacare.20.4.568
   Snoek FJ, 1997, DIABETIC MED, V14, P871, DOI 10.1002/(SICI)1096-9136(199710)14:10<871::AID-DIA457>3.3.CO;2-P
   Zambanini A, 1999, DIABETES RES CLIN PR, V46, P239, DOI 10.1016/S0168-8227(99)00099-6
   Zambanini A, 1997, DIABETIC MED, V14, P321, DOI 10.1002/(SICI)1096-9136(199704)14:4<321::AID-DIA356>3.0.CO;2-H
NR 18
TC 61
Z9 61
U1 0
U2 3
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND
SN 0742-3071
J9 DIABETIC MED
JI Diabetic Med.
PD AUG
PY 2001
VL 18
IS 8
BP 671
EP 674
DI 10.1046/j.1464-5491.2001.00547.x
PG 4
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 475UK
UT WOS:000171186300012
PM 11553207
DA 2019-01-08
ER

PT J
AU McIntyre, RS
   McCann, SM
   Kennedy, SH
AF McIntyre, RS
   McCann, SM
   Kennedy, SH
TI Antipsychotic metabolic effects: Weight gain, diabetes mellitus, and
   lipid abnormalities
SO CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE
LA English
DT Review
DE weight gain; obesity; obesity comorbidity; diabetes mellitus;
   triglyceride; atypical antipsychotics; conventional antipsychotics
ID SERUM TRIGLYCERIDE LEVELS; BIPOLAR DISORDER; BODY-WEIGHT; LEPTIN LEVELS;
   PLASMA-LEVELS; FOOD-INTAKE; CLOZAPINE; OLANZAPINE; SCHIZOPHRENIA;
   RECEPTORS
AB Objective: To review published and nonpublished literature describing changes in weight, glucose homeostasis, and lipid milieu with antipsychotics.
   Methods: A Medline search was completed using the words weight gain, diabetes mellitus, cholesterol, triglycerides, risperidone, clozapine, olanzapine, quetiapine, ziprasidone, predictors, prolactin, obesity, and conventional antipsychotics. Publications, including original articles, review articles, letters to the editor abstracts or posters presented at professional meetings in the last 4 years, and references from published articles, were collected. Manufacturers, including Eli Lilly Canada Inc, Janssen-Ortho Inc, Pfizer Canada Inc, AstraZeneca Inc, and Novartis Pharmaceuticals, were contacted to retrieve additional medical information.
   Results: The topic of antipsychotic-induced weight gain is understudied, and there ave relatively few well-controlled studies. Weight gain as a side effect has been described with both conventional and atypical antipsychotics. Moreover, some atypical antipsychotics are associated with de novo diabetes mellitus and increased serum triglyceride levels. Predictors of weight gain may be age, baseline body, mass index, appetite stimulation, previous antipsychotic exposure, and antipsychotic treatment duration.
   Conclusion: Significant weight gain is reported with the existing atypical antipsychotics, The weight gain described is highly distressing to patients, may reduce treatment adherence, and may increase the relative risk for diabetes mellitus and hypertriglyceridemia. Physicians employing these agents should routinely monitor weight, fasting blood glucose, and lipid profiles.
C1 Ctr Addict & Mental Hlth, Mood & Anxiety Disorders Program, Toronto, ON M5T 1R8, Canada.
   Univ Toronto, Dept Psychiat, Toronto, ON, Canada.
RP McIntyre, RS (reprint author), Ctr Addict & Mental Hlth, Mood & Anxiety Disorders Program, Clarke Site,250 Coll St, Toronto, ON M5T 1R8, Canada.
EM roger_meintyre@camh.net
CR Allison DB, 1999, J CLIN PSYCHIAT, V60, P215, DOI 10.4088/JCP.v60n0402
   Allison DB, 1999, AM J PSYCHIAT, V156, P1686
   AMERY W, 1997, 10 EUR COLL NEUR C S
   [Anonymous], 1998, OBES RES S2, p51S, DOI DOI 10.1002/J.1550-8528.1998.TB00690.X
   AULAKH CS, 1992, PSYCHOPHARMACOLOGY, V109, P444, DOI 10.1007/BF02247721
   AWAD AG, 1999, 11 WORLD C PSYCH AUG
   BAPTISTA T, 1990, PHARMACOL BIOCHEM BE, V37, P227, DOI 10.1016/0091-3057(90)90325-C
   Baptista T, 1999, PROG NEURO-PSYCHOPH, V23, P277, DOI 10.1016/S0278-5846(98)00096-7
   BAPTISTA T, 1987, PHARMACOL BIOCHEM BE, V27, P399, DOI 10.1016/0091-3057(87)90340-6
   Beasley CM, 1997, J CLIN PSYCHIAT, V58, P13
   BERNSTEIN JG, 1992, OBESITY
   BRESCAN CM, 1997, 150 M AM PSYCH ASS M
   Bromel T, 1998, MOL PSYCHIATR, V3, P76, DOI 10.1038/sj.mp.4000352
   Bustillo JR, 1996, AM J PSYCHIAT, V153, P817
   Bymaster FP, 1999, SCHIZOPHR RES, V37, P107, DOI 10.1016/S0920-9964(98)00146-7
   CABRERA R, 1988, MOL CELL ENDOCRINOL, V58, P167, DOI 10.1016/0303-7207(88)90151-7
   CALBRESE JR, 1998, ANN M AM PSYCH ASS J
   CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778
   CHENGAPPA RKN, 1999, BIPOLAR DISORD, V1, P42
   CLARK ML, 1970, CLIN PHARMACOL THER, V11, P680
   Cleland R, 1998, COMMERCIAL WEIGHT LO
   CONLEY RR, 1999, US PSYCH MENT HLTH C
   CSERNANSKY J, 1999, BIOL PSYCHIAT S, V45, pS1
   Dickson RA, 1999, SCHIZOPHR RES, V35, pS75, DOI 10.1016/S0920-9964(98)00159-5
   DOSS FW, 1979, J CLIN PSYCHIAT, V40, P528
   Dursun SM, 1999, J PSYCHIATR NEUROSCI, V24, P453
   Farooqi IS, 1999, NEW ENGL J MED, V341, P879, DOI 10.1056/NEJM199909163411204
   Frye MA, 1998, J AFFECT DISORDERS, V48, P91, DOI 10.1016/S0165-0327(97)00160-2
   GALLANT DM, 1973, CURR THER RES CLIN E, V15, P915
   Ganguli R, 1999, J CLIN PSYCHIAT, V60, P20
   GARATTINI S, 1989, BRIT J PSYCHIAT, V155, P41, DOI 10.1192/S0007125000291757
   GARDOS G, 1977, AM J PSYCHIAT, V134, P302
   Gaulin BD, 1999, AM J PSYCHIAT, V156, P1270
   Ghaeli P, 1996, AM J HEALTH-SYST PH, V53, P2079
   Goldstein LE, 1999, PSYCHOSOMATICS, V40, P438, DOI 10.1016/S0033-3182(99)71210-7
   GOODALL E, 1988, BRIT J PSYCHIAT, V153, P208, DOI 10.1192/bjp.153.2.208
   GOPALASWAMY AK, 1985, ACTA PSYCHIAT SCAND, V72, P254, DOI 10.1111/j.1600-0447.1985.tb02603.x
   Gordon A, 1999, AM J PSYCHIAT, V156, P968
   Greenberg I, 1999, J CLIN PSYCHIAT, V60, P31
   Guille C, 2000, J CLIN PSYCHIAT, V61, P638, DOI 10.4088/JCP.v61n0907
   Hebebrand J, 1997, MOL PSYCHIATR, V2, P330, DOI 10.1038/sj.mp.4000282
   Henderson DC, 2000, AM J PSYCHIAT, V157, P975, DOI 10.1176/appi.ajp.157.6.975
   Heymsfield SB, 1999, JAMA-J AM MED ASSOC, V282, P1568, DOI 10.1001/jama.282.16.1568
   HOLDEN J M C, 1970, Psychosomatics, V11, P551
   Hummer M, 1995, EUR NEUROPSYCHOPHARM, V5, P437, DOI 10.1016/0924-977X(95)00012-E
   HUSSAIN MZ, 1998, 48 ANN M CAN PSYCH A
   ISOJARVI JIT, 1993, NEW ENGL J MED, V329, P1383, DOI 10.1056/NEJM199311043291904
   JOHNSON DAW, 1979, ACTA PSYCHIAT SCAND, V59, P525, DOI 10.1111/j.1600-0447.1979.tb00252.x
   JUBERT P, 1995, ANN INTERN MED, V122, P397
   KAMRAN A, 1994, AM J PSYCHIAT, V151, P1395
   Kelly DL, 1998, J CHILD ADOL PSYCHOP, V8, P151, DOI 10.1089/cap.1998.8.151
   KHAN SA, 1987, AM FAM PHYSICIAN, V36, P107
   KINON BJ, 1998, 38 ANN M NCDEU NEW C
   KLETT CJ, 1960, J NEUROPSYCHIATRY, V2, P102
   Koren W, 1997, ANN PHARMACOTHER, V31, P168, DOI 10.1177/106002809703100206
   Kostakoglu AE, 1996, ACTA PSYCHIAT SCAND, V93, P217, DOI 10.1111/j.1600-0447.1996.tb10635.x
   KOVAL MS, 1994, AM J PSYCHIAT, V151, P1520
   Kraus T, 1999, AM J PSYCHIAT, V156, P312
   KRYSPIN-EXNER W, 1947, Wien Klin Wochenschr, V59, P531
   KUSAMAKER V, 1999, 3 INT C BIP DIS JUN
   LAMBERTI JS, 1992, AM J PSYCHIAT, V149, P689
   LEADBETTER R, 1992, AM J PSYCHIAT, V149, P68
   Leysen JE, 1996, SEROTONIN ANTIPSYCHO, P51
   Lindenmayer JP, 1999, AM J PSYCHIAT, V156, P1471
   MANSON JE, 1995, NEW ENGL J MED, V333, P677, DOI 10.1056/NEJM199509143331101
   Marcotte D, 1998, J AFFECT DISORDERS, V50, P245, DOI 10.1016/S0165-0327(98)00110-4
   MARTIN A, 1992, AM J PSYCHIAT, V149, P714
   MCELROY SL, 1998, 21 C C INT NEUR PSYC
   McEvoy JP, 1999, BIOL PSYCHIAT, V46, P125, DOI 10.1016/S0006-3223(98)00377-1
   MCINTYRE RS, 2000, ACTA NEUROPSYCHAITRI, V12, P42
   MCINTYRE RS, 1999, PRIMARY CARE PSYCHIA, V5, P41
   Melamed Y, 1998, CAN J PSYCHIAT, V43, P956
   MELKERSSON KL, IN PRESS J CLIN PSYC
   Meltzer S, 1998, CAN MED ASSOC J, V159, pS1
   Mokdad AH, 1999, JAMA-J AM MED ASSOC, V282, P1519, DOI 10.1001/jama.282.16.1519
   Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185
   MURZI E, 1991, BRAIN RES BULL, V26, P321, DOI 10.1016/0361-9230(91)90001-Z
   Osser DN, 1999, J CLIN PSYCHIAT, V60, P767, DOI 10.4088/JCP.v60n1109
   PARADA MA, 1988, PHARMACOL BIOCHEM BE, V30, P917, DOI 10.1016/0091-3057(88)90120-7
   Peterson GA, 1996, AM J PSYCHIAT, V153, P737
   PLANANSKY KAREL, 1959, JOUR CLIN AND EXPTL PSYCHOPATH, V20, P53
   Popli AP, 1997, J CLIN PSYCHIAT, V58, P108, DOI 10.4088/JCP.v58n0304
   Raison CL, 1997, AM J PSYCHIAT, V154, P711
   Reinstein MJ, 1999, CLIN DRUG INVEST, V18, P99, DOI 10.2165/00044011-199918020-00002
   Remington G, 1999, J PSYCHIATR NEUROSCI, V24, P431
   Rosenbaum M, 1996, J CLIN ENDOCR METAB, V81, P3424, DOI 10.1210/jc.81.9.3424
   SACHS G, 1999, 11 C PSYCH AUG HAMB
   SCHOTTE A, 1996, PSYCHOPHARMACOLOGY, V17, P263
   Serdula MK, 1999, JAMA-J AM MED ASSOC, V282, P1353, DOI 10.1001/jama.282.14.1353
   SHANK RP, 1994, EPILEPSIA, V35, P450, DOI 10.1111/j.1528-1157.1994.tb02459.x
   Sheitman BB, 1999, AM J PSYCHIAT, V156, P1471
   Sobel M, 1999, J CLIN PSYCHIAT, V60, P556, DOI 10.4088/JCP.v60n0809f
   STANTON JM, 1995, SCHIZOPHRENIA BULL, V21, P463, DOI 10.1093/schbul/21.3.463
   TECOTT LH, 1995, NATURE, V374, P542, DOI 10.1038/374542a0
   Tohen M, 1998, J CLIN PSYCHIAT, V59, P38
   Tran PV, 1997, J CLIN PSYCHOPHARM, V17, P407, DOI 10.1097/00004714-199710000-00010
   UMBRICHT DSG, 1994, J CLIN PSYCHIAT, V55, P157
   UvnasMoberg K, 1996, NEUROENDOCRINOLOGY, V63, P269, DOI 10.1159/000126970
   VAMPINI C, 1994, NEUROPSYCHOPHARMACOL, V10, pS249
   Verrotti A, 1999, NEUROLOGY, V53, P230, DOI 10.1212/WNL.53.1.230
   WADE GN, 1992, NEUROSCI BIOBEHAV R, V16, P235, DOI 10.1016/S0149-7634(05)80183-6
   WALSH AES, 1994, PSYCHOPHARMACOLOGY, V116, P120, DOI 10.1007/BF02244883
   WANG DY, 1987, EUR J CANCER CLIN ON, V23, P1541, DOI 10.1016/0277-5379(87)90098-8
   Wetterling T, 1999, J CLIN PSYCHOPHARM, V19, P316, DOI 10.1097/00004714-199908000-00006
   *WHO, 1997, WHONUTNCD981
   Wirshing DA, 1998, BIOL PSYCHIAT, V44, P778, DOI 10.1016/S0006-3223(98)00100-0
   Wirshing DA, 1999, J CLIN PSYCHIAT, V60, P358, DOI 10.4088/JCP.v60n0602
   YAMADA J, 1995, LIFE SCI, V57, P819, DOI 10.1016/0024-3205(95)02010-G
   Yanovski JA, 1999, JAMA-J AM MED ASSOC, V282, P1504, DOI 10.1001/jama.282.16.1504
   ZOLER ML, 1999, CLIN PSYCHIAT NEWS, V27, P20
   ZORN SH, 1998, INTERACTIVE MONOAMIN, V4, P377
NR 111
TC 195
Z9 199
U1 0
U2 9
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0706-7437
EI 1497-0015
J9 CAN J PSYCHIAT
JI Can. J. Psychiat.-Rev. Can. Psychiat.
PD APR
PY 2001
VL 46
IS 3
BP 273
EP 281
DI 10.1177/070674370104600308
PG 9
WC Psychiatry
SC Psychiatry
GA 421UR
UT WOS:000168082400009
PM 11320682
DA 2019-01-08
ER

PT J
AU Sarici, SU
   Alpay, F
   Dundaroz, MR
   Gokcay, E
AF Sarici, SU
   Alpay, F
   Dundaroz, MR
   Gokcay, E
TI Neonatal diabetes mellitus: Patient report and review of the literature
SO JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID PATERNAL UNIPARENTAL DISOMY; TRANSIENT; CHROMOSOME-6; ISODISOMY; 6Q
AB A female infant born at 33 weeks gestation to a gestationally diabetic mother developed apnea and respiratory distress at 6 hours of age. Laboratory investigation demonstrated persistent hyperglycemia, and the patient was treated with continuous intravenous and subsequent subcutaneous insulin therapy, Detailed laboratory investigation to reveal the etiology of hyperglycemia and further endocrine evaluation were not significant. The baby's insulin requirement has continued thereafter, and she is being followed up in an outpatient clinic still under insulin therapy at 18 months of age. Neonatal diabetes mellitus should be considered in the differential diagnosis of neonatal hyperglycemia, and it may develop in newborns born to diabetic mothers, as well as neonatal hypoglycemia. Insulin treatment with close blood glucose monitoring is essential as long as hyperglycemia persists since neonatal diabetes mellitus may be either transient or permanent and it is not possible to differentiate these two outcomes before 18 months of age.
C1 Gulhane Mil Med Acad, Dept Pediat, Div Newborn Med, TR-06018 Ankara, Turkey.
RP Sarici, SU (reprint author), Gulhane Mil Med Acad, Dept Pediat, Div Newborn Med, TR-06018 Ankara, Turkey.
CR ABRAMOWICZ MJ, 1994, J CLIN INVEST, V94, P418, DOI 10.1172/JCI117339
   Arthur EI, 1997, EUR J HUM GENET, V5, P417
   Bappal B, 1999, ARCH DIS CHILD, V80, pF209, DOI 10.1136/fn.80.3.F209
   Battin M, 1996, J Perinatol, V16, P288
   Cave H, 2000, DIABETES, V49, P108, DOI 10.2337/diabetes.49.1.108
   Christian SL, 1999, J PEDIATR-US, V134, P42, DOI 10.1016/S0022-3476(99)70370-7
   Gardner RJ, 1998, CLIN GENET, V54, P522
   Gardner RJ, 1999, J MED GENET, V36, P192
   GOTTSCHALK ME, 1992, DIABETES CARE, V15, P1273, DOI 10.2337/diacare.15.10.1273
   Hermann R, 2000, PEDIATRICS, V105, P49, DOI 10.1542/peds.105.1.49
   Hermann R, 1997, EUR J PEDIATR, V156, P740
   HUME R, 1998, FORFAR ARNEILLS TXB, P298
   KALKAN SC, 1997, NEONATAL PERINATAL M, P1462
   Kruger C, 1997, EUR J PEDIATR, V156, P1
   Marquis E, 2000, EUR J HUM GENET, V8, P137, DOI 10.1038/sj.ejhg.5200401
   NIELSEN F, 1989, ACTA PAEDIATR SCAND, V78, P469, DOI 10.1111/j.1651-2227.1989.tb11114.x
   POLK DH, 1998, AVERYS DIS NEWBORN, P1240
   SALERNO M, 1994, J PEDIATR ENDOCRINOL, V7, P47
   Shehadeh N, 1996, ACTA PAEDIATR, V85, P1415
   Shehadeh N, 1998, J PEDIATR ENDOCR MET, V11, P575
   SHIELD JPH, 1995, ARCH DIS CHILD, V72, P56, DOI 10.1136/adc.72.1.56
   TEMPLE IK, 1995, NAT GENET, V9, P110, DOI 10.1038/ng0295-110
   VONMUHLENDAHL E, 1995, NEW ENGL J MED, V333, P704, DOI 10.1056/NEJM199509143331105
   WEIMERSKIRCH D, 1993, J PEDIATR-US, V122, P598, DOI 10.1016/S0022-3476(05)83544-9
   Whiteford ML, 1997, J MED GENET, V34, P167, DOI 10.1136/jmg.34.2.167
NR 25
TC 7
Z9 8
U1 0
U2 1
PU WALTER DE GRUYTER GMBH
PI BERLIN
PA GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY
SN 0334-018X
EI 2191-0251
J9 J PEDIATR ENDOCR MET
JI J. Pediatr. Endocrinol. Metab.
PD APR
PY 2001
VL 14
IS 4
BP 451
EP 454
PG 4
WC Endocrinology & Metabolism; Pediatrics
SC Endocrinology & Metabolism; Pediatrics
GA 421XJ
UT WOS:000168088600013
PM 11327380
DA 2019-01-08
ER

PT J
AU Weinger, K
   Jacobson, AM
AF Weinger, K
   Jacobson, AM
TI Psychosocial and quality of life correlates of glycemic control during
   intensive treatment of type 1 diabetes
SO PATIENT EDUCATION AND COUNSELING
LA English
DT Article
DE type 1 diabetes; quality of life; emotional distress; barriers
ID BLOOD-GLUCOSE CONTROL; METABOLIC CONTROL; SELF-CARE; MELLITUS; THERAPY;
   HYPOGLYCEMIA; MANAGEMENT; DEPRESSION; BEHAVIORS; EDUCATION
AB To identify emotional and attitudinal barriers to improved glycemic control (HbA(1c)) during intensive diabetes treatment, 55 patients attending a 4-5 month intensive diabetes medical/education clinic were followed. Subjects completed a battery of psychological surveys, had HbA(1c) and body mass index measured, and rated their attitude toward weight gain and the extent of problems with specific self-management behaviors before and after the medical intervention. Although HbA(1c) improved on average, 29% had only modest improvement and 16% showed no improvement. The number of diabetes-related annoyances, worry about hypoglycemia, and diabetes-related emotional distress diminished. Only the satisfaction subscale of the Diabetes Quality of Life survey, diabetes-related emotional distress, and problems with self-management behaviors correlated with HbA(1c). Treatment-related frustration and emotional distress may initially act as motivators to improve glycemia but can later become barriers to that goal. Interventions designed to help patients overcome attitudinal barriers should be incorporated into medical programs geared toward improving glycemia. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.
C1 Harvard Univ, Sch Med, Joslin Diabet Ctr, Sect Behav & Mental Hlth Res, Boston, MA 02215 USA.
RP Weinger, K (reprint author), Harvard Univ, Sch Med, Joslin Diabet Ctr, Sect Behav & Mental Hlth Res, Boston, MA 02215 USA.
FU NINR NIH HHS [F32 NR007157-03, F32 NR007157-01A1, F32 NR007157-02,
   NR07157]; NIDDK NIH HHS [R01 DK042315-08, NIDDK42315]
CR Anderson B, 1997, J PEDIATR-US, V130, P257, DOI 10.1016/S0022-3476(97)70352-4
   Beck A. T., 1976, COGNITIVE THERAPY EM
   Bradley C, 1994, HDB PSYCHOL DIABETES, P65
   COX DJ, 1984, HEALTH PSYCHOL, V3, P63, DOI 10.1037/0278-6133.3.1.63
   COX DJ, 1987, DIABETES CARE, V10, P617, DOI 10.2337/diacare.10.5.617
   Day JL, 1996, DIABETIC MED, V13, P564, DOI 10.1002/(SICI)1096-9136(199606)13:6<564::AID-DIA127>3.0.CO;2-0
   Diabet Control Complications Trial Res Grp, 1996, DIABETES CARE, V19, P195
   Diabet Control Complications Trial Res Grp, 1995, DIABETES CARE, V18, P1415
   GLASGOW RE, 1987, J CHRON DIS, V40, P399, DOI 10.1016/0021-9681(87)90173-1
   Grey M, 1999, APPL NURS RES, V12, P3, DOI 10.1016/S0897-1897(99)80123-2
   JACOBSON AM, 1990, DIABETES CARE, V13, P375, DOI 10.2337/diacare.13.4.375
   JACOBSON AM, 1994, DIABETES CARE, V17, P267, DOI 10.2337/diacare.17.4.267
   Jacobson AM, 1998, ANN INTERN MED, V129, P656, DOI 10.7326/0003-4819-129-8-199810150-00016
   Jacobson AM, 1996, NEW ENGL J MED, V334, P1249, DOI 10.1056/NEJM199605093341907
   Keefe F J, 1993, Arthritis Care Res, V6, P213, DOI 10.1002/art.1790060408
   Kinsley BT, 1999, DIABETES CARE, V22, P1022, DOI 10.2337/diacare.22.7.1022
   LOCKINGTON TJ, 1989, DIABETIC MED, V6, P309, DOI 10.1111/j.1464-5491.1989.tb01170.x
   LUSTMAN PJ, 1986, J NERV MENT DIS, V174, P736, DOI 10.1097/00005053-198612000-00005
   Lustman PJ, 1998, ANN INTERN MED, V129, P613, DOI 10.7326/0003-4819-129-8-199810150-00005
   MAZZE RS, 1984, DIABETES CARE, V7, P360, DOI 10.2337/diacare.7.4.360
   *MED OUTC TRUST, 1993, SCOR SF 36 HLTH SURV, P19
   PEYROT M, 1985, PSYCHOSOM MED, V47, P542, DOI 10.1097/00006842-198511000-00004
   POLONSKY WH, 1995, DIABETES CARE, V18, P754, DOI 10.2337/diacare.18.6.754
   POLONSKY WH, 1992, HEALTH PSYCHOL, V11, P199, DOI 10.1037/0278-6133.11.3.199
   REICHARD P, 1993, NEW ENGL J MED, V329, P304, DOI 10.1056/NEJM199307293290502
   RUBIN RR, 1989, DIABETES CARE, V12, P673, DOI 10.2337/diacare.12.10.673
   RUBIN RR, 1991, DIABETES CARE, V14, P335, DOI 10.2337/diacare.14.4.335
   SHAMOON H, 1993, NEW ENGL J MED, V329, P977
   vanDulmen AM, 1996, PSYCHOSOM MED, V58, P508, DOI 10.1097/00006842-199609000-00013
   WEINBERG JS, 1987, COGNITIVE THERAPY AP, P213
NR 30
TC 49
Z9 51
U1 0
U2 1
PU ELSEVIER SCI IRELAND LTD
PI CLARE
PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE,
   IRELAND
SN 0738-3991
J9 PATIENT EDUC COUNS
JI Patient Educ. Couns.
PD FEB
PY 2001
VL 42
IS 2
BP 123
EP 131
DI 10.1016/S0738-3991(00)00098-7
PG 9
WC Public, Environmental & Occupational Health; Social Sciences,
   Interdisciplinary
SC Public, Environmental & Occupational Health; Social Sciences - Other
   Topics
GA 392XW
UT WOS:000166438700004
PM 11118778
DA 2019-01-08
ER

PT J
AU Magee, LA
AF Magee, LA
TI Treating hypertension in women of child-bearing age and during pregnancy
SO DRUG SAFETY
LA English
DT Review
ID FOR-GESTATIONAL-AGE; CONVERTING-ENZYME-INHIBITORS;
   SOCIETY-CONSENSUS-CONFERENCE; BLOOD-PRESSURE MEASUREMENT; MILD CHRONIC
   HYPERTENSION; FETAL GROWTH-RETARDATION; CORONARY HEART-DISEASE; MEAN
   ARTERIAL-PRESSURE; BIRTH-WEIGHT INFANTS; LOW-DOSE ASPIRIN
AB Hypertension is found among 1 to 6% of young women, Treatment aims to decrease cardiovascular risk, the magnitude of which is less dependent on the absolute level of blood pressure (BP) than on associated cardiovascular risk factors, hypertension-related target organ damage and/or concomitant disease. Lifestyle modifications are recommended for all hypertensive individuals. The threshold of BP at which antihypertensive therapy should be initiated is based on absolute cardiovascular risk. Most young women are at low risk and not in need of anti-hypertensive therapy. All antihypertensive agents appear to be equally efficacious: choice depends on personal preference, social circumstances and an agent's effect on cardiovascular risk factors, target organ damage and/or concomitant disease.
   Although most agents are appropriate for, and tolerated well by, young women, another consideration remains that of pregnancy, 50% of which are unplanned. A clinician must be aware of a woman's method of contraception and the potential of an antihypertensive agent to cause birth defects following inadvertent exposure in earl pregnancy. Conversely, if an oral contraceptive is effective and well tolerated, but the woman's BP becomes mildly elevated, continuing the contraceptive and initiating antihypertensive treatment mat; not be contraindicated, especially if the ability to plan pregnancy is important (e.g, in type 1 diabetes mellitus). No commonly used antihypertensive is known to he teratogenic, although ACE inhibitors and angiotensin receptor antagonists should be discontinued, and any antihypertensive drugs should be continued in pregnancy only if anticipated benefits out-weigh potential reproductive risk(s).
   The hypertensive disorders of pregnancy complicate 5 to 10% of pregnancies and are a leading cause of maternal and perinatal mortality and morbidity. Treatment aims to improve pregnancy outcome. There is consensus that severe maternal hypertension (systolic BP greater than or equal to 170mm Hg and/or diastolic BP greater than or equal to 110mm Hg) should be treated immediately to avoid maternal stroke, death and, possibly, eclampsia. Parenteral hydralazine may he associated with a higher risk of maternal hypotension, and intravenous labetalol with neonatal bradycardia. There is no consensus as to whether mild-to-moderate hyper tension in pregnancy should be treated: the risks of transient severe hypertension, antenatal hospitalisation, proteinuria at delivery and neonatal respiratory distress syndrome, may be decreased by therapy, but intrauterine fetal grow th may also be impaired, particularly by atenolol. Methyldopa and other beta -blockers have been used most extensively. Reporting bias and the uncertainty of outcomes as defined warrant cautious interpretation of these findings and preclude treatment recommendations.
C1 Univ British Columbia, Childrens & Womens Hlth Ctr British Columbia, Vancouver, BC V6H 3N1, Canada.
RP Magee, LA (reprint author), Univ British Columbia, Childrens & Womens Hlth Ctr British Columbia, 1U59 4500 Oak St, Vancouver, BC V6H 3N1, Canada.
EM lmagee@cw.bc.ca
CR ALES K, 1990, AM J OBSTET GYNECOL, V162, P288, DOI 10.1016/0002-9378(90)90867-7
   *AM AC PED COMM DR, 1994, PEDIATRICS, V93, P137
   ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356
   [Anonymous], 1990, AM J OBSTET GYNECOL, V163, P1689
   AUGUST P, 1990, AM J OBSTET GYNECOL, V163, P1612, DOI 10.1016/0002-9378(90)90639-O
   Badawi N, 1998, BRIT MED J, V317, P1549, DOI 10.1136/bmj.317.7172.1549
   Barker DJP, 1997, CLIN OBSTET GYNECOL, V40, P853, DOI 10.1097/00003081-199712000-00019
   BARR M, 1994, TERATOLOGY, V50, P399, DOI 10.1002/tera.1420500606
   Barton J. R., 1999, American Journal of Obstetrics and Gynecology, V180, pS48
   Bernstein IM, 2000, AM J OBSTET GYNECOL, V182, P198, DOI 10.1016/S0002-9378(00)70513-8
   Briggs GG, 1994, DRUGS PREGNANCY LACT
   BROUWER RM, 1985, CARDIOVASC PHARM, V7, pS88
   Brown MA, 1996, MED J AUSTRALIA, V165, P360
   Brown MA, 2000, AUST NZ J OBSTET GYN, V40, P133, DOI 10.1111/j.1479-828X.2000.tb01136.x
   Brown MA, 1997, MED J AUSTRALIA, V166, P640
   BURROWS RF, 1995, AM J OBSTET GYNECOL, V173, P929, DOI 10.1016/0002-9378(95)90368-2
   Burrows RF, 1998, AUST NZ J OBSTET GYN, V38, P306, DOI 10.1111/j.1479-828X.1998.tb03072.x
   Burrows RF, 1996, AM J OBSTET GYNECOL, V174, P800, DOI 10.1016/S0002-9378(96)70477-5
   BUTTERS L, 1990, BMJ-BRIT MED J, V301, P587, DOI 10.1136/bmj.301.6752.587
   Chappell LC, 1999, LANCET, V354, P810, DOI 10.1016/S0140-6736(99)80010-5
   Coetzee EJ, 1998, BRIT J OBSTET GYNAEC, V105, P300, DOI 10.1111/j.1471-0528.1998.tb10090.x
   COLLINS R, 1985, BMJ-BRIT MED J, V290, P17, DOI 10.1136/bmj.290.6461.17
   DAVEY DA, 1986, CLIN EXP HYPERTENS B, V5, P97, DOI 10.3109/10641958609023478
   *DEP HLTH, 1989, REP CONF ENQ MAT DEA
   Department of Health, 1998, WHY MOTH DIE REP CON
   Department of Health Welsh Office Scottish Office Department of Health Department of Health and Social Services Northern Ireland, 1996, REP CONF ENQ MAT DEA
   DOUGLAS KA, 1994, BMJ-BRIT MED J, V309, P1395, DOI 10.1136/bmj.309.6966.1395
   DUCEY JP, 1992, ANESTHESIOLOGY, V77, P829, DOI 10.1097/00000542-199210000-00034
   Dwyer T, 1999, BRIT MED J, V319, P1325, DOI 10.1136/bmj.319.7221.1325
   Easterling TR, 1999, OBSTET GYNECOL, V93, P725, DOI 10.1016/S0029-7844(98)00522-5
   *ECL TRIAL COLL GR, 1995, LANCET, V345, P1455
   Eriksson JG, 1999, BMJ-BRIT MED J, V318, P427, DOI 10.1136/bmj.318.7181.427
   ESKENAZI B, 1993, AM J OBSTET GYNECOL, V169, P1112, DOI 10.1016/0002-9378(93)90265-K
   Feldman RD, 1999, CAN MED ASSOC J, V161, pS1
   FERRAZZANI S, 1990, AM J OBSTET GYNECOL, V162, P366, DOI 10.1016/0002-9378(90)90387-M
   Ferrer RL, 2000, OBSTET GYNECOL, V96, P849, DOI 10.1016/S0029-7844(00)00938-8
   Forsen T, 1999, BRIT MED J, V319, P1403, DOI 10.1136/bmj.319.7222.1403
   FORSEN T, 1999, BMJ-BRIT MED J, V315, P837
   Friedman E A, 1976, Perspect Nephrol Hypertens, V5, P13
   Friedman SA, 1999, CHESLEYS HYPERTENSIV, P201
   GALLERY EDM, 1979, Q J MED, V48, P593
   GALLERY EDM, 1999, CHESLEYS HYPERTENSIV, P327
   Gifford RW, 2000, AM J OBSTET GYNECOL, V183, pS1, DOI 10.1067/mob.2000.107928
   GILSTRAP LC, 1978, SEMIN PERINATOL, V2, P73
   Greer IA, 1999, LANCET, V353, P1258, DOI 10.1016/S0140-6736(98)10265-9
   Gress TW, 2000, NEW ENGL J MED, V342, P905, DOI 10.1056/NEJM200003303421301
   GUYTON AC, 1991, SCIENCE, V252, P1813, DOI 10.1126/science.2063193
   HACK M, 1995, FUTURE CHILD, V5, P176, DOI 10.2307/1602514
   Hales CN, 1997, BRIT MED BULL, V53, P109
   Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6
   Hauth JC, 2000, OBSTET GYNECOL, V95, P24, DOI 10.1016/S0029-7844(99)00462-7
   Helewa ME, 1997, CAN MED ASSOC J, V157, P715
   Heyborne KD, 2000, AM J OBSTET GYNECOL, V183, P523, DOI 10.1067/mob.2000.106757
   Horsager R, 1995, 15 ANN M SOC PER OBS
   HURST JA, 1995, CLIN DYSMORPHOL, V4, P359, DOI 10.1097/00019605-199510000-00013
   IMPEY L, 1993, BRIT J OBSTET GYNAEC, V100, P959, DOI 10.1111/j.1471-0528.1993.tb15120.x
   JACKSON R, 1993, BRIT MED J, V307, P107, DOI 10.1136/bmj.307.6896.107
   JOFFRES MR, 1992, CAN MED ASSOC J S, V146, P28
   *JOINT NAT COMM PR, 1997, ARCH INTERN MED, V157, P2413, DOI DOI 10.1001/ARCHINTE.157.21.2413
   KHONG TY, 1986, BRIT J OBSTET GYNAEC, V93, P1049, DOI 10.1111/j.1471-0528.1986.tb07830.x
   Kim CR, 1996, ARCH PEDIAT ADOL MED, V150, P686, DOI 10.1001/archpedi.1996.02170320032005
   Kok JH, 1998, BRIT J OBSTET GYNAEC, V105, P162, DOI 10.1111/j.1471-0528.1998.tb10046.x
   Lapillonne A, 1997, ACTA PAEDIATR, V86, P173
   LAW CM, 1993, BRIT MED J, V306, P24, DOI 10.1136/bmj.306.6869.24
   Leon DA, 1998, BMJ-BRIT MED J, V317, P241, DOI 10.1136/bmj.317.7153.241
   Lindberg B S, 1992, Int J Technol Assess Health Care, V8 Suppl 1, P57
   Lip GYH, 1997, AM J CARDIOL, V79, P1436, DOI 10.1016/S0002-9149(97)00163-X
   Lip GYH, 1997, LANCET, V350, P1446, DOI 10.1016/S0140-6736(05)64207-9
   Liu LS, 1998, J HYPERTENS, V16, P1823, DOI 10.1097/00004872-199816120-00016
   LONG PA, 1980, BRIT J OBSTET GYNAEC, V87, P13, DOI 10.1111/j.1471-0528.1980.tb04419.x
   LUCAS MJ, 1995, NEW ENGL J MED, V333, P201, DOI 10.1056/NEJM199507273330401
   Lydakis C, 1999, AM J HYPERTENS, V12, P541, DOI 10.1016/S0895-7061(99)00031-X
   MABIE WC, 1986, OBSTET GYNECOL, V67, P197, DOI 10.1097/00006250-198602000-00008
   MacMahon S, 1993, J VASC MED BIOL, V4, P265
   Magee L, 2000, LANCET, V355, P1367, DOI 10.1016/S0140-6736(05)72600-3
   Magee LA, 1999, BRIT MED J, V318, P1332, DOI 10.1136/bmj.318.7194.1332
   Magee LA, 1996, AM J OBSTET GYNECOL, V174, P823, DOI 10.1016/S0002-9378(96)70307-1
   Magee LA, 2000, EUR J OBSTET GYN R B, V88, P15, DOI 10.1016/S0301-2115(99)00113-X
   MAGEE LA, 1996, THESIS U TORONTO TOR
   MAGEE LA, 1997, EMBRYONIC MED THERAP, P390
   MATERSON BJ, 1993, NEW ENGL J MED, V328, P914, DOI 10.1056/NEJM199304013281303
   McIntire DD, 1999, NEW ENGL J MED, V340, P1234, DOI 10.1056/NEJM199904223401603
   Misra DP, 1996, PAEDIATR PERINAT EP, V10, P244, DOI 10.1111/j.1365-3016.1996.tb00048.x
   MOORE MP, 1983, BRIT MED J, V287, P580, DOI 10.1136/bmj.287.6392.580
   Moutquin JM, 1997, CAN MED ASSOC J, V157, P907
   NAEYE RL, 1987, AM J DIS CHILD, V141, P50, DOI 10.1001/archpedi.1987.04460010050022
   NAEYE RL, 1979, AM J OBSTET GYNECOL, V133, P8, DOI 10.1016/0002-9378(79)90402-2
   NIMROD CA, 1999, MED FETUS MOTHER, P267
   ORNSTEIN M, IN PRESS HDB HYPERTE
   OSMOND C, 1993, BRIT MED J, V307, P1519, DOI 10.1136/bmj.307.6918.1519
   PAGE EW, 1976, AM J OBSTET GYNECOL, V126, P821, DOI 10.1016/0002-9378(76)90671-2
   PAGE EW, 1976, AM J OBSTET GYNECOL, V125, P740, DOI 10.1016/0002-9378(76)90839-5
   Peek M, 1996, OBSTET GYNECOL, V88, P1030, DOI 10.1016/S0029-7844(96)00350-X
   Penny JA, 1998, AM J OBSTET GYNECOL, V178, P521, DOI 10.1016/S0002-9378(98)70432-6
   PIETRANTONI M, 1994, CLIN EXP HYPERTENS, V16, P479, DOI 10.3109/10641969409067957
   Poppas A, 1997, CIRCULATION, V95, P2407, DOI 10.1161/01.CIR.95.10.2407
   Psaty BM, 1997, JAMA-J AM MED ASSOC, V277, P739, DOI 10.1001/jama.277.9.739
   Ramsay LE, 1999, BRIT MED J, V319, P630, DOI 10.1136/bmj.319.7210.630
   Rey E, 1997, CAN MED ASSOC J, V157, P1245
   REY E, 1994, AM J OBSTET GYNECOL, V171, P410, DOI 10.1016/0002-9378(94)90276-3
   RichEdwards JW, 1997, BRIT MED J, V315, P396, DOI 10.1136/bmj.315.7105.396
   ROBERTS JM, 1993, LANCET, V341, P1447, DOI 10.1016/0140-6736(93)90889-O
   SAFTLAS AF, 1990, AM J OBSTET GYNECOL, V163, P460, DOI 10.1016/0002-9378(90)91176-D
   Saudan P, 1998, BRIT J OBSTET GYNAEC, V105, P1177, DOI 10.1111/j.1471-0528.1998.tb09971.x
   SHEAR R, 1999, CAN J CME        FEB, P69
   Shennan A, 1996, LANCET, V347, P139, DOI 10.1016/S0140-6736(96)90338-4
   SIBAI BM, 1987, OBSTET GYNECOL, V70, P323
   SIBAI BM, 1983, OBSTET GYNECOL, V61, P571
   SIBAI BM, 1986, OBSTET GYNECOL, V67, P517
   SIBAI BM, 1984, OBSTET GYNECOL, V64, P319
   Sibai BM, 1998, NEW ENGL J MED, V339, P667, DOI 10.1056/NEJM199809033391004
   SIBAI BM, 1992, AM J OBSTET GYNECOL, V167, P879, DOI 10.1016/S0002-9378(12)80005-6
   SKRABANEK P, 1992, LANCET, V340, P1208, DOI 10.1016/0140-6736(92)92902-R
   Staessen JA, 1997, LANCET, V350, P757, DOI 10.1016/S0140-6736(97)05381-6
   Stanley CA, 1999, NEW ENGL J MED, V340, P1200, DOI 10.1056/NEJM199904153401510
   Strauss RS, 2000, JAMA-J AM MED ASSOC, V283, P625, DOI 10.1001/jama.283.5.625
   *TER SOC PUBL AFF, 1994, TERATOLOGY, V49, P446
   TYSON JE, 1995, PEDIATRICS, V95, P534
   UMANS JG, 1999, CHESLEYS HYPERTENSIV, P581
   United States Food and Drug Administration, 1979, FED REGISTER, V44, P37434
   van Pampus MG, 1998, EUR J OBSTET GYN R B, V76, P31, DOI 10.1016/S0301-2115(97)00146-2
   Visser W, 1995, EUR J OBSTET GYN R B, V63, P147, DOI 10.1016/0301-2115(95)02260-0
   von Dadelszen P, 2000, LANCET, V355, P87, DOI 10.1016/S0140-6736(98)08049-0
   WAISMAN GD, 1988, AM J OBSTET GYNECOL, V159, P308, DOI 10.1016/S0002-9378(88)80072-3
   *WHO EXP COMM, 1996, 862 WHO EXP COMM
   WHO. World Health Organization-International Society of Hypertension Guideline for the Management of Hypertension (Guideline Sub-Committee), 1999, J HYPERTENS, P151
   WITTMANN BK, 1988, CAN MED ASSOC J, V139, P37
   Woodall SM, 1996, PEDIATR RES, V40, P438, DOI 10.1203/00006450-199609000-00012
   YEMINI M, 1989, EUR J OBSTET GYN R B, V30, P193, DOI 10.1016/0028-2243(89)90068-3
   1997, MMWR MORB MORTAL WKL, V46, P240
NR 130
TC 40
Z9 43
U1 0
U2 8
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 0114-5916
EI 1179-1942
J9 DRUG SAFETY
JI Drug Saf.
PY 2001
VL 24
IS 6
BP 457
EP 474
DI 10.2165/00002018-200124060-00004
PG 18
WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy;
   Toxicology
SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy;
   Toxicology
GA 432BJ
UT WOS:000168666600004
PM 11368252
DA 2019-01-08
ER

PT J
AU Snoek, FJ
   Pouwer, F
   Welch, GW
   Polonsky, WH
AF Snoek, FJ
   Pouwer, F
   Welch, GW
   Polonsky, WH
TI Diabetes-related emotional distress in Dutch and US diabetic patients -
   Cross-cultural validity of the problem areas in diabetes scale
SO DIABETES CARE
LA English
DT Article
ID QUESTIONNAIRE; PREVALENCE; MELLITUS; STRESS; PEOPLE
AB OBJECTIVE - To examine the cross-cultural validity of the Problem Areas in Diabetes Scale (PAID) in Dutch and U.S. diabetic patients.
   RESEARCH DESIGN AND METHODS - A total of 1,472 Dutch people with diabetes completed the PAID along with other self-report measures of affect. Statistics covered Cronbach's or, exploratory factor analysis (EFA), and confirmatory factor analysis (CFA), Pearson's product-moment correlation, and t tests. Psychometric properties of PAID were compared for Dutch and U.S. diabetic patients.
   RESULTS - Internal consistency of the Dutch PAID was high and stable across sex and type of diabetes. Test-retest reliability was high. Principal component analyses confirmed 1 general 20-item factor, whereas EFA identified 4 new subdimensions: negative emotions, treatment problems, food-related problems, and lack of social support. These dimensions were confirmed with CFA and were replicated in the U.S. sample. The PAID and its subscales demonstrated moderate to high associations in the expected direction with other measures of affect. Dutch and U.S. subjects reported having the same problem areas, with U.S. patients reporting higher emotional distress levels both in type 1 and type 2 diabetes.
   CONCLUSIONS - The Dutch and U.S. 20-item PAID appeared to be psychometrically equivalent, which allowed for cross-cultural comparisons.
C1 Free Univ Amsterdam, Med Ctr, Dept Med Psychol, NL-1081 BT Amsterdam, Netherlands.
   Joslin Diabet Ctr, Behav Res Sect, Boston, MA 02215 USA.
   Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA.
RP Snoek, FJ (reprint author), Free Univ Amsterdam, Med Ctr, Dept Med Psychol, Van der Boechorststr 7, NL-1081 BT Amsterdam, Netherlands.
CR AIKENS JE, 1992, J CONSULT CLIN PSYCH, V60, P113, DOI 10.1037/0022-006X.60.1.113
   Bentler P.M., 1995, EQS WINDOWS USERS GU
   Bijl RV, 1998, SOC PSYCH PSYCH EPID, V33, P587, DOI 10.1007/s001270050098
   BRADLEY C, 1990, DIABETIC MED, V7, P445, DOI 10.1111/j.1464-5491.1990.tb01421.x
   COX DJ, 1987, DIABETES CARE, V10, P617, DOI 10.2337/diacare.10.5.617
   COX DJ, 1992, J CONSULT CLIN PSYCH, V60, P628, DOI 10.1037//0022-006X.60.4.628
   Floyd FJ, 1995, PSYCHOL ASSESSMENT, V7, P286, DOI 10.1037/1040-3590.7.3.286
   GAFVELS C, 1993, DIABETIC MED, V10, P768, DOI 10.1111/j.1464-5491.1993.tb00162.x
   Glasgow RE, 1999, DIABETES CARE, V22, P832, DOI 10.2337/diacare.22.5.832
   GLASGOW RE, 1997, DIABETES SPECTRUM, V10, P12
   Herschbach P, 1997, HEALTH PSYCHOL, V16, P171, DOI 10.1037/0278-6133.16.2.171
   Ishii H. W. G., 1999, DIABETES S1, V48, pA139
   Jacobson AM, 1996, NEW ENGL J MED, V334, P1249, DOI 10.1056/NEJM199605093341907
   KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8
   MAZZE RS, 1984, DIABETES CARE, V7, P360, DOI 10.2337/diacare.7.4.360
   Meadows K, 1996, QUAL LIFE RES, V5, P242, DOI 10.1007/BF00434746
   METSCH J, 1995, INT J BEHAV MED, V2, P104, DOI 10.1207/s15327558ijbm0202_2
   Nichols GA, 2000, DIABETES CARE, V23, P273, DOI 10.2337/diacare.23.3.273
   Nouwen A, 1997, HEALTH PSYCHOL, V16, P263
   Plowright R, 1999, QUAL LIFE RES, V8, P650
   POLONSKY WH, 1995, DIABETES CARE, V18, P754, DOI 10.2337/diacare.18.6.754
   Pouwer F, 1999, DIABETES CARE, V22, P2004, DOI 10.2337/diacare.22.12.2004
   RUBIN RR, 1992, DIABETES CARE, V15, P1640, DOI 10.2337/diacare.15.11.1640
   Snoek F, 1996, GEDRAG GEZONDHEID, V24, P287
   SPIELBERGER CD, 1983, MANUAL STATE TRAIT A
   SPSS, 1997, SPSS BASE 7 5 APPL G
   Van der Ploeg H. M., 1999, HANDLEIDING BIJ ZELF
   WELBORN TA, 1983, DIABETES CARE, V6, P315, DOI 10.2337/diacare.6.3.315
   Welch GW, 1997, DIABETES CARE, V20, P760, DOI 10.2337/diacare.20.5.760
   West S. G., 1995, STRUCTURAL EQUATION
NR 30
TC 225
Z9 229
U1 5
U2 24
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1660 DUKE ST, ALEXANDRIA, VA 22314 USA
SN 0149-5992
J9 DIABETES CARE
JI Diabetes Care
PD SEP
PY 2000
VL 23
IS 9
BP 1305
EP 1309
DI 10.2337/diacare.23.9.1305
PG 5
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 348UT
UT WOS:000089005400018
PM 10977023
OA Bronze
DA 2019-01-08
ER

PT J
AU Meadows, KA
   Abrams, C
   Sandbaek, A
AF Meadows, KA
   Abrams, C
   Sandbaek, A
TI Adaptation of the Diabetes Health Profile (DHP-1) for use with patients
   with Type 2 diabetes mellitus: psychometric evaluation and
   cross-cultural comparison
SO DIABETIC MEDICINE
LA English
DT Article
DE cross-cultural adaptation; diabetes mellitus; diabetes-related
   psychological distress and behaviour; reliability; validity
ID QUALITY-OF-LIFE; INSTRUMENTS; RELIABILITY
AB Aims To adapt the Diabetes Health Profile (DHP-1) for use with English speaking patients with Type 2 diabetes mellitus and to evaluate the psychometric properties of the adapted measure in a UK; and Danish sample of insulin, tablet and diet-treated patients with Type 2 diabetes.
   Methods Following linguistic adaptation using the forward-backward translation procedure, the 32-item DHP-1 was sent to 650 and 800 consecutively selected UK and Danish patients with Type 2 diabetes. Construct validity was assessed using principal axis factoring. Factor stability was assessed across language groups using the coefficient of congruence. Reliability was evaluated using Cronbach's alpha and multi-trait analysis, including item convergent/discriminant validity. Subscale discriminant validity was assessed through known groups with one-way ANOVA and post hoc Scheffe tests for multiple comparisons.
   Results Eighteen items (56.25%) were retained following initial item analysis. A three-factor solution accounting for 45.6% and 40.3% of the total explained variance was identified in the UK and Danish samples, respectively. Factors were interpreted as psychological distress (PD), barriers to activity (BA and disinhibited eating (DE). Factor congruence between language groups ranged from 0.98 to 0.99 and Cronbach's alpha ranged between 0.70 and 0.88. Item scaling success for both language versions was 88.9%. BA scores discriminated between treatment groups in both language groups (F = 24.24, P < 0.001; F = 7.68, P < 0.001) and PD scores in the UK sample (F = 20.97, P < 0.001).
   Conclusions The DHP-18 developed for use with patients with Type 2 diabetes has been shown to have satisfactory internal reliability and validity and measurement equivalence across language groups.
C1 Univ Hull, Appl Stat Ctr, Hlth & Survey Res Unit, Kingston Upon Hull HU6 7RX, N Humberside, England.
RP Meadows, KA (reprint author), Univ Hull, Appl Stat Ctr, Hlth & Survey Res Unit, Kingston Upon Hull HU6 7RX, N Humberside, England.
EM k.a.meadows@maths.hull.ac.uk
CR BRADLEY C, 1990, DIABETIC MED, V7, P445, DOI 10.1111/j.1464-5491.1990.tb01421.x
   Brislin RW, 1973, CROSS CULTURAL RES M
   BUCQUET D, 1990, SOC SCI MED, V30, P829, DOI 10.1016/0277-9536(90)90207-9
   BULLINGER M, 1993, QUAL LIFE RES, V2, P451, DOI 10.1007/BF00422219
   CATTELL RB, 1966, HDB MULTIVARIATE EXP
   Child D., 1970, ESSENTIALS FACTOR AN
   CRONBACH LJ, 1951, PSYCHOMETRIKA, V16, P297, DOI DOI 10.1007/BF02310555
   DCCT Res Grp, 1988, DIABETES CARE, V11, P725
   DUNTEMAN GH, 1994, FACTOR ANAL RELATED, P157
   FILLENBAUM GG, 1984, J HLTH ILLNESS, V20, P45
   Goddijn P, 1996, QUAL LIFE RES, V5, P433, DOI 10.1007/BF00449918
   Goddijn PPM, 1999, DIABETIC MED, V16, P23, DOI 10.1046/j.1464-5491.1999.00002.x
   GUILLEMIN F, 1993, J CLIN EPIDEMIOL, V46, P1417, DOI 10.1016/0895-4356(93)90142-N
   Harman HH, 1960, MODERN FACTOR ANAL
   HAYS RD, 1990, BEHAV RES METH INSTR, V22, P167, DOI 10.3758/BF03203140
   HAYS RD, 1993, QUAL LIFE RES, V2, P441, DOI 10.1007/BF00422218
   Herdman M, 1997, QUAL LIFE RES, V6, P237
   HUI CH, 1985, J CROSS CULT PSYCHOL, V16, P131, DOI 10.1177/0022002185016002001
   MEADOWS K, 1994, QUAL LIFE RES, V3, P67
   Meadows K, 1996, QUAL LIFE RES, V5, P242, DOI 10.1007/BF00434746
   Nunnally JC, 1994, PSYCHOMETRIC THEORY, P752
   POLONSKY WH, 1995, DIABETES CARE, V18, P754, DOI 10.2337/diacare.18.6.754
   Rasch G, 1980, PROBABILISTIC MODELS
   *SPSS INC, 1998, SPSS WIND VERS 8 0 2
   TABACHNIK C, 1983, USING MULTIVARIATE S
   Ware JE, 1998, QUAL LIFE RES, V7, P235, DOI 10.1023/A:1024946316424
   WARE JEJ, 1993, SF36 HLTH SURVEY MAN
   WILSON AE, 1993, DIABETIC MED, V10, P378, DOI 10.1111/j.1464-5491.1993.tb00084.x
   YOUNGMAN MB, 1980, ANAL SOCIAL ED RES D
NR 29
TC 47
Z9 47
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0742-3071
EI 1464-5491
J9 DIABETIC MED
JI Diabetic Med.
PD AUG
PY 2000
VL 17
IS 8
BP 572
EP 580
DI 10.1046/j.1464-5491.2000.00322.x
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 363CE
UT WOS:000089816100003
PM 11073178
DA 2019-01-08
ER

PT J
AU Herpertz, S
   Albus, C
   Lichtblau, K
   Kohle, K
   Mann, K
   Senf, W
AF Herpertz, S
   Albus, C
   Lichtblau, K
   Kohle, K
   Mann, K
   Senf, W
TI Relationship of weight and eating disorders in type 2 diabetic patients:
   A multicenter study
SO INTERNATIONAL JOURNAL OF EATING DISORDERS
LA English
DT Article
DE diabetes mellitus; eating disorder; obesity; glycemic control
ID OBESE PATIENTS; BINGE; VALIDATION; PSYCHOPATHOLOGY; OVERWEIGHT; FEMALES
AB Objective: Previous work suggested that the degree of psychiatric symptomatology evidenced in overweight individuals was related to the severity of binge eating problems and not related to the severity of overweight. In a multicenter study, we investigated the relationship between weight and eating disorders (EDs) in a sample of type 2 diabetic patients. Methods: Three hundred twenty-two patients with type 2 diabetes were stratified to various weight categories. Glycemic control, eating and body-related psychological problems, self-esteem, depressive, and general psychopathology of diabetic patients with and without an ED were compared. Results: Eighty-one percent of all type 2 diabetic patients were overweight or obese. Prevalence rates of EDs ranged from 6.5% to 9.0%. Binge eating disorder was the most diagnosed ED. There was a strong relationship between body mass index (BMI) and eating disturbance-related variables and a weak or no relationship between BMI and depression or general psychopathologic variables. Patients with an ED showed a greater psychopathology compared to patients without an ED. The diagnosis of an ED did not seem to have a specific influence on glycemic control. Conclusions: Our results in a type 2 diabetic sample indicate that weight might have an impact on body and eating- related psychological distress in type 2 diabetic patients, but is of minor or no importance for depressive symptomatology, lower self-esteem, and general psychiatric symptomatology. Type 2 diabetic patients with an ED, however, suffer from considerable psychiatric symptomatology. (C) 2000 by John Wiley & Sons, Inc.
C1 Univ Essen Gesamthsch, Clin Psychotherapy & Psychosomat, D-45030 Essen, Germany.
   Univ Cologne, Dept Psychosomat & Psychotherapy, Cologne, Germany.
   Univ Essen Gesamthsch, Med Clin, Dept Endocrinol, Essen, Germany.
RP Herpertz, S (reprint author), Univ Essen Gesamthsch, Clin Psychotherapy & Psychosomat, Postfach 103043, D-45030 Essen, Germany.
RI Albus, Christian/C-1701-2015
CR American Psychiatric Association, 1994, DIAGN STAT MAN MENT
   BERGER M, 1996, FORDERUNGEN STVINCEN
   BRUCE B, 1992, INT J EAT DISORDER, V12, P365, DOI 10.1002/1098-108X(199212)12:4<365::AID-EAT2260120404>3.0.CO;2-M
   COOPER PJ, 1987, INT J EAT DISORDER, V6, P485, DOI 10.1002/1098-108X(198707)6:4<485::AID-EAT2260060405>3.0.CO;2-O
   DEROGATIS LR, 1977, J CLIN PSYCHOL, V33, P981, DOI 10.1002/1097-4679(197710)33:4<981::AID-JCLP2270330412>3.0.CO;2-0
   DEZWAAN M, 1994, INT J EAT DISORDER, V15, P43, DOI 10.1002/1098-108X(199401)15:1<43::AID-EAT2260150106>3.0.CO;2-6
   *DTSCH AD GES, 1995, ADIPOSITAS, V5, P6
   Fichter MM, 1998, INT J EAT DISORDER, V24, P227, DOI 10.1002/(SICI)1098-108X(199811)24:3<227::AID-EAT1>3.0.CO;2-O
   GARNER DM, 1983, INT J EAT DISORDER, V2, P15, DOI 10.1002/1098-108X(198321)2:2<15::AID-EAT2260020203>3.0.CO;2-6
   GARROW JS, 1985, INT J OBESITY, V9, P147
   GORTMAKER SL, 1993, NEW ENGL J MED, V329, P1008, DOI 10.1056/NEJM199309303291406
   Hautzinger M, 1995, BECK DEPRESSIONS INV
   Herpertz S, 1998, J PSYCHOSOM RES, V44, P503, DOI 10.1016/S0022-3999(97)00274-2
   KENARDY J, 1994, DIABETES CARE, V17, P1197, DOI 10.2337/diacare.17.10.1197
   MARCUS MD, 1992, DIABETES CARE, V15, P253, DOI 10.2337/diacare.15.2.253
   MARCUS MD, 1985, ADDICT BEHAV, V10, P163, DOI 10.1016/0306-4603(85)90022-X
   MARCUS MD, 1990, INT J EAT DISORDER, V9, P68
   MEHNERT H, 1984, DIABETOLOGIE KLIN PR, P186
   Nielsen S, 1998, EUR EAT DISORD REV, V6, P1
   POLIVY J, 1985, AM PSYCHOL, V40, P191
   SOREMBE V, 1979, SKALA ERFASSUNG SELB
   SPITZER RL, 1993, INT J EAT DISORDER, V13, P137
   SPITZER RL, 1992, INT J EAT DISORDER, V11, P191, DOI 10.1002/1098-108X(199204)11:3<191::AID-EAT2260110302>3.0.CO;2-S
   STEEL JM, 1987, BRIT MED J, V294, P859, DOI 10.1136/bmj.294.6576.859
   STEWART AL, 1983, AM J PUBLIC HEALTH, V73, P171, DOI 10.2105/AJPH.73.2.171
   STHERPERTZ, 1998, DIABETES CARE, V21, P1
   TELCH CF, 1994, INT J EAT DISORDER, V15, P53, DOI 10.1002/1098-108X(199401)15:1<53::AID-EAT2260150107>3.0.CO;2-0
   TELCH CF, 1988, INT J EAT DISORDER, V7, P115, DOI 10.1002/1098-108X(198801)7:1<115::AID-EAT2260070112>3.0.CO;2-W
   THIEL A, 1988, Z DIFFERENTIELLE DIA, V9, P267
   Waadt S., 1992, BULIMIE
   WADDEN TA, 1984, J CONSULT CLIN PSYCH, V52, P1104, DOI 10.1037//0022-006X.52.6.1104
   WING RR, 1990, DIABETES CARE, V13, P170, DOI 10.2337/diacare.13.2.170
   WING RR, 1989, INT J EAT DISORDER, V8, P671, DOI 10.1002/1098-108X(198911)8:6<671::AID-EAT2260080608>3.0.CO;2-5
NR 33
TC 38
Z9 41
U1 0
U2 5
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0276-3478
J9 INT J EAT DISORDER
JI Int. J. Eating Disord.
PD JUL
PY 2000
VL 28
IS 1
BP 68
EP 77
DI 10.1002/(SICI)1098-108X(200007)28:1<68::AID-EAT8>3.0.CO;2-R
PG 10
WC Psychology, Clinical; Nutrition & Dietetics; Psychiatry; Psychology
SC Psychology; Nutrition & Dietetics; Psychiatry
GA 313GH
UT WOS:000086991600008
PM 10800015
DA 2019-01-08
ER

PT J
AU Fisher, L
   Chesla, CA
   Skaff, MA
   Gilliss, C
   Kanter, RA
   Lutz, CP
   Bartz, RJ
AF Fisher, L
   Chesla, CA
   Skaff, MA
   Gilliss, C
   Kanter, RA
   Lutz, CP
   Bartz, RJ
TI Disease management status: A typology of Latino and Euro-American
   patients with type 2 diabetes
SO BEHAVIORAL MEDICINE
LA English
DT Article
DE chronic disease management; type 2 diabetes; typology
ID QUALITY-OF-LIFE; PHYSICAL-ACTIVITY; HEALTH; PSYCHOLOGY; CARE
AB The number of indicators of chronic disease management is large and no practical framework is available to guide selection for use in intervention programs. In addition, it is often difficult to integrate multiple disease management indicators into a comprehensive picture of patient functioning The authors present a heuristic framework for creating a profile of disease management and an empirically based descriptive typology of disease manage ment behavior: From the literature, they identified 5 domains of disease management indicators: biologic, general health and functional status, emotional tone, quality of life, and behavioral. They selected II scales and assessed 187 patients with type 2 diabetes. Five statistically replicable patient disease management types were derived from exploratory and confirmatory cluster analyses and a descriptive narrative was created for each: balanced (33%), problematic (6%), coasters (34%), discouraged (16%), and distressed (11%). The typology describes different presentations of disease management that can be linked with patient-tailored interventions for patients with type 2 diabetes.
C1 Univ Calif San Francisco, Dept Family & Community Med, San Francisco, CA 94143 USA.
   Yale Univ, New Haven, CT 06520 USA.
   Kaiser Permanente, Oakland, CA 94612 USA.
RP Fisher, L (reprint author), Univ Calif San Francisco, Dept Family & Community Med, Box 0900, San Francisco, CA 94143 USA.
EM fisher@itsa.ucsf.edu
FU NIDDK NIH HHS [DK-49816]
CR ADA (American Diabetics Association), 1994, DIABETES CARE, V17, P519
   Anderson RM, 1997, DIABETES CARE, V20, P299, DOI 10.2337/diacare.20.3.299
   ANDERSON RM, 1990, PATIENT EDUC COUNS, V16, P231, DOI 10.1016/0738-3991(90)90072-S
   BORGEN FH, 1987, J COUNS PSYCHOL, V34, P456, DOI 10.1037/0022-0167.34.4.456
   Boyer JG, 1997, MED CARE, V35, P440, DOI 10.1097/00005650-199705000-00003
   CATTELL RB, 1966, HDB MULTIVARIATE EXP
   Coyne JC, 1994, J FAMILY PSYCHOL, V8, P43, DOI DOI 10.1037/0893-3200.8.1.43
   DCCT Res Grp, 1988, DIABETES CARE, V11, P725
   DEROGATIS L R, 1973, Psychopharmacology Bulletin, V9, P13
   DORGAN JF, 1994, AM J EPIDEMIOL, V139, P662, DOI 10.1093/oxfordjournals.aje.a117056
   ELLWOOD PM, 1988, NEW ENGL J MED, V318, P1549, DOI 10.1056/NEJM198806093182329
   FISHER L, 1995, FAM PROCESS, V34, P161, DOI 10.1111/j.1545-5300.1995.00161.x
   Fisher L, 1996, J FAM PSYCHOL, V10, P180
   FISHER L, 1992, FAM PROCESS, V32, P399
   FISHER L, 1998, HLTH PSYCHOL, V17, P1
   Frankenfield DC, 1998, J AM DIET ASSOC, V98, P439, DOI 10.1016/S0002-8223(98)00100-X
   GAVARD JA, 1993, DIABETES CARE, V16, P1167, DOI 10.2337/diacare.16.8.1167
   GLASGOW RE, 1995, DIABETES CARE, V18, P117, DOI 10.2337/diacare.18.1.117
   GLASGOW RE, IN PRESS ANN BEHAV M
   GOODALL T, 1991, HLTH PSYCHOL, V11, P1
   Harris J, 1919, BIOMETRIC STUDY BASA
   Heyman R. E., 1994, J FAMILY PSYCHOL, V8, P432, DOI DOI 10.1037/0893-3200.8.4.432
   JACOBSON AM, 1994, DIABETES CARE, V17, P267, DOI 10.2337/diacare.17.4.267
   Johnson D., 1980, BASIC DATA DEPRESSIV
   JOHNSON SB, 1992, DIABETES CARE, V15, P1658, DOI 10.2337/diacare.15.11.1658
   KAPLAN RM, 1994, HEALTH PSYCHOL, V13, P451, DOI 10.1037//0278-6133.13.6.451
   KAPLAN RM, 1990, AM PSYCHOL, V45, P1211, DOI 10.1037/0003-066X.45.11.1211
   KLEINMAN A, 1978, ANN INTERN MED, V88, P251, DOI 10.7326/0003-4819-88-2-251
   Kleinman A., 1980, PATIENTS HEALERS CON
   LAPORTE RE, 1983, J GERONTOL, V38, P394, DOI 10.1093/geronj/38.4.394
   Lorr M, 1983, CLUSTER ANAL SOCIAL
   MARIN G, 1991, APPL SOCIAL RES METH
   MILLIGAN GW, 1980, PSYCHOMETRIKA, V45, P325, DOI 10.1007/BF02293907
   Myers L, 1998, ADHERENCE TREATMENT, P1
   PAFFENBARGER RS, 1993, MED SCI SPORT EXER, V25, P60, DOI 10.1249/00005768-199301000-00010
   PEARLIN LI, 1980, J HEALTH SOC BEHAV, V22, P333
   TOOBERT DJ, 1994, HDB PSYCHOL DIABETES, P351
   VanderDoes FEE, 1996, DIABETES CARE, V19, P204, DOI 10.2337/diacare.19.3.204
   WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002
   1992, VITAL STAT US
NR 40
TC 17
Z9 17
U1 0
U2 5
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 0896-4289
EI 1940-4026
J9 BEHAV MED
JI Behav. Med.
PD SUM
PY 2000
VL 26
IS 2
BP 53
EP 66
DI 10.1080/08964280009595752
PG 14
WC Behavioral Sciences; Psychiatry
SC Behavioral Sciences; Psychiatry
GA 384JC
UT WOS:000165938200001
PM 11147290
DA 2019-01-08
ER

PT J
AU Mollema, ED
   Snoek, FJ
   Pouwer, F
   Heine, RJ
   van der Ploeg, HM
AF Mollema, ED
   Snoek, FJ
   Pouwer, F
   Heine, RJ
   van der Ploeg, HM
TI Diabetes fear of injecting and self-testing questionnaire - A
   psychometric evaluation
SO DIABETES CARE
LA English
DT Article
ID PHOBIA; VALIDATION; DISTRESS; SCALE
AB OBJECTIVE - To study the psychometric properties of the Diabetes Fear of Injecting and Self-Testing Questionnaire (D-FISQ).
   RESEARCH DESIGN AND METHODS - Two groups of patients were studied. Sample A consisted of 252 insulin-treated diabetes patients. Sample B incorporated 24 insulin-treated patients with high scores (greater than or equal to 95th percentile) on the D-FISQ. Test-retest correlations were assessed in both samples. Discriminant and convergent validity of the D-FISQ were assessed with questionnaires concerning fear of hypoglycemia, trait anxiety, and fear of bodily injury, illness, or death. To evaluate criterion-related validity, sample B participated in a behavioral avoidance test (BAT), in which the current level of avoidance of either self-injecting or self-testing was determined. Exploratory factor analysis (EM) was performed to study whether 2 factors (fear of self-injecting [FSI] and fear of self-testing [FST]) could be detected.
   RESULTS- Test-retest correlations ranged from 0.50 to 0.68 (P < 0.001). Correlations between D-FISQ and fear of hypoglycemia, trait anxiety, and fear of bodily injury, illness, or death ranged from 0.28 to 0.45 (P < 0.001). Patients who refused to do a BA? for self-injecting or self-testing had higher scores on FSI (P = 0.095) and FST (P = 0.01). EFA yielded 2 separate factors, FSI and FST.
   CONCLUSIONS - Results from this study support reliability and validity of the D-FISQ, a self-report instrument that can be used for both clinical and research purposes.
C1 Free Univ Amsterdam, Fac Med, EMGO Inst, NL-1081 BT Amsterdam, Netherlands.
   Free Univ Amsterdam, Dept Med Psychol, NL-1081 BT Amsterdam, Netherlands.
   Free Univ Amsterdam, Res Inst Endocrinol Reprod & Metab, NL-1081 BT Amsterdam, Netherlands.
RP Mollema, ED (reprint author), Free Univ Amsterdam, Fac Med, EMGO Inst, Boechorststr 7, NL-1081 BT Amsterdam, Netherlands.
CR ARRINDELL WA, 1980, BEHAV RES THER, V18, P229, DOI 10.1016/0005-7967(80)90080-7
   ARRINDELL WA, 1986, SCL90 HANDLEIDING EE
   Berlin I, 1997, DIABETES CARE, V20, P176, DOI 10.2337/diacare.20.2.176
   Bodzin B, 1996, Home Healthc Nurse, V14, P378, DOI 10.1097/00004045-199605000-00009
   BOUMAN TK, 1987, THESIS U GRONINGEN
   BRADLEY C, 1994, HDB PSYCHOL DIABETES, P89
   Floyd FJ, 1995, PSYCHOL ASSESSMENT, V7, P286, DOI 10.1037/1040-3590.7.3.286
   Herrmann C, 1997, J PSYCHOSOM RES, V42, P17, DOI 10.1016/S0022-3999(96)00216-4
   Irvin A, 1994, HDB PSYCHOL DIABETES, P133
   JACOBSON AM, 1994, DIABETES CARE, V17, P267, DOI 10.2337/diacare.17.4.267
   Kindt M, 1996, BEHAV RES THER, V34, P277, DOI 10.1016/0005-7967(95)00069-0
   KOLKO DJ, 1980, J BEHAV THER EXP PSY, V11, P273, DOI 10.1016/0005-7916(80)90070-1
   LUTEIJN F, 1979, HANDLEIDING NPV MANU
   METSCH J, 1995, INT J BEHAV MED, V2, P104, DOI 10.1207/s15327558ijbm0202_2
   Mollema E. D., 1997, Diabetologia, V40, pA637
   MOORE KE, 1995, CLIN PEDIATR, V34, P530, DOI 10.1177/000992289503401004
   OST LG, 1992, BEHAV THER, V23, P263, DOI 10.1016/S0005-7894(05)80385-5
   Pouwer F, 1999, DIABETES CARE, V22, P2004, DOI 10.2337/diacare.22.12.2004
   RAINWATER N, 1988, CHILD FAM BEHAV THER, V10, P19
   Snoek F, 1996, GEDRAG GEZONDHEID, V24, P287
   Snoek FJ, 1997, DIABETIC MED, V14, P871, DOI 10.1002/(SICI)1096-9136(199710)14:10<871::AID-DIA457>3.3.CO;2-P
   SPIELBERGER CD, 1983, MANUAL STATE TRAIT A
   *SPSS, 1997, SPSS BAS 7 5 WIND US
   Streiner DL, 1995, HLTH MEASUREMENT SCA
   VANDERPLOEG HM, 1980, HANDLEIDING ZELF BEO
   Welch G, 1994, HDB PSYCHOL DIABETES, P400
   Welch GW, 1997, DIABETES CARE, V20, P760, DOI 10.2337/diacare.20.5.760
   Zambanini A, 1997, DIABETIC MED, V14, P321, DOI 10.1002/(SICI)1096-9136(199704)14:4<321::AID-DIA356>3.0.CO;2-H
   ZAMBANINI A, 1999, DIABETES RES CLIN PR, V46, P289
NR 29
TC 51
Z9 52
U1 0
U2 2
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1660 DUKE ST, ALEXANDRIA, VA 22314 USA
SN 0149-5992
J9 DIABETES CARE
JI Diabetes Care
PD JUN
PY 2000
VL 23
IS 6
BP 765
EP 769
DI 10.2337/diacare.23.6.765
PG 5
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 318ZF
UT WOS:000087314000011
PM 10840993
OA Bronze
DA 2019-01-08
ER

PT J
AU Janssen, MMJ
   Snoek, FJ
   de Jongh, RT
   Casteleijn, S
   Deville, W
   Heine, RJ
AF Janssen, MMJ
   Snoek, FJ
   de Jongh, RT
   Casteleijn, S
   Deville, W
   Heine, RJ
TI Biological and behavioural determinants of the frequency of mild,
   biochemical hypoglycaemia in patients with Type 1 diabetes on multiple
   insulin injection therapy
SO DIABETES-METABOLISM RESEARCH AND REVIEWS
LA English
DT Article
DE hypoglycaemia; Type 1 diabetes mellitus; multiple insulin injection
   therapy
ID SEVERE HYPOGLYCEMIA; IDDM; AWARENESS; ADULTS; RISK; UNAWARENESS;
   MELLITUS
AB Background Severe hypoglycaemic episodes are an important source of morbidity in people with Type 1 diabetes. The occurrence of severe hypoglycaemia is strongly related to the frequency of low blood glucose readings. The aim of this exploratory study was to identify determinants of the frequency of mild, biochemical hypoglycaemia in patients with Type I diabetes treated with multiple insulin injection therapy.
   Methods We studied 31 patients with Type 1 diabetes in reasonable glycaemic control (HbA(1c)less than or equal to 8.3%) during multiple injection therapy. The study had a prospective, observational design. We used standardised home blood glucose monitoring (HBGM) diaries to assess the frequency of hypoglycaemia (HBGM readings<3.5 mmol/L) over a period of 6 weeks. Potential determinants studied included biological factors, self-management factors (including weekly total physical activity and vigorous physical activity), psychological factors (including psychological distress) and mediating factors [average and standard deviation (SD) of the HBGM readings and self-reported hypoglycaemia awareness].
   Results Determinants of mild hypoglycaemia frequency identified in univariate regression analyses were: SD and mean of HBGM (beta 0.6, p = 0.001 and beta -0.6, p = 0.001), diabetes duration (beta 0.5, p = 0.008) and self-reported hypoglycaemia unawareness (beta -0.5, p = 0.003). A trend was observed for performance of vigorous physical activities (beta 0.3, p = 0.06) and external eating behaviour (beta -0.3, p = 0.1). These relations were confirmed in multivariate analyses.
   Conclusions Patients with Type I diabetes who have a high blood glucose variability and low average blood glucose concentration, diabetes of long duration, low body mass index, self-reported impaired awareness of hypoglycaemia and those participating in vigorous physical activities, specifically require interventions aimed at preventing hypoglycaemia. Copyright (C) 2000 John Wiley & Sons, Ltd.
C1 Free Univ Amsterdam Hosp, Dept Endocrinol, Res Inst Endocrinol Reprod & Metab, NL-1007 MB Amsterdam, Netherlands.
   Free Univ Amsterdam, Fac Med, Dept Epidemiol & Biostat, NL-1081 BT Amsterdam, Netherlands.
RP Heine, RJ (reprint author), Free Univ Amsterdam Hosp, Dept Endocrinol, Res Inst Endocrinol Reprod & Metab, POB 7057, NL-1007 MB Amsterdam, Netherlands.
RI Deville, Walter/B-5160-2013
CR ARRINDELL WA, 1975, SCL 90 HANDLEIDING M
   Boyle PJ, 1995, NEW ENGL J MED, V333, P1726, DOI 10.1056/NEJM199512283332602
   Cameron M E, 1988, MANUAL METHODOLOGY F
   Clarke WL, 1997, DIABETES EDUCATOR, V23, P55, DOI 10.1177/014572179702300107
   Clarke WL, 1999, DIABETES CARE, V22, P580, DOI 10.2337/diacare.22.4.580
   CLARKE WL, 1995, DIABETES CARE, V18, P517, DOI 10.2337/diacare.18.4.517
   CRYER PE, 1997, HYPOGLYCEMIA PATHOPH, P91
   *DIAB CONTR COMPL, 1997, DIABETES, V46, P271, DOI DOI 10.2337/DIABETES.46.2.271
   Diabet Control Complications Trial Res Grp, 1996, DIABETES CARE, V19, P195
   Diabet Control Complications Trial Res Grp, 1995, DIABETES CARE, V18, P1415
   Ferrannini E, 1997, J CLIN INVEST, V100, P1166, DOI 10.1172/JCI119628
   GOLD AE, 1994, DIABETES CARE, V17, P697, DOI 10.2337/diacare.17.7.697
   GONDERFREDERICK LA, 1990, HEALTH PSYCHOL, V9, P503, DOI 10.1037//0278-6133.9.5.503
   HELLER SR, 1991, DIABETES, V40, P223, DOI 10.2337/diabetes.40.2.223
   Kovatchev BP, 1998, DIABETES CARE, V21, P1870, DOI 10.2337/diacare.21.11.1870
   MAYER EJ, 1991, AM J CLIN NUTR, V53, P812
   METSCH J, 1995, INT J BEHAV MED, V2, P104, DOI 10.1207/s15327558ijbm0202_2
   MONTOYE H, 1996, MEASURING PHYSICAL A
   Pampanelli S, 1996, DIABETOLOGIA, V39, P677
   PRAMMING S, 1990, J INTERN MED, V228, P641, DOI 10.1111/j.1365-2796.1990.tb00292.x
   SALLIS JF, 1985, AM J EPIDEMIOL, V121, P91, DOI 10.1093/oxfordjournals.aje.a113987
   THORSTEINSSON B, 1986, DIABETIC MED, V3, P147, DOI 10.1111/j.1464-5491.1986.tb00726.x
   VANSTRIEN T, 1984, 01186 AGR U DEP HUM
   VENEMAN T, 1993, DIABETES, V42, P1233, DOI 10.2337/diabetes.42.9.1233
   WREDLING RAM, 1992, DIABETES CARE, V15, P518, DOI 10.2337/diacare.15.4.518
   1996, NEVO TABEL NEDERLAND
NR 26
TC 20
Z9 20
U1 0
U2 3
PU JOHN WILEY & SONS LTD
PI W SUSSEX
PA BAFFINS LANE CHICHESTER, W SUSSEX PO19 1UD, ENGLAND
SN 1520-7552
J9 DIABETES METAB RES
JI Diabetes-Metab. Res. Rev.
PD MAY-JUN
PY 2000
VL 16
IS 3
BP 157
EP 163
DI 10.1002/1520-7560(0000)9999:9999<::AID-DMRR104>3.0.CO;2-U
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 328DR
UT WOS:000087834000002
PM 10867714
DA 2019-01-08
ER

PT J
AU Ladwig, KH
   Muhlberger, N
   Walter, H
   Schumacher, K
   Popp, K
   Holle, R
   Zitzmann-Roth, E
   Schomig, A
AF Ladwig, KH
   Muhlberger, N
   Walter, H
   Schumacher, K
   Popp, K
   Holle, R
   Zitzmann-Roth, E
   Schomig, A
TI Gender differences in emotional disability and negative health
   perception in cardiac patients 6 months after stent implantation
SO JOURNAL OF PSYCHOSOMATIC RESEARCH
LA English
DT Article
DE gender differences; emotional disability; health perception; stent
   implantation; coronary artery disease
ID ACUTE MYOCARDIAL-INFARCTION; CORONARY-ARTERY DISEASE; REGIMEN ISAR
   TRIAL; HOSPITAL ANXIETY; FOLLOW-UP; THROMBOLYTIC THERAPY; DEPRESSION
   SCALE; WOMEN; MORTALITY; RISK
AB Objectives: In this study we evaluate gender differences in affective adaptation and health perception in patients 6 months after stent implantation. Background: Assessment of gender-specific behavioral strategies to cope with serious cardiac disease conditions has not been given much attention until now. preliminary data suggest greater impairments in female patients, which might be of clinical relevance. Methods: Three hundred seventeen patients were eligible for the 6-month follow-up investigation, 78 (24.6%) of whom were women. The women were significantly older but did not differ from men in their cardiac risk features and treatment procedures. There were no gender differences in prevalence of hypertension, hyper-cholesterolemia, and family history. Men had a significantly higher prevalence of smoking than women, whereas women had a significantly higher prevalence of diabetes than men. A structured interview and a standardized psychodiagnostic assessment was carried out, which covered domains of affective dysfunction (depression, anxiety, intrusion, and avoidance), vegetative symptoms (sleeping disorders), and parameters of negative health perception. Results: There were no significant gender differences in the prevalence of depressive symptoms. Women exhibited higher mean values of anxiety than men, which did not reach significance. Sleeping disorders were significantly more prevalent ill women. The absolute level of being distressed by intrusive thoughts and avoidance behavior related to the severe underlying disease process was low in the total group of patients examined. Measurable gender differences did not emerge. Fifty-one (16.5%) patients exhibited pessimistic anticipation of dire consequences and severe signs of negative health perception (NHP group). There was a trend, although not statistically significant, toward more women being in the NHP group. The distribution of cardiac risk factors, however, was completely balanced in the NHP+ and NHP- patient groups. Objective somatic cardiac disease parameters did not account for the negative health perception. NHP was. however, associated with significantly more prestent angina pectoris (p < 0.040) and poststent angina pectoris (p < 0.0001). High levels of anxiety, depression. and of disturbed sleep also led to a sharp separation between patients with high degrees of an anticipated incapacitation due to the disease process. Univariate regression analysis suggested an effect of female gender on the occurrence of NHP (odds ratio 1.70; 95% CI 0.88 to 3.25), which was of borderline significance. Control for confounders in a multiple regression model, however, eliminated the gender effect (odds ratio 1.04, 95% CI 0.48 to 2.23). Poststent chest pain (odds ratio 7.75, 95% CI 3.28 to 18.32) and sleeping disorders (odds ratio 1.32, 95% CI 1.16 to 1.51) were identified as the most powerful confounders of the gender-NHP association. Conclusion: Contrary to expectation. women were not per se more distressed than men in all areas of adaptation of the midterm course after stent implantation, although the higher levels of anxiety and sleeping disorders in women deserve attention. A considerable proportion of patients exhibited a pessimistic disease perspective independent of their somatic status. which was associated with affective morbidity. The tendency toward more negative health perception in women may be due to their more frequent occurrence of chest pain and sleeping disorders. (C) 2000 Elsevier Science Inc. All rights reserved.
C1 Tech Univ Munich, Klinikum Rechts Isar, Inst & Poliklin Psychosomat Med Med Psychol & Psy, D-81675 Munich, Germany.
   GSF, Natl Res Ctr Environm & Hlth, MEDIS Inst Med Informat & Hlth Serv Res, Munich, Germany.
   Tech Univ Munich, Klinikum Rechts Isar, Med Klin 1, D-8000 Munich, Germany.
RP Ladwig, KH (reprint author), Tech Univ Munich, Klinikum Rechts Isar, Inst & Poliklin Psychosomat Med Med Psychol & Psy, Langerstraae 3, D-81675 Munich, Germany.
RI Ladwig, Karl-Heinz/B-5351-2014; Holle, Rolf/D-9333-2013
OI Ladwig, Karl-Heinz/0000-0003-0710-1720; Holle, Rolf/0000-0001-5395-2695
CR APPELS A, 1988, EUR HEART J, V9, P758, DOI 10.1093/eurheartj/9.7.758
   Asplund R, 1998, J INTERN MED, V243, P209
   AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401
   Barefoot JC, 1996, AM J CARDIOL, V78, P613, DOI 10.1016/S0002-9149(96)00380-3
   BERGELSON BA, 1995, CHEST, V108, P1510, DOI 10.1378/chest.108.6.1510
   Billing E, 1997, EUR HEART J, V18, P911
   Boogard M, 1985, J CARDIOPULMONARY RE, V5, P379
   BUENO H, 1995, CIRCULATION, V92, P1133, DOI 10.1161/01.CIR.92.5.1133
   Collijn DH, 1996, J PSYCHOSOM RES, V40, P271, DOI 10.1016/0022-3999(95)00547-1
   CONN VS, 1991, J ADV NURS, V16, P1026, DOI 10.1111/j.1365-2648.1991.tb03362.x
   Crowe JM, 1996, HEART LUNG, V25, P98, DOI 10.1016/S0147-9563(96)80111-7
   DITTRICH H, 1988, AM J CARDIOL, V62, P1, DOI 10.1016/0002-9149(88)91356-2
   EAKER ED, 1992, AM J EPIDEMIOL, V135, P854, DOI 10.1093/oxfordjournals.aje.a116381
   Frasure-Smith N, 1999, PSYCHOSOM MED, V61, P26, DOI 10.1097/00006842-199901000-00006
   FRASURESMITH N, 1993, JAMA-J AM MED ASSOC, V270, P1819, DOI 10.1001/jama.270.15.1819
   Friedman BH, 1998, BIOL PSYCHOL, V47, P243, DOI 10.1016/S0301-0511(97)00027-6
   HEALY B, 1991, NEW ENGL J MED, V325, P274, DOI 10.1056/NEJM199107253250408
   HERRMANN C, 1991, PSYCHOTHER PSYCH MED, V41, P83
   HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004
   Irvine J, 1998, CLIN PSYCHOL PSYCHOT, V5, P86
   KAPLAN GA, 1983, AM J EPIDEMIOL, V117, P292, DOI 10.1093/oxfordjournals.aje.a113541
   Kastrati A, 1997, CIRCULATION, V96, P462
   KOP WJ, 1993, INT J CARDIOL, V42, P269, DOI 10.1016/0167-5273(93)90059-P
   Ladwig KH, 1997, EUR HEART J, V18, P582
   LADWIG KH, 1991, EUR HEART J, V12, P959
   LADWIG KH, 1994, LANCET, V343, P20, DOI 10.1016/S0140-6736(94)90877-X
   Lesperance F, 1996, PSYCHOSOM MED, V58, P99, DOI 10.1097/00006842-199603000-00001
   MAYNARD C, 1991, AM J CARDIOL, V68, P529, DOI 10.1016/0002-9149(91)90791-I
   MURPHY JM, 1986, ACTA PSYCHIAT SCAND, V73, P113, DOI 10.1111/j.1600-0447.1986.tb10576.x
   Oka RK, 1996, AM J CARDIOL, V78, P861, DOI 10.1016/S0002-9149(96)00457-2
   Perkins S, 1998, HEART LUNG, V27, P37, DOI 10.1016/S0147-9563(98)90067-X
   Petrie KJ, 1996, BRIT MED J, V312, P1191
   RIEGEL B, 1995, HEART LUNG, V24, P457, DOI 10.1016/S0147-9563(95)80023-9
   Schiaffino KM, 1998, HEALTH PSYCHOL, V17, P262, DOI 10.1037/0278-6133.17.3.262
   SCHLEIFER SJ, 1989, ARCH INTERN MED, V149, P1785, DOI 10.1001/archinte.149.8.1785
   SCHRON EB, 1991, CIRCULATION S2, V84, P245
   Schuhlen H, 1997, CIRCULATION, V95, P2015, DOI 10.1161/01.CIR.95.8.2015
   SILVERSTONE PH, 1994, J PSYCHOSOM RES, V38, P441, DOI 10.1016/0022-3999(94)90105-8
   *STAT BUND, 1998, GES STAT BUND, V12
   STERN MJ, 1976, J CHRON DIS, V29, P513, DOI 10.1016/0021-9681(76)90015-1
   VERMURA K, 1988, WORLD HLTH STAT Q, V41, P155
   Weaver WD, 1996, JAMA-J AM MED ASSOC, V275, P777, DOI 10.1001/jama.275.10.777
   WENGER NK, 1993, NEW ENGL J MED, V329, P247, DOI 10.1056/NEJM199307223290406
   WIKLUND I, 1989, EUR HEART J, V10, P464, DOI 10.1093/oxfordjournals.eurheartj.a059511
   WIKLUND I, 1993, EUR HEART J, V14, P1315, DOI 10.1093/eurheartj/14.10.1315
   ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x
NR 46
TC 17
Z9 17
U1 0
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0022-3999
J9 J PSYCHOSOM RES
JI J. Psychosomat. Res.
PD APR-MAY
PY 2000
VL 48
IS 4-5
BP 501
EP 508
DI 10.1016/S0022-3999(99)00111-7
PG 8
WC Psychiatry
SC Psychiatry
GA 329HA
UT WOS:000087900500022
PM 10880672
DA 2019-01-08
ER

PT J
AU Nichols, GA
   Hillier, TA
   Javor, K
   Brown, JB
AF Nichols, GA
   Hillier, TA
   Javor, K
   Brown, JB
TI Predictors of glycemic control in insulin-using adults with type 2
   diabetes
SO DIABETES CARE
LA English
DT Article
ID FORM HEALTH SURVEY; METABOLIC CONTROL; WEIGHT CHANGE; MELLITUS; DISEASE;
   RETINOPATHY; PROGRESSION; CHILDREN; GLUCOSE; CARE
AB OBJECTIVE - To determine the characteristics that influence glycemic control among insulin-using adults with type 2 diabetes.
   RESEARCH DESIGN AND METHODS - We studied all 1,333 eligible members of a large not-for-profit health maintenance organization who responded to a 1997 survey We tested associations among demographic, treatment, and psychometric variables with mean 1997 HbA(1c) values. The Problem Areas in Diabetes (PAID) instrument was used to assess the emotional effect of living with diabetes, and the Short Form 12 Physical Function Scale was used to assess the effect of physical limitations on daily activities. Based on differences between and within treatment groups, we built models to predict glycemic control for subgroups of subjects who were using insulin alone and those who were using insulin in combination with an oral hypoglycemic agent.
   RESULTS - Younger age, lower BMI, and increased emotional distress about diabetes (according to the PAID scale) were all significant predictors (P < 0.05) of worse glycemic control. However, except among individuals with an HbA(1c) level of >8.0 who were receiving combination therapy, only similar to 100% of the variance in glycemic control could be predicted by demographic, treatment, or psychometric characteristics.
   CONCLUSIONS - Personal characteristics explain little of the variation in glycemic control in insulin-using adults with type 2 diabetes. Possible explanations are that the reduced complexity of control in type 2 diabetes makes the disease less sensitive to personal factors than control in type 1 diabetes, that health-related behavior is less driven by personal and environmental characteristics among older individuals, or that, in populations exposed to aggressive glycemic control with oral hypoglycemic agents and nurse care managers, personal differences become largely irrelevant.
C1 Kaiser Permanente, Ctr Hlth Res, NW Div, Portland, OR 97227 USA.
   Eli Lilly & Co, Indianapolis, IN 46285 USA.
RP Nichols, GA (reprint author), Kaiser Permanente, Ctr Hlth Res, NW Div, 3800 N Kaiser Ctr Dr, Portland, OR 97227 USA.
CR *AM DIAB ASS, 1999, DIABETES CARE S1, V22, pS27
   *AM DIAB ASS, 1997, DIABETES CARE, V20, P23
   ANDERSON BJ, 1981, DIABETES CARE, V4, P586, DOI 10.2337/diacare.4.6.586
   Brown JB, 1999, DIABETES CARE, V22, P1116, DOI 10.2337/diacare.22.7.1116
   Cowie CC, 1995, DIABETES AM, V2, P85
   Davidson MB, 1998, DIABETES CARE, V21, P2152, DOI 10.2337/diacare.21.12.2152
   DAVIS WK, 1987, HEALTH PSYCHOL, V6, P1
   Edelman SV, 1998, MED CLIN N AM, V82, P665, DOI 10.1016/S0025-7125(05)70019-5
   Gandek B, 1998, J CLIN EPIDEMIOL, V51, P1171, DOI 10.1016/S0895-4356(98)00109-7
   GREENLICK M, 1998, HLTH CARE RES HMO 2
   Harris MI, 1999, DIABETES CARE, V22, P403, DOI 10.2337/diacare.22.3.403
   HENSRUD DD, 1995, OBES RES, V3, pS217, DOI 10.1002/j.1550-8528.1995.tb00467.x
   HEYDEN S, 1985, J CHRON DIS, V38, P281, DOI 10.1016/0021-9681(85)90073-6
   Jenkinson C, 1997, J PUBLIC HEALTH MED, V19, P179, DOI 10.1093/oxfordjournals.pubmed.a024606
   Kannel William B., 1996, American Journal of Clinical Nutrition, V63, p419S, DOI 10.1093/ajcn/87.6.1602
   KENNY SJ, 1995, DIABETES AM, P47
   Klein BEK, 1998, DIABETES CARE, V21, P236, DOI 10.2337/diacare.21.2.236
   KLEIN R, 1994, ARCH OPHTHALMOL-CHIC, V112, P1217, DOI 10.1001/archopht.1994.01090210105023
   KOVACS M, 1989, DIABETES CARE, V12, P409, DOI 10.2337/diacare.12.6.409
   Mayfield Jennifer, 1998, Clinical Diabetes, V16, P161
   Meigs JB, 1997, AM J MED, V102, P38, DOI 10.1016/S0002-9343(96)00383-X
   *NAT COMM QUAL ASS, 1999, HEDIS 2000, V2, P91
   NOPPA H, 1980, AM J EPIDEMIOL, V111, P693, DOI 10.1093/oxfordjournals.aje.a112947
   OHKUBO Y, 1995, DIABETES RES CLIN PR, V28, P103, DOI 10.1016/0168-8227(95)01064-K
   POLONSKY WH, 1995, DIABETES CARE, V18, P754, DOI 10.2337/diacare.18.6.754
   Rosilio M, 1998, DIABETES CARE, V21, P1146, DOI 10.2337/diacare.21.7.1146
   Scanlon D P, 1998, Jt Comm J Qual Improv, V24, P5
   SHAMOON H, 1993, NEW ENGL J MED, V329, P977
   Testa MA, 1998, JAMA-J AM MED ASSOC, V280, P1490, DOI 10.1001/jama.280.17.1490
   Trief PM, 1998, DIABETES CARE, V21, P241, DOI 10.2337/diacare.21.2.241
   Turner RC, 1998, LANCET, V352, P837
   Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003
   Welch GW, 1997, DIABETES CARE, V20, P760, DOI 10.2337/diacare.20.5.760
   WILSON W, 1986, DIABETES CARE, V9, P614, DOI 10.2337/diacare.9.6.614
NR 34
TC 79
Z9 81
U1 0
U2 6
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1660 DUKE ST, ALEXANDRIA, VA 22314 USA
SN 0149-5992
J9 DIABETES CARE
JI Diabetes Care
PD MAR
PY 2000
VL 23
IS 3
BP 273
EP 277
DI 10.2337/diacare.23.3.273
PG 5
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 289GA
UT WOS:000085611100003
PM 10868850
OA Bronze
DA 2019-01-08
ER

PT J
AU Aalto, AM
   Uutela, A
   Aro, AR
AF Aalto, AM
   Uutela, A
   Aro, AR
TI Disease-related distress among insulin-treated diabetic patients -
   Associations with health status, psychosocial factors and self-care
   practices
SO EUROPEAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
DE diabetes cognitions; diabetes distress; health status; insulin-treated
   diabetes; social support
ID QUALITY-OF-LIFE; LONG-TERM RECOVERY; SOCIAL SUPPORT; METABOLIC CONTROL;
   GLYCOSYLATED HEMOGLOBIN; EMOTIONAL ADJUSTMENT; MELLITUS; COMPLICATIONS;
   EFFICACY; SCALES
AB Background: Diabetes is a chronic illness that affects many domains of life. This cross sectional study examined disease-related distress and its associations with health and psychosocial factors among insulin treated diabetic persons. Method: The sample (n=423) was drawn from the Social Insurance Institution's drug registry. Health indicators were duration of diabetes, complications, and glycaemic control. Psychosocial measures included general and diabetes-specific social support, diabetes locus of control (DLC), self-efficacy, diabetes health beliefs and self-care practices and subjective health. Results: Most respondents reported moderate diabetes-related distress. In multivariate analysis, severe diabetes distress was related to lower net benefits of regimen (beta = -0.29, and p<0.001), poorer perceived health (beta = -0.25, and p<0.001), higher perceived threat of complications (beta = 0.19, and p<0.001), less adequate social support (beta = -0.16, and p<0.01), stronger beliefs in chance (beta = 0.15, and p<0.01) and internal DLC (beta = 0.11, and p<0.05) and more frequent exercising (beta = 0.10, and p<0.05). Conclusions: The results suggest that emotional adjustment to diabetes is predominantly determined by diabetes related cognitions and subjective health and to a lesser degree by objective diabetes indicators, which underlines the importance of assisting the patient with adjustment with the disease in health care centres.
C1 Natl Res & Dev Ctr Welf & Hlth, FIN-00531 Helsinki, Finland.
   Natl Publ Hlth Inst, Helsinki, Finland.
RP Aalto, AM (reprint author), Natl Res & Dev Ctr Welf & Hlth, POB 220, FIN-00531 Helsinki, Finland.
CR Aalto AM, 1997, PATIENT EDUC COUNS, V30, P215, DOI 10.1016/S0738-3991(96)00963-9
   AALTO AM, 1993, SOSIAALILAAKETIETEEL, V30, P328
   ARY DV, 1986, DIABETES CARE, V9, P168, DOI 10.2337/diacare.9.2.168
   BANDURA A, 1977, PSYCHOL REV, V84, P191, DOI 10.1037/0033-295X.84.2.191
   BECKER MH, 1975, MED CARE, V13, P10, DOI 10.1097/00005650-197501000-00002
   CHASE HP, 1989, JAMA-J AM MED ASSOC, V261, P1155, DOI 10.1001/jama.261.8.1155
   CONNELL CM, 1994, HEALTH PSYCHOL, V13, P263, DOI 10.1037//0278-6133.13.3.263
   CRONENWETT LR, 1985, NURS RES, V34, P93
   CUNNINGHAM AJ, 1991, PATIENT EDUC COUNS, V17, P71, DOI 10.1016/0738-3991(91)90052-7
   DUNN SM, 1986, DIABETES CARE, V9, P480, DOI 10.2337/diacare.9.5.480
   FERRARO LA, 1987, PSYCHOL REP, V61, P763, DOI 10.2466/pr0.1987.61.3.763
   GAFVELS C, 1993, DIABETIC MED, V10, P768, DOI 10.1111/j.1464-5491.1993.tb00162.x
   GIVEN CW, 1983, RES NURS HEALTH, V6, P127, DOI 10.1002/nur.4770060306
   GROSSMAN HY, 1987, DIABETES CARE, V10, P324, DOI 10.2337/diacare.10.3.324
   HANESTAD BR, 1991, SCAND J SOC MED, V19, P57, DOI 10.1177/140349489101900111
   Harris R, 1987, Diabetes Educ, V13, P292, DOI 10.1177/014572178701300310
   House J. S., 1981, WORK STRESS SOCIAL S
   KANGAS T, 1995, 58 GUMM KIRJ OY
   KING KB, 1993, HEALTH PSYCHOL, V12, P56, DOI 10.1037/0278-6133.12.1.56
   KLEIN R, 1988, JAMA-J AM MED ASSOC, V260, P2864, DOI 10.1001/jama.260.19.2864
   KUGLER J, 1994, J PSYCHOSOM RES, V38, P403, DOI 10.1016/0022-3999(94)90101-5
   Lasar M, 1993, Schweiz Arch Neurol Psychiatr (1985), V144, P147
   LENNON MC, 1990, SOC SCI MED, V31, P477, DOI 10.1016/0277-9536(90)90043-R
   LEWIS KS, 1990, DIABETIC MED, V7, P148, DOI 10.1111/j.1464-5491.1990.tb01350.x
   LITTLEFIELD CH, 1990, HEALTH PSYCHOL, V9, P737, DOI 10.1037//0278-6133.9.6.737
   LLOYD CE, 1992, DIABETES CARE, V15, P166, DOI 10.2337/diacare.15.2.166
   LUNDMAN B, 1990, RES NURS HEALTH, V13, P255, DOI 10.1002/nur.4770130408
   MANNE SL, 1989, J PERS SOC PSYCHOL, V56, P608, DOI 10.1037//0022-3514.56.4.608
   MASON C, 1985, SOC SCI MED, V21, P1329, DOI 10.1016/0277-9536(85)90436-8
   NAESS S, 1995, SCAND J SOC MED, V23, P179
   PADGETT DK, 1993, J NERV MENT DIS, V181, P123, DOI 10.1097/00005053-199302000-00008
   PASTOR MA, 1993, BRIT J RHEUMATOL, V32, P484
   PEACOCK I, 1984, J CLIN PATHOL, V37, P841, DOI 10.1136/jcp.37.8.841
   PRAMMING S, 1991, DIABETIC MED, V8, P217, DOI 10.1111/j.1464-5491.1991.tb01575.x
   PRIMOMO J, 1990, RES NURS HEALTH, V13, P153, DOI 10.1002/nur.4770130304
   REID DW, 1984, RES LOCUS CONTROL CO, V3, P361
   RUBIN RR, 1991, DIABETES CARE, V14, P335, DOI 10.2337/diacare.14.4.335
   SCHAFER LC, 1986, DIABETES CARE, V9, P179, DOI 10.2337/diacare.9.2.179
   STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007
   WALLSTON BS, 1978, HEALTH EDUC QUART, V6, P107, DOI 10.1177/109019817800600107
   WEINBERGER M, 1994, MED CARE, V32, P1173, DOI 10.1097/00005650-199412000-00002
   WIKBLAD KF, 1990, J ADV NURS, V15, P1083, DOI 10.1111/j.1365-2648.1990.tb01990.x
   WIKBY A, 1993, QUAL LIFE RES, V2, P281, DOI 10.1007/BF00434799
   YATES BC, 1995, RES NURS HEALTH, V18, P193, DOI 10.1002/nur.4770180303
NR 44
TC 5
Z9 5
U1 0
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1101-1262
J9 EUR J PUBLIC HEALTH
JI Eur. J. Public Health
PD MAR
PY 2000
VL 10
IS 1
BP 68
EP 74
DI 10.1093/eurpub/10.1.68
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 302ED
UT WOS:000086351700015
OA Bronze
DA 2019-01-08
ER

PT J
AU Phillips, KA
AF Phillips, KA
TI Quality of life for patients with body dysmorphic disorder
SO JOURNAL OF NERVOUS AND MENTAL DISEASE
LA English
DT Article; Proceedings Paper
CT 152nd Annual Meeting of the American-Psychiatric-Association
CY MAY 15-20, 1999
CL WASHINGTON, D.C.
SP Amer Psychiat Assoc
ID OBSESSIVE-COMPULSIVE SCALE; STRUCTURED CLINICAL INTERVIEW; FORM HEALTH
   SURVEY; OF-LIFE; IMAGINED UGLINESS; RELIABILITY; VALIDITY; PREVALENCE;
   DEPRESSION; FEATURES
AB Body dysmorphic disorder (BDD) is a relatively common, distressing and impairing disorder. Quality of life in BDD, however, has not been investigated. in this study, 62 consecutive outpatients with BDD were evaluated with the self-report Medical Out-comes Study 36-Item Short-Form Health Survey (SF-36) and other scales. SF-36 scores were descriptively compared to published norms fbr several populations. Physical health-related quality of life scares were generally worse than general U.S. population norms and better than norms for outpatients with a medical illness or depression. However, in all mental health domains, BDD subjects' scores were notably worse than norms for the general U.S. population and for patients with depression, diabetes, or a recent myocardial infarction. More severe BDD symptoms and greater delusionality were associated with poorer mental health-related quality of life. These results indicate that patients with BDD have notably poor mental health status and mental health-related quality of life.
C1 Butler Univ, Providence, RI 02906 USA.
   Brown Univ, Sch Med, Dept Psychiat & Human Behav, Providence, RI 02906 USA.
RP Phillips, KA (reprint author), Butler Univ, 345 Blackstone Blvd, Providence, RI 02906 USA.
FU NIMH NIH HHS [R-29MH54841]
CR American Psychiatric Association, 1994, DIAGN STAT MAN MENT
   Awad AG, 1997, J PSYCHIATR NEUROSCI, V22, P229
   Cotterill JA, 1997, BRIT J DERMATOL, V137, P246, DOI 10.1046/j.1365-2133.1997.18131897.x
   COTTERILL JA, 1981, BRIT J DERMATOL, V104, P611, DOI 10.1111/j.1365-2133.1981.tb00746.x
   Cotterill JA, 1996, DERMATOL CLIN, V14, P457, DOI 10.1016/S0733-8635(05)70373-9
   DeMarco LM, 1998, J NERV MENT DIS, V186, P724, DOI 10.1097/00005053-199811000-00011
   DENCKER SJ, 1992, NORD J PSYCHIAT, V46, P91
   Eisen JL, 1998, AM J PSYCHIAT, V155, P102, DOI 10.1176/ajp.155.1.102
   GOODMAN WK, 1989, ARCH GEN PSYCHIAT, V46, P1006
   GOODMAN WK, 1989, ARCH GEN PSYCHIAT, V46, P1012
   HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56
   HAY GG, 1970, BRIT J PSYCHIAT, V116, P399, DOI 10.1192/bjp.116.533.399
   KOBLENZER CS, 1985, ARCH DERMATOL, V121, P780
   Koran LM, 1996, AM J PSYCHIAT, V153, P783
   MASSION AO, 1993, AM J PSYCHIAT, V150, P600
   MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006
   Perugi G, 1998, COMPR PSYCHIAT, V39, P63, DOI 10.1016/S0010-440X(98)90080-3
   Perugi G, 1997, Int J Psychiatry Clin Pract, V1, P77, DOI 10.3109/13651509709024707
   PHILLIPS KA, 1994, PSYCHOPHARMACOL BULL, V30, P179
   Phillips KA, 1996, J NERV MENT DIS, V184, P125, DOI 10.1097/00005053-199602000-00012
   PHILLIPS KA, 1993, AM J PSYCHIAT, V150, P302
   PHILLIPS KA, 1991, AM J PSYCHIAT, V148, P1138
   Phillips KA, 1997, PSYCHOPHARMACOL BULL, V33, P17
   Phillips KA, 1995, 148 ANN M AM PSYCH A, P157
   PHILLIPS KA, 1996, BROKEN MIRROR UNDERS
   PHILLIPS KA, 1996, AM J PSYCHIAT
   Revicki DA, 1997, HARVARD REV PSYCHIAT, V5, P75, DOI 10.3109/10673229709034730
   Russo J, 1998, MED CARE, V36, P752, DOI 10.1097/00005650-199805000-00015
   SIMEON D, 1995, AM J PSYCHIAT, V152, P1207
   SPITZER RL, 1992, ARCH GEN PSYCHIAT, V49, P624
   Veale D, 1996, BRIT J PSYCHIAT, V169, P196, DOI 10.1192/bjp.169.2.196
   Ware JE, 1993, SF 36 HLTH SURVEY MA
   WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI 10.1001/jama.262.7.914
   WILLIAMS JBW, 1992, ARCH GEN PSYCHIAT, V49, P630
NR 34
TC 90
Z9 90
U1 1
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0022-3018
J9 J NERV MENT DIS
JI J. Nerv. Ment. Dis.
PD MAR
PY 2000
VL 188
IS 3
BP 170
EP 175
DI 10.1097/00005053-200003000-00007
PG 6
WC Clinical Neurology; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 294QV
UT WOS:000085922600007
PM 10749282
DA 2019-01-08
ER

EF